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Summary 
Malaria is one of the most important and life-threatening infectious diseases worldwide. In 
2015 malaria claimed about 429 000 lives, mostly among children below five year of age in 
sub‐Saharan Africa, and caused 212 million clinical episodes in a population of 
approximately 3.3 billion people living in regions at risk of infection. The development of an 
effective malaria vaccine is recognized as one of the most promising approaches for 
preventing infections and reducing transmission. To date, there is no vaccine on the market 
for prevention of malaria and only a few candidate vaccines were able to induce some 
protective efficacy. Thus, there is an urgent need to accelerate the pace of design and 
development of new malaria vaccine candidates that induce broad and long-lasting protective 
immunity. Reverse vaccinology and structural vaccinology are two complementary 
techniques that hold much promise in this regard. 
The pathogenesis of malaria is primarily associated with blood-stage infection and there is 
strong evidence that antibodies specific for parasite blood-stage antigens can control 
parasitemia. This provides a strong rationale for incorporation of asexual blood-stage antigen 
components into an effective multivalent malaria subunit vaccine. 
 
In this thesis, we exploited the great potential of the ‘omics’ sciences for the selection of 
hypothetical surface-exposed protein and the evaluation of their potential as vaccine candidate 
antigens. For the characterization of selected antigens we have exploited an entirely cell-
based, rapid and reliable approach for the generation of antigen-specific and parasite cross-
reactive monoclonal antibodies (mAbs): (I) generation of mammalian cell lines expressing 
high levels of the selected predicted malaria antigens as transmembrane proteins; (II) 
living-cell immunization of mice; (III) generation of hybridoma cell lines producing mAbs 
capable of recognizing the endogenous antigen in its native context.  
This strategy has led us to the identification of the Plasmodium falciparum Cysteine-Rich 
Protective Antigen (PfCyRPA) as promising blood-stage malaria vaccine candidate: (I) 
PfCyRPA has limited natural immunogenicity, (II) is highly conserved among P. falciparum 
isolates and (III) forms together with the Reticulocyte-binding Homolog 5 (PfRH5) and the 
PfRH5-interacting Protein (PfRipr) a multiprotein complex crucial for P. falciparum 
erythrocyte invasion; (IV) PfCyRPA-specific mAbs showed parasite in vitro 
growth-inhibitory activity due to inhibition of merozoite invasion; (V) passive immunization 
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experiments in P. falciparum infected NOD-scid IL2Rγnull mice engrafted with human 
erythrocytes demonstrated in vivo growth-inhibitory activity of PfCyRPA specific mAbs.  
 
To investigate whether growth inhibitory anti-PfCyRPA and anti-PfRH5 Abs can be induced 
by active immunization with the adjuvanted recombinant proteins, PfCyRPA and PfRH5 were 
recombinantly expressed as soluble protein in mammalian and insect cells respectively, 
purified from culture supernatant and employed for immunization of mice. mAbs raised 
against recombinant PfCyRPA and PfRH5 proteins showed potent parasite growth-inhibitory 
activity both in vitro and in vivo. Furthermore, both in vitro and in vivo anti-PfCyRPA and 
anti-PfRH5 antibodies showed more potent parasite growth inhibitory activity in combination 
than on their own, supporting a combined delivery of PfCyRPA and PfRH5 in a vaccine. 
 
To examine the 3D structure of PfCyRPA and to explore the dynamics of its surface loops, 
we generated co-crystals of it in complex with an inhibitory mAb and elucidated the 3D 
structure of PfCyRPA and of the epitope–paratope interface by X-ray crystallography. 
Elucidation of the structure of the epitope recognized by the protective mAb will strongly 
facilitate design of peptidomimetics in a structural vaccinology approach. The overall 
structure of PfCyRPA is a six-bladed β-propeller with each blade of the propeller being a 
four-stranded anti-parallel β-sheet. The five disulfide bonds of the protein are located within 
blades 1-5, stabilizing each individual blade. Since the 6th blade is composed of β-strands 
both from the N- and the C-terminus and has no disulfide bond, PfCyRPA has the potential to 
undergo large conformational changes by disassembly of blade 6.  
 
Among additional hypothetical antigens investigated in the framework of this thesis, 
PF14_0044 showed interesting features: while none of the generated PF14_0044-specific 
mAbs significantly inhibited parasite growth, a synergistic in vitro inhibitory activity was 
observed when anti-PF14_0044 mAbs were combined with anti-PfCyRPA mAbs. Applying 
the principle of reverse vaccinology, we thus identified PfCyRPA and PF14_0044 as targets 
of merozoite invasion‐inhibitory antibodies.   
Taken together results show how a combination of reverse and structural vaccinology 
approaches can enable the identification of new target antigens for incorporation into subunit 
vaccines. 
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Introduction 
Global epidemiology of Malaria and control strategies 
Malaria is an infectious disease of humans and other animals caused by parasitic protozoans 
belonging to the genus Plasmodium and transmitted by female Anopheles mosquitoes (1). 
There are four different malaria species (P. falciparum, P. vivax, P. malariae and P. ovale) 
infecting humans, of which P. falciparum and P. vivax are the most prevalent and P. 
falciparum is the most dangerous. P. knowlesi is a zoonotic plasmodium that is also known to 
infect humans. 
Despite being preventable and treatable, malaria still represents a massive global public health 
problem, threatening the lives of nearly half the world’s population. 
 
 
Figure 1. Countries endemic for malaria in 2000 and 2016. 
Countries with 3 consecutive years of zero indigenous cases are considered to have eliminated malaria. No country in the 
WHO European region reported indigenous cases in 2015 but Tajikistan has not yet had 3 consecutive years of zero 
indigenous cases, its last case being reported in July 2014. Source: WHO database  
According to latest available data, an estimated 212 million cases occurred (range: 148 
million–304 million) in 2015. In the same year, the disease killed about 429 000 people 
(range: 235 000–639 000). Approximately 90% of malaria cases and 92% of malaria deaths 
occurred in Africa, with children aged under 5 years and pregnant women most severely 
affected (2). Between 2010 and 2015, an expansion of malaria interventions helped to reduce 
malaria incidence by 21% globally and in Africa. During the same period, malaria mortality 
rates decreased by an estimated 29% worldwide and by 31% in the African Region.  
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In the under-five age group, mortality rates have declined by by 29% since 2010, but malaria 
remains a major killer of children, taking the life of a child every 2 minutes. The prevalence 
of malaria parasite infection (including both symptomatic and asymptomatic infections) has 
decreased significantly in Africa since 2000: the number of people infected fell from 173 
million in 2000 to 114 million in 2015 – a reduction of 34%. 
In 2000, malaria was identified as one of the biggest impediments to global development and 
selected as a critical global target of the Millennium Development Goals (MDGs) (3).  
 
The target to halt and begin to reverse the incidence of malaria by 2015 has been reached: at 
the beginning of 2016, malaria was considered to be endemic in 91 countries and territories, 
of the 108 countries that had malaria transmission in 2000 (4–6).  
Despite this tremendous progress, a lot still needs to be done: millions of people at risk of 
malaria still do not have access to interventions such as insecticide-treated mosquito nets 
(ITNs), diagnostic testing and artemisinin-based combination therapies (ACTs). There is an 
urgent need to further scale up and sustain malaria control efforts, and ensure that the most 
vulnerable populations have access to life-saving interventions. The WHO-recommended 
package of core interventions to prevent infection and reduce morbidity and mortality 
comprises vector control, chemoprevention, diagnostic testing and treatment. 
In May 2015, the World Health Assembly adopted the Global Technical Strategy for Malaria 
2016–2030 (7): the strategy set ambitious yet achievable targets for 2030; namely, to reduce 
malaria incidence and mortality rates globally by at least 90% by 2030, with a milestone of at 
least a 40% reduction by 2020. The GTS also set a target to eliminate malaria from at least 35 
countries by 2030 (with a milestone of elimination in at least 10 countries by 2020), and 
simultaneously to prevent the re-establishment of malaria in all countries that were malaria 
free in 2015. Progress towards the GTS country elimination milestone is on track however, 
progress towards other GTS targets must be accelerated to meet the GTS milestone of a 40% 
reduction in malaria case incidence by 2020. 
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Plasmodium falciparum life cycle 
The life cycle of Plasmodium is extraordinarily complex involving both invertebrate 
(mosquito) and vertebrate (mammalian) hosts, multiple parasites stages (asexual and sexual), 
different infected cell types within the hosts, and numerous intracellular and extracellular 
environments in which the parasite develops.  
During a blood meal, a malaria-infected female Anopheles mosquito inoculates sporozoites (a 
motile infective form) into the human host, thus acting as a transmission vector. Sporozoites 
travel through the blood vessels to liver cells, where they reproduce asexually (tissue 
schizogony) maturing into schizonts, which rupture and release thousands of merozoites in 
the blood stream (over 5-16 days)*. Merozoites infect red blood cells and initiate a series of 
asexual multiplication cycles (blood schizogony). Within erythrocytes, merozoites develop 
from ring- to trophozoite-stages, and mature into schizonts that produce up to 36 new 
infective merozoites, at which point the cells burst and the infective cycle begins anew. In 
non-immune humans, the infection is amplified about 20-fold each cycle, which takes 
approximately 48h.  
Some of the merozoites leave the cycle of asexual multiplication and develop into immature 
sexual stages (gametocytes). The gametocytes, male (microgametocytes) and female 
(macrogametocytes), are ingested by Anopheles mosquitos during a blood meal, where they 
grow and reproduce sexually (sporogonic cycle). In the mosquito gut, gametocytes develop 
into mature sex cells (gametes). Male and female gametes fuse to form ookinetes — fertilized, 
motile zygotes that invade the midgut wall and develop into oocysts. The oocysts undergo 
massive schizogony, rupture and release thousands of sporozoites (after ca. 8-15 days), which 
eventually migrate to the salivary glands. Inoculation of the sporozoites into a new human 
host, during a subsequent blood meal, perpetuates the malaria life cycle (8).  
  
                                                
* Of note, in P. vivax and P. ovale a dormant stage (hypnozoites) can persist in the liver and cause relapses by 
invading the bloodstream weeks, or even years later. 
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Malaria: pathophysiology and control interventions 
Malaria infections may result in a wide variety of symptoms and the disease can be 
categorized as uncomplicated or severe. In general, malaria is curable if diagnosed and treated 
promptly and correctly. All the clinical symptoms associated with the disease are caused by 
the asexual blood-stage parasites. When the parasite develops within the erythrocytes, 
numerous waste substances, such as hemozoin and other toxic factors, accumulate in the 
infected red blood cells. Upon schizonts burst, together with the newly formed merozoites, 
these toxins are dumped into the bloodstream and stimulate host cells to produce cytokines 
and other soluble factors that produce fever, and probably influence other severe 
pathophysiology associated with malaria.  
Typically, following the infective bite by the Anopheles mosquito, the incubation period 
varies from 7 to 30 days. The first clinical signs are chills, fever, headache, muscle ache, 
nausea, vomiting, diarrhea, and abdominal cramps. Fever occurs in periodic attacks that last 6 
to 10 hours and recur at intervals of approximately 48 hours (tertian malaria – P. falciparum, 
P. vivax, and P. ovale) or 72 hours (quartan malaria – P. malarie), in conjunction with the 
synchronized release of each new generation of merozoites into the bloodstream.  
Besides febrile attacks, malaria patients commonly have anemia (owing to the destruction of 
red blood cells by the parasites) and splenomegaly (enlargement of the spleen, the organ 
responsible for ridding the body of degenerate red blood cells).  
Infections due to P. falciparum are by far the most dangerous: patients may deteriorate 
rapidly from mild symptoms to coma and death unless they are diagnosed and treated 
promptly and properly. The greater virulence of P. falciparum is associated with the high 
levels of parasitemia (compared to the other three human malaria species) and the tendency to 
clump together and adhere to endothelial cells of capillaries. This results in obstruction of the 
blood flow in various organs, leading to serious organ failure. When the sequestration of 
infected erythrocytes occurs in the vessels of the brain, it causes the severe disease syndrome 
known as cerebral malaria, which is associated with high mortality (9–13). 
In countries where cases of malaria are infrequent, the symptoms may be attributed to 
influenza or other common infections resulting in misdiagnosis or delayed diagnosis. 
Conversely, in highly endemic countries, residents often recognize the symptoms as malaria 
and treat themselves without diagnostic confirmation ("presumptive treatment"). 
WHO recommends malaria diagnosis either by microscopy or rapid diagnostic test (RDT) in 
all patients with suspected malaria before any treatment is administered (14). 
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According to the WHO guidelines (15), uncomplicated P. falciparum malaria cases should be 
treated with orally administered artemisinin-based combination therapies (ACTs). The 
combination of two active ingredients with different mode of action is the most effective 
antimalarial first-line treatment and is thought to delay the emergence of artemisinin 
resistances. P. vivax infections should be treated with chloroquine instead.  
Infants, children under five years of age, pregnant women, patients with HIV/AIDS, as well 
as non-immune migrants, mobile populations and travelers, are at considerably higher risk of 
contracting malaria, and developing a severe disease progression. Special measures should be 
taken to protect these population groups from malaria infection: WHO recommends 
preventive therapies including intermittent preventive treatment of pregnant women (IPTp), 
intermittent preventive treatment of infants (IPTi), and seasonal malaria chemoprevention 
(SMC) in children under five years of age in areas with highly seasonal malaria transmission 
(15). For non-immune travelers, preventive measures against mosquito bites are the first line 
of defense against malaria. Depending on the malaria risk in the area to be visited, preventive 
medication (chemoprophylaxis) might be required and should be chosen according to local 
recommendations. 
Together with proper diagnosis and treatment, vector control is a central, critical component 
of all malaria control strategies. Vector control interventions have proven to successfully 
reduce or interrupt disease transmission, particularly in areas of high endemicity. Insecticide-
treated mosquito nets (ITNs) have been shown to reduce the incidence of malaria cases by 
50% in a variety of settings (16, 17). Remarkably, during the past 10 years, coverage with 
vector control interventions increased substantially in sub-Saharan Africa. Indoor residual 
spraying (IRS) and long-lasting insecticidal nets (LLINs) are the two most important 
measures that protect humans from the bite of malaria-infected mosquitoes (18). Of the 65 
countries reporting monitoring data for 2010–2013, 53 reported resistance to at least one 
insecticide class. Therefore, endemic countries are urged to draw up and implement 
comprehensive insecticide resistance management strategies and ensure entomological and 
resistance monitoring (19). 
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Immune responses to malaria infections 
Adults living in malaria endemic areas rarely experience malaria episodes: partial protection 
of adults is mediated by naturally acquired immunity (NAI) and protects against symptomatic 
disease and high-density parasitemia, but is not effective in offering sterile immunity (20).  
 
Natural immunity to malaria is initially mediated by maternal IgG antibodies, which are 
acquired by the fetus in utero during the third trimester of pregnancy. Infants remain 
remarkably resistant to high parasitemia, fever, and severe disease until about 6 months of 
age. Maternal IgG levels decrease from birth over the first year of life and, as consequence, 
the prevalence of parasitemia start to increase at about 5 months of age (21). Subsequently, 
active immunity slowly develops as a result of repeated exposure to malaria, and children 
gradually develop clinical protection against mild disease (22). The development of clinical 
and parasitological immunity to malaria is marked by the ability to control disease and 
parasite density, but require continuous re-exposure. Nonetheless, sterilizing immunity 
against infection is never fully achieved, and an asymptomatic carrier status is the rule among 
adults. Conversely, in naïve individuals of any age, P. falciparum infection is almost always 
symptomatic and clinical symptoms can be observed even at very low parasitemia.  
 
Protective immunity against malaria involves both the branches of the immune system and 
requires a well-coordinated “cross-talk” between the innate and adaptive immunity, involving 
dendritic cells (DCs), natural killer cells (NKs), B cells, CD4+, CD8+ and CD3+γδ T cells. 
However, despite intense research efforts, our knowledge about the acquired immunity 
developed against the disease remains limited and incomplete. 
 
The protective role of antibodies was first demonstrated in 1961 by Cohen et al., showing that 
passive transfer of immunoglobulins from immune adults to naïve, infected children resulted 
in rapid reduction of parasitemia and cease of clinical symptoms (23). B cells secreting 
pathogen-specific antibodies, with CD4+ T helper cells enhancement, are essential for 
clearance of the parasitemia (24). Indeed, merozoite-specific antibodies can prevent 
erythrocytes invasion and mediate clearance of infected red blood cells by phagocytic cells 
via antibody-dependent cellular inhibition (22). 
 
In addition to the humoral arm of adaptive immunity, cell-mediated immune responses are 
also crucial for protection against malaria. CD8+ and CD4+ T cells kill infected hepatocytes 
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through diverse mechanisms and induce sterile protection in mouse models (25). Sterile 
protection, involving both sporozoite-specific antibodies and T cells, has also been observed 
in humans in sporozoite challenge experiments following vaccination with whole sporozoites 
(26). 
Malaria vaccine development: challenges and progress 
Successful vaccinations have proven to prevent infectious diseases by reducing both 
incidence and mortality, and to significantly contribute to improve public health worldwide. 
Despite tremendous efforts, many infections that represent a major cause of mortality 
worldwide are still not vaccine-preventable. Until now, vaccines against certain infections 
that fail to induce sterilizing immunity upon natural infection (i.e., malaria and respiratory 
syncytial virus – RSV), those that lead to persistent or latent infection (i.e., HIV-1 and 
hepatitis C virus – HCV), or those with high degrees of variability (i.e., malaria, dengue and 
HIV-1) have not been developed (27). 
Despite the remarkable improvements achieved in malaria control, emerging antimalarial drug 
resistances, along with reported insecticide resistances, underline the need of new tools to 
control and prevent malaria (22, 28). From that perspective, the development of an effective 
malaria vaccine is recognized as a most promising tool for preventing and controlling malaria. 
However, complexity of the Plasmodium spp. parasite as well as the host response to the 
parasite has hindered the development of a highly effective vaccine until now. From the 
immunological point of view, the Plasmodium genus presents to the host immune system a 
myriad of antigens, mostly highly polymorphic, which vary throughout the different stages of 
the life cycle and successive waves of parasitemia, and against which sequential consecutive 
immune responses are required. This peculiar antigenic variability, together with the ability of 
the parasite to hide within host cells (including the MHC class I and II deficient erythrocytes) 
significantly contributes to immune evasion and appears to be critical for the parasite's 
survival. 
 
Moreover, no appropriate animal model exists and the only way of testing the efficacy of a 
candidate vaccine depends on clinical trials being carried out in malaria endemic areas. The 
high cost of developing a malaria vaccine candidate (e.g., the development of the RTS,S 
vaccine has received more than $550 million from the Bill & Melinda Gates Foundation and 
GSK to date, and another $260 million are expected to be invested before the completion of 
the project - (29)) and the length of the process before it can be marketed (up to 10–12 years), 
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has discouraged pharmaceutical companies from extensively investing in vaccines destined to 
a market too poor in resources to pay for them.  
So far, no surrogate of immunity has been found and there is neither certainty about which 
specific antigens are relevant for the development of immunity, nor which immune effector 
mechanisms play the most important role in the immunity developed against the disease. 
In spite of these challenges, field and clinical studies showed that some degree of clinical 
immunity can be acquired naturally with age and exposure or induced by passive or active 
immunization (23, 30, 31). Those studies support the idea that a malaria vaccine is feasible 
and pointed out the importance of antibodies as crucial components of the immune response 
against blood stage parasites. Antimalarial vaccines can break the parasite life cycle at 
different stages: infection-blocking vaccines targeting hepatic stages, anti-morbidity vaccines 
targeting the asexual blood stages, and transmission-blocking vaccines targeting the sexual 
stages. To achieve effective protection, the ideal malaria vaccine is thought to target several 
steps of the parasite life-cycle in a multistage combination vaccine (32).  
 
Currently, with more than 20 projects in clinical trial phase or advanced preclinical 
development (33–35), three candidate vaccines are in Phase IIB clinical trials and one, the 
pre-erythrocytic subunit vaccine RTS,S/AS01, has completed Phase III clinical testing (36). 
 
The updated Malaria Vaccine Roadmap has called for the development and licensing, by 
2030, of malaria vaccines, targeting both P. falciparum and P. vivax, with protective efficacy 
of at least 75% (37). As new technologies emerged and our understanding of host-pathogen 
interactions and immunity constantly grows, the achievement of such an ambitious goal may 
become realistically possible. 
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Pre-erythrocytic vaccines 
Effective immune responses targeting pre-erythrocytic stages would eliminate the parasites 
before they leave the liver and enter the blood-stream, leading both to protection from clinical 
disease and to transmission-blocking effects. T cell-mediated responses, specific for liver-
stage antigens and able to interfere with the intra-hepatic schizogony, may further limit the 
infection intensity.  
Whole Sporozoite Vaccination 
Immunization with attenuated whole parasites, already in late 1960s, has shown to confer 
highly effective and long-lasting pre-erythrocytic stage immunity against sporozoites 
challenge in animal models and in humans (26, 38–40). These first clinical trials 
unequivocally demonstrated the feasibility of vaccination as protection against malaria and 
made the radiation-attenuated sporozoites (RAS) approach the gold standard for malaria 
vaccine development.  
In 2002, Stephen L. Hoffman founded Sanaria, a biotechnology company, with the mission to 
develop and commercialize radiation-attenuated, purified and cryopreserved P. falciparum 
sporozoites (PfSPZ). After many technical and quality manufacturing hurdles were overcome 
(41, 42), a Phase I/IIa clinical trial in 40 adults showed that radiation-attenuated PfSPZ can be 
highly efficacious if administered intravenously (IV) (43). The vaccine was safe and well 
tolerated, and induced sterile protection against CHMI (controlled human malaria infection) 
in six out of six volunteers who received 5 doses of 1.35x105 PfSPZ. 
Genetically attenuated parasites (GAP), with selected genes crucial for liver-stage 
development knocked out, have also been investigated. In general, GAP-based vaccines have 
the advantage of being genetically defined and homogenous, however absolute attenuation is 
essential and need always to be proved (44). Since the first knockout parasites that cause early 
liver-stage arrest were described (45, 46), a number of parasite genes involved in the liver-
stage development were identified and tested in animal model and humans (47–50). Parasites 
that are capable of developing into late liver stages, when compared to early-stage-arresting 
parasites, have been shown to induce a superior effector and memory CD8+ T cell response 
and confer higher levels of protective immunity (51).  
Administration of non-attenuated sporozoites under chemoprophylaxis regimen has also been 
tested and successfully established. In the first human clinical trials (52, 53) all the volunteers 
exposed to P. falciparum infected mosquitoes under chloroquine treatment (leading to 
elimination of blood-stage trophozoites without any effect on liver-stages parasites) 
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developed long lasting, sterile protection against homologous CHMI. Currently, other 
antimalarial drugs and antibiotics are being investigated (54–56). 
Pre-erythrocytic subunit vaccines 
The development of a pre-erythrocytic (targeting sporozoites and/or liver-stage parasites) 
subunit vaccine capable of inducing sterile protection would prevent both disease and 
transmission associated with blood stage infections. The limited antigenic variation (in 
comparison to blood-stage parasites) certainly represents strength and prospects the 
possibility of raising strain-transcending immunity. However, pre-erythrocytic subunit 
vaccines need to be broadly and highly effective because parasites escape from the immune 
surveillance in the liver, would lead to the onset of blood-stage infection and eventually 
malaria disease and transmission. Several pre-erythrocytic antigens have been investigated, 
but the main focus was laid on the circumsporozoite protein (CSP), the most prominent 
surface antigen on sporozoites, well know to play an important role in the attachment to the 
hepatocytes and invasion (57). Initial vaccine formulations based on soluble CSP protein 
failed to provide substantial protection (58, 59). Based on the first genetically engineered 
hepatitis B vaccine, GlaxoSmithKline (GSK) developed the RTS,S, the most advanced pre-
erythrocytic vaccine candidate, and the only malaria vaccine candidate that has proven 
efficacy, albeit limited, in malaria-naïve, semi-immune adults, as well as children and infants 
living in endemic regions. 
The RTS,S contains the repeat region (R) and T cell epitopes (T) of the P. falciparum CSP 
fused to the hepatitis-B virus surface antigen – HBsAg – (S) and additional unfused copies of 
HBsAg (S) (60). HBsAg, and derived fusion proteins, are capable of spontaneous assembly 
into virus-like particles (VLPs) that stimulate strong humoral and cellular immune responses 
and exhibit self-adjuvanting capabilities. Encouraging results in Phase II clinical trials in 
African countries, confirmed that both the adult and pediatric doses vaccine conferred partial 
protection against malaria (61, 62). In 2009, the first Phase III malaria vaccine trial was 
initiated: a multicenter study of RTS,S/AS01 was undertaken in 11 research centers across 7 
countries with various patterns of malaria transmission. Results, including the effect of a 
booster dose at month 20, have now been published (36). Overall, protection against clinical 
and severe malaria was 36% and 32%, respectively. When considering infants aged 6-12 
weeks at first vaccination, estimates of vaccine efficacy were lower if compared to the older 
age category. Vaccine efficacy against clinical malaria, over the whole study (average follow-
up 38 months) was 18% without a booster dose, and 26% with a booster dose. There was no 
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evidence for protection against severe malaria. Although RTS,S/AS01 Phase III results 
showed the potential for a significant impact on the malaria burden, a vaccine with higher 
levels of efficacy, broader age target and duration of vaccination-induced protection, would 
be needed to fulfill the ambitious goals fixed by the Malaria Vaccine Roadmap (37). 
In July 2015, the European Medicine Agency (EMA) has adopted a positive scientific opinion 
for the RTS,S/AS01 in children aged 6 weeks to 17 months and, in October 2015, two 
independent WHO advisory groups recommended the pilot implementation of RTS,S/AS01 in 
parts of 3 to 5 sub-Saharan African countries. WHO has adopted these recommendations and 
is strongly supportive of the need to proceed with the pilots as the next step for the world’s 
first malaria vaccine (63). RTS,S/AS01 is being evaluated in a Phase IV pharmacovigilance 
baseline study (the study is currently recruiting participants - Clinicaltrials.gov: 
NCT02374450) as a complementary malaria control measure that could be added to – but not 
replace – the core package of proven malaria preventive, diagnostic and treatment tools. 
 
Viral vectors have also been investigated for delivering the DNA sequence of vaccine 
antigens and promoting strong cellular immune responses (the antigen of interest is produced 
within the host cells, processed and then presented on MHCI/II molecules to induce T cell 
responses) (64). The most advanced viral vectored malaria vaccine is based on the 
thrombospondin-related adhesive protein (TRAP), a surface sporozoite protein essential for 
motility and infectivity (65, 66). Immunization with plasmid DNA followed by a recombinant 
replication-deficient modified vaccinia virus Ankara (MVA), both expressing ME-TRAP, 
showed promising results both in animal models and humans (67, 68). The use of more potent 
recombinant replication-deficient adenoviral vectors (HAdV5, HAdV35, ChAd63) coding 
different malaria antigens (PfTRAP, PvTRAP, CSP, AMA-1, MSP-1- alone and in different 
combinations) was also considered. Encouraging immunogenicity data (both high antibodies 
titers and strong T cell responses) have been shown (69–71) and are being evaluated 
(Clinicaltrials.gov: NCT01366534, NCT01635647, NCT02083887). Of particular interest is 
the combination of anti-sporozoite and anti-liver-stage subunit vaccines to assess eventual 
benefits rising from synergistic vaccine efficacy (72). The initial results of the first clinical 
trial combining RTS,S/AS01B and ChAd63-MVA ME-TRAP showed an 82% (14/17) sterile 
protection achieved in a Phase IIa CHMI study (NCT01883609). In this perspective, 
numerous on-going efforts are trying to identify novel antigens: the combination of new 
functional and bioinformatic approaches holds significant promise for the identification and 
clinical development of novel pre-erythrocytic vaccine antigen targets in the near future. 
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Asexual blood stage vaccines 
Although the acquisition of protective anti-disease immunity in endemic populations 
(naturally acquired immunity – NAI) has been largely reported and associated with antibody 
responses against blood-stage parasites, the development of vaccines against the asexual 
blood-stage parasite has been extremely challenging and has not reported significant efficacy. 
However, sterilizing immunity is not absolutely essential for an effective blood-stage vaccine: 
if the parasitemia can be contained during the early growth cycles, then disease severity and 
mortality would still be prevented, whilst allowing for induction of additional naturally 
acquired responses. Moreover, the reduction of infected red blood cells (iRBC) density would 
also affect gametocyte availability and, in turn, malaria transmission. Blood-stage vaccines 
are also regarded as crucial components for the development of a multi-component/multi-
stage malaria vaccine, especially in the context of partially effective pre-erythrocytic 
vaccines. 
Despite the broad number of antigens expressed by blood-stage parasites, most efforts in 
vaccine research have focused on a few antigens implicated in the invasion of red blood cells 
(RBC) by the merozoites, in particular the P. falciparum merozoite surface protein 1, 2 and 3 
(MSP1, MSP2, MSP3) (73–75), apical membrane antigen 1 (AMA1) (76), glutamate-rich 
protein (GLURP) (77), serine repeat antigen 5 (SERA5) (78), and the erythrocyte-binding 
antigen 175 kDa (EBA-175) (79). 
One of the major problems associated with these vaccine candidates, which have mainly been 
investigated and tested as recombinant protein-in-adjuvant formulations, has been the 
extensive antigenic polymorphism exhibited (80), coupled with the high titers of antigen-
specific antibodies required to achieve protective effects (81). 
Prime-boost regimes using replication-deficient adenoviruses and poxviruses encoding blood-
stage antigens have been investigated and shown to be favorable compared to protein-in-
adjuvant formulations in terms of inducing both antibody and T cell responses in mice and 
NHPs (82, 83). However, clinical trials (Phase I and II) conducted with MSP1, AMA1 and 
their combination (ChAd63-MVA prime-boost regime), failed to provide any convincing 
evidence that cellular immunity induced by viral vectors can impart blood-stage protection in 
malaria-naïve individuals (84–86). 
Despite disappointing efficacy levels of MSP1- and AMA1-based vaccines, the recent 
identification and assessment of novel merozoites target antigens has rose encouraging 
optimism (87–90). Since the full genome of P. falciparum 3D7 was sequenced and annotated 
in 2002 (91), large-scale genomic, proteomic, transcriptomic and comparative data, including 
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different P. falciparum strains, field isolates, and other Plasmodium species have become 
available (92). These extensive data sets offer valuable and powerful tools for rational search 
for new candidate antigens, and have made reverse vaccinology the most promising strategy 
for vaccine development (93, 94). Based on these dataset, large libraries of merozoites 
proteins have been compiled (87–90) and new antigens with great potential as blood-stage 
vaccine candidates have been discovered (95). 
On the basis of available genome-wide transcriptomic and proteomic data, Dreyer et al. (89) 
have selected uncharacterized surface proteins, with specific expression in extracellular 
parasite stages, to evaluate their potential as vaccine candidate antigens. This strategy has led 
to the identification of the Plasmodium falciparum Cysteine-Rich Protective Antigen 
(PfCyRPA). PfCyRPA forms together with the Reticulocyte-binding Homolog 5 (PfRH5) and 
the PfRH5-interacting Protein (PfRipr) a multiprotein complex crucial for P. falciparum 
erythrocyte invasion (96). PfRH5 has been shown to play a key role in the attachment of 
merozoites to the erythrocyte surface via the interaction with the host receptor basigin (97, 
98). PfRH5 is currently regarded as a leading blood-stage malaria vaccine candidate: it 
demonstrated poor natural immunogenicity and has been shown to induce invasion-inhibitory 
antibodies that are effective across common PfRH5 genetic variants and PfRH5-based 
vaccines can protect Aotus monkeys against virulent vaccine-heterologous P. falciparum 
challenges (87, 99–101). Interestingly, PfCyRPA and PfRH5 genes are located in close 
proximity in the genome and have no substantial sequence polymorphisms. Also, Reddy et al. 
(96) reported a synergistic in vitro inhibitory activity for the combination of polyclonal anti-
PfCyRPA and anti-PfRH5 antibodies. These findings suggest that additional investigation is 
needed for an in depth characterization of the invasion complex, and make CyRPA and 
PfRH5 appealing candidates for the development of new antimalarial vaccine strategies. The 
first RH5 clinical trial using the ChAd63-MVA platform was initiated in Oxford in 2014 
(NCT02181088), the results of which are eagerly awaited. 
To date, only one clinical trial has been conducted for P. vivax (NCT01816113) – a ChAd63-
MVA viral vectored vaccine targeting region II of the Duffy-binding protein, largely reported 
to be essential for reticulocyte invasion by this parasite (102). Results remain awaited. 
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Transmission blocking vaccines 
Transmission-blocking vaccines (TBV) target sexual blood-stage gametocyte or mosquito-
stage parasite antigens to induce antibodies in human hosts, which are ingested by Anopheles 
mosquitoes during blood meals and, eventually, inhibit parasite development in the mosquito 
midgut (103). Vaccinated individuals would not gain direct benefit or protection but, in the 
context of community vaccination campaigns, reduced transmission rates would instead 
confer indirect protection from becoming infected. These vaccines, which include also pre-
erythrocytic and asexual blood-stage vaccines capable of reducing gametocyte densities, are 
described as ‘community-acquired vaccines’ and ‘vaccines that interrupt malaria 
transmission’ (VIMT) (104).  
P. falciparum surface protein 25 (Pfs25), Pfs48/45, and Pfs230 (105) are the most studied and 
most advanced TBV antigens (106). To date the only TBV antigens evaluated in human 
clinical trials are Pfs25 and its orthologue in P. vivax, Pvs25. These antigens are exclusively 
expressed on zygote and ookinete stages of parasites within the mosquito, but not in the 
human host. As not under human immune selection pressure, the antigens are extremely 
conserved between field isolates however, after vaccination the antibody response cannot be 
boosted through natural infection.  
A Phase Ia clinical trial with recombinant Pvs25 protein in combination with Alhydrogel® 
showed modest transmission blocking activity, correlated with limited antibody titers (107). 
To improve immunogenicity, different adjuvant system (108), conjugates to Pseudomonas 
aeruginosa ExoProtein (109, 110), virus-like particle containing a Pfs25 recombinant protein 
fused to the Alfalfa Mosaic Virus coat protein (NCT02013687), and recombinant replication-
deficient viral vectors in prime-boost regimes (111) have been evaluated. The first human 
clinical trial with ChAd63-MVA vectors encoding Pfs25 fused to IMX313 (heptamerization 
domain (112)) is currently recruiting patients (NCT02532049). 
A number of additional candidates are under intensive investigation at the preclinical stage 
and/or are progressing towards clinical trials (i.e. Pfs230, Pfs48/45-GLURP fusion protein, 
Pfs28, PfHAP2). 
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Objectives 
Plasmodium falciparum has a 23-megabase genome that contains an estimated 5,300 
predicted proteins, many of which are expressed in different stages of the parasite life cycle. 
However, so far only a small handful of historical candidate antigens have been extensively 
investigated as malaria vaccine components, and the results from human clinical trials have 
been discouraging. 
The last 15 years have seen the publication of the genomic sequences of the parasite 
Plasmodium falciparum (91), the mosquito vector Anopheles gambiae (113) and the human 
host (114). Clearly, the onset of the –omics era combined with the advent of new strategies 
(e.g. reverse and structural vaccinology) creates an unprecedented potential to revolutionize 
the malaria vaccine field.  
In fact, many novel antigens are already being identified from the parasite’s genome (87, 88, 
90), renewing hope that more effective antigens can be developed as vaccine formulations and 
offer higher levels of protection at multiple stages of the parasite’s complex life cycle. 
In this thesis, we applied reverse vaccinology (Obj. 1–3) and structural vaccinology (Obj. 4) 
strategies for the rational discovery and optimization of novel malaria subunit vaccine 
candidates. Our strategy is based on the selection of uncharacterized parasite proteins that are 
predicted to be accessible to immune surveillance by antibodies, and their subsequent 
functional characterization using specific monoclonal antibodies. 
Within the framework of this PhD project, specific objectives were: 
1. Identification of novel vaccine candidates and characterization of selected antigens 
exploiting a rapid and efficient mammalian cell-based approach for the generation of 
monoclonal antibodies (mAbs) capable of recognizing endogenous antigens in their 
native context; 
2. Functional characterization and assessment of their potential as malaria subunit 
vaccine components by in vitro and in vivo functional assays with generated antigen-
specific mAbs; 
3. Active immunization in mice with purified recombinant proteins and evaluation of 
their immunogenicity in protein-in-adjuvant vaccine formulations. 
4. Elucidation of the 3D structure of the Plasmodium falciparum Cysteine-Rich 
Protective antigen (PfCyRPA), to identify the protective B-cell epitopes targeted by 
parasite growth inhibitory antibodies.   
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Abstract 25 
An effective malaria vaccine could prove to be the most cost-effective and efficacious means 26 
of preventing severe disease and death from malaria. In an endeavor to identify novel vaccine 27 
targets, we tested predicted Plasmodium falciparum open reading frames for proteins that 28 
elicit parasite-inhibitory Abs. This has led to the identification of the cysteine-rich protective 29 
Ag (CyRPA). CyRPA is a cysteine-rich protein harboring a predicted signal sequence. The 30 
stage-specific expression of CyRPA in late schizonts resembles that of proteins known to be 31 
involved in merozoite invasion. Immunofluorescence staining localized CyRPA at the apex of 32 
merozoites. The entire protein is conserved as shown by sequencing of the CyRPA encoding 33 
gene from a diverse range of P. falciparum isolates. CyRPA-specific mAbs substantially 34 
inhibited parasite growth in vitro as well as in a P. falciparum animal model based on NOD- 35 
scid IL2Rgnull mice engrafted with human erythrocytes. In contrast to other P. falciparum 36 
mouse models, this system generated very consistent results and evinced a dose-response 37 
relationship and therefore represents an unprecedented in vivo model for quantitative 38 
comparison of the functional potencies of malaria-specific Abs. Our data suggest a role for 39 
CyRPA in erythrocyte invasion by the merozoite. Inhibition of merozoite invasion by 40 
CyRPA-specific mAbs in vitro and in vivo renders this protein a promising malaria asexual 41 
blood-stage vaccine candidate Ag. 42 
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Introduction 44 
Although preventable and curable, malaria was estimated to have claimed 781,000 lives in 45 
2009 (1). Besides other control measures, implementation of an effective vaccine  46 
against malaria is regarded as a cost-effective measure to reduce mortality and morbidity. 47 
Three different malaria vaccine strategies can be distinguished: infection-blocking vaccines 48 
targeting pre-erythrocytic stages, anti-morbidity vaccines targeting the erythrocytic stages, 49 
and transmission-blocking vaccines targeting the sexual stages. It is assumed that a highly 50 
effective malaria vaccine needs to target multiple stages of the parasite life cycle (2, 3).  51 
The importance of a parasite blood-stage component in a malaria subunit vaccine is evident, 52 
as clinical symptoms of malaria are mainly attributed to asexual blood stages. In exposed 53 
humans, protection from symptomatic disease is acquired after repeated exposure over years 54 
(4). This naturally acquired immunity is attributed at least in part to Ab responses targeting 55 
blood-stage Ags. This was demonstrated by passive immunotherapy studies, in which transfer 56 
of Igs from immune individuals to malaria patients led to very substantial reductions of 57 
parasitemia and clinical symptoms (5–7).  58 
The feasibility of an asexual blood-stage vaccine is supported by studies in humans and 59 
animal models (8–13). To date, research in this field has focused on a few protein candidates 60 
including merozoite surface protein (MSP)-1 (14), MSP-2 (8), MSP-3 (15– 18), apical 61 
membrane Ag 1 (AMA-1) (19), erythrocyte binding Ag 175 (EBA-175) (20), glutamate-rich 62 
protein (GLURP) (15, 21), and serine repeat Ag 5 (SERA5) (22). These Ags are all merozoite 63 
proteins, either located on the merozoite surface or contained within apical invasion 64 
organelles. In contrast to intraerythrocytic stages, which are largely hidden within the RBCs, 65 
free merozoites are directly accessible to Abs. Abs are thought to interfere with the invasion 66 
of erythrocytes by binding to merozoite surface proteins or proteins released from apical 67 
organelles. Merozoite invasion involves a complex series of orchestrated molecular 68 
interactions but nevertheless takes less than a minute to be completed (23, 24). After low- 69 
affinity attachment of a freshly released merozoite to an erythrocyte, the merozoite reorients 70 
to its apical pole. Released microneme and rhoptry neck resident proteins mediate high- 71 
affinity attachment by the establishment of a tight junction. This in turn initiates the release of 72 
rhoptry bulb resident proteins, which are involved in the formation of a membrane to 73 
surround the parasitophorous vacuole. Mediated by an actomyosin motor complex, the tight 74 
junction is then moved toward the anterior pole, terminating with the sealing of the 75 
parasitophorous vacuole membrane at the posterior pole of the merozoite (for a review, see 76 
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reference 25). Most proteins currently regarded as key malaria blood-stage vaccine candidate 77 
Ags were shown or are thought to be involved in the invasion process. These Ags are targets 78 
of invasion inhibitory Abs, which interfere with different steps of the invasion process. 79 
Parasite growth inhibitory Abs specific for MSP-1, the most abundant protein on the surface 80 
of merozoites assumed to be involved in the initial attachment, were for example shown to 81 
inhibit merozoite invasion either by preventing MSP-1 processing or by agglutination 82 
preventing the dispersal of released merozoites (26, 27). By contrast, inhibitory Abs specific 83 
for AMA-1, a micronemal protein and constituent of the tight junction, were shown to 84 
interfere sterically with the assembly of the protein complex forming the tight junction (28). 85 
The modes of action of all invasion inhibitory Abs have not been identified, but suggested 86 
mechanisms also include opsonization and destruction of merozoites by phagocytic cells (29, 87 
30), complement activation (31), or neutrophil respiratory bursts (32).  88 
To date, relatively few blood-stage Ags are in clinical development as vaccine components 89 
(33). Unfortunately, the most advanced blood-stage vaccine Ags, AMA-1 and MSP-1, have 90 
not demonstrated efficacy in African children to date (14, 34, 35). However, a multistage 91 
vaccine comprising an AMA-1 component showed a 50% reduced incidence rate of clinical 92 
malaria episodes in child vaccinees compared with that of control children (36). But whether 93 
protection is associated with AMA-1–specific responses remains to be shown. The extensive 94 
polymorphisms of current candidate Ags is deemed to be a major hurdle for blood-stage 95 
vaccine development (37–41). Hence, although a couple of bloodstage Ags are under vaccine 96 
development, it is possible to search for more vaccine candidates. The comparison of a large 97 
range of protein Ags in preclinical assays would allow a more rational prioritization of 98 
candidates for inclusion into a vaccine. Since the availability of the Plasmodium falciparum 99 
genome in 2002, reverse vaccinology is considered an opportunity to identify novel vaccine 100 
candidates in a more rational way (42–50). On the basis of the genome-wide transcriptomic 101 
and proteomic information generated since 2002, we selected the P. falciparum open reading 102 
frame (ORF) PFD1130w for further characterization. PFD1130w was selected because the 103 
available information suggested that the protein is a merozoite protein involved in erythrocyte 104 
invasion: 1) transcription has been shown to be upregulated in late asexual blood stages (46, 105 
47); 2) the encoded protein is predicted to contain a N-terminal secretion signal peptide (51); 106 
3) a genomewide in silico study based on gene coexpression, sequence homology, and 107 
domain–domain and yeast two-hybrid interaction data showed that PFD1130w clustered into 108 
an interaction network implicated in merozoite invasion (48); and 4) the pfd1130w gene lies 109 
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in close proximity to genes encoding proteins known to be involved in RBC invasion, such as 110 
reticulocyte-binding homolog 4 (RH4) and reticulocyte-binding homolog 5 (RH5) proteins, 111 
SURFIN4.2, and glideosome-associated protein with multiplemembrane spans 2 (GAPM2) 112 
(Fig. 1) (52–55). On the basis of these data, we selected PFD1130w for generation of mouse 113 
mAbs (56), which allowed us further to characterize the protein and to perform functional 114 
assays.  115 
In this study we carried out an in-depth characterization of PFD1130w and demonstrate its 116 
potential as a malaria asexual blood-stage vaccine candidate. PFD1130w is a conserved 117 
cysteine-rich protein that we designated cysteine-rich protective Ag (CyRPA). Our data on 118 
localization, stage-specific expression pattern, and functional assays suggest a role of CyRPA 119 
in erythrocyte invasion by the merozoite. Importantly, CyRPA elicits Abs that inhibit 120 
merozoite invasion in vitro and in vivo. Furthermore, our passive immunization studies in P. 121 
falciparum-infected NOD-scid IL2Rgnull mice with anti-CyRPA mAbs identified this animal 122 
model as an unprecedented system to quantitatively evaluate functional potencies of malaria- 123 
specific Abs. 124 
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Materials and Methods  126 
Ethics statement  127 
This study was carried out in strict accordance with the Rules and Regulations for the 128 
Protection of Animal Rights (Tierschutzverordnung) of the Swiss Bundesamt fu ̈r 129 
Veterina ̈rwesen. The protocol was ethically approved by the Ethikkommission beider Basel 130 
(Permit Number 2375). Human sera were obtained from adult volunteers after receiving 131 
written informed consent. Ethical clearance was obtained from the institutional ethical review 132 
board of the Navrongo Health Research Center (Navrongo, Ghana).  133 
Culture of parasites  134 
P. falciparum strains 3D7, 7G8, D6, W2mef, and K1 were cultured essentially as described 135 
previously (57). The culture medium was supplemented with 0.5% AlbuMAX (Life 136 
Technologies) as a substitute for human serum (58). Cultures were synchronized by sorbitol 137 
treatment (59). Erythrocytes for passages were obtained from the Swiss Red Cross (Basel, 138 
Switzerland).  139 
Isolation of free merozoites  140 
To obtain P. falciparum merozoites, erythrocytes infected with highly synchronous schizont- 141 
stage parasites were centrifuged at 700 3 g for 5 min to separate released merozoites from 142 
unruptured schizonts and uninfected erythrocytes. Supernatants containing free merozoites 143 
were centrifuged at 3000 3 g for 10 min to collect merozoites.  144 
Western blot analysis  145 
Blood-stage parasite lysates were prepared essentially as described previously by saponin 146 
lysis of P. falciparum 3D7-infected erythrocytes (57). In brief, cultured parasites were washed 147 
once with PBS. Pelleted infected RBCs were lysed in 20 volumes of 0.06% (w/v) saponin in 148 
PBS for 20 min. Parasites were washed, and the final pellet was resuspended in 3 volumes of 149 
PBS and stored at 280 ̊C until further use.  150 
Cell lysate of transfected HEK cells was prepared as described previously (56).  151 
For SDS-PAGE, cell or parasite lysate was resolved on precast 4–12% gradient gels 152 
(NuPAGE Novex 4–12% Bis-Tris Gel; Invitrogen) with MES running buffer according to the 153 
manufacturer’s directions. The proteins were electrophoretically transferred to nitrocellulose 154 
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membrane using a dry-blotting system (iBlot; Invitrogen). After blocking the membrane, 155 
specific proteins were detected with appropriate dilutions of anti-CyRPA mAbs (56) or anti– 156 
hexa-his tag mAb (56) followed by HRP-conjugated goat anti-mouse IgG mAb (Kirkegaard 157 
& Perry Laboratories). Blots were developed using ECL Western blotting detection reagents 158 
(ECL Western Blotting Substrate; Pierce).  159 
Immunofluorescence staining of infected erythrocytes and free merozoites  160 
For indirect immunofluorescence microscopy, smears of infected RBCs were fixed in 60% 161 
methanol and 40% acetone for 2 min at 220 ̊C and blocked with 1% BSA in PBS. Isolated 162 
free merozoites were spotted and fixed onto L-lysine–coated multitest glass slides as 163 
described previously (60). Cells were probed with the following primary or secondary Abs: 164 
biotin-labeled mouse anti-CyRPA mAb c06 (56), Alexa 488-labeled mouse anti–RAP-1 5-2 165 
mAb (61), Alexa 488-labeled mouse anti–AMA-1 DV5a mAb (60), Alexa 488-labeled mouse 166 
anti–MSP-1 MC7.2 mAb (G. Pluschke, unpublished observations), Alexa 488-labeled mouse 167 
anti–GAPDH 1.4a mAb (62), anti–MSP-2 rabbit serum (MRA-318; Malaria Research and 168 
Reference Reagent Resource Center), anti–MSP-4 rabbit serum (63), anti–MSP-5 rabbit 169 
serum (64), Alexa 568-labeled streptavidin (Invitrogen), and Alexa 488-labeled chicken anti- 170 
rabbit IgG (H+L) (Invitrogen). The slides were mounted in mounting medium containing 171 
DAPI (ProLong Gold antifade reagent with DAPI; Invitrogen). Fluorescence microscopy was 172 
performed on a Leica DM-5000B using a 360 oil immersion objective lens and documented 173 
with a Leica DFC300FX digital camera system. Images were processed using Leica 174 
Application Suite and Adobe Photoshop CS3.  175 
Immunofluorescence staining of live versus fixed merozoites  176 
Isolated merozoites were incubated with Alexa 488-labeled mouse anti– MSP-1 MC7.2 mAb 177 
(G. Pluschke, unpublished observations), Alexa 488-labeled mouse anti-GAPDH 1.4a mAb 178 
(62), or biotin-labeled mouse anti-CyRPA mAb c06 (56) and Alexa 568-labeled streptavidin 179 
(Invitrogen) diluted in parasite culture medium. Thereafter, cells were washed two times with 180 
PBS and then fixed 30 min in 4% PFA in PBS. For staining of fixed merozoites, cells were 181 
first incubated for 30 min in 4% PFA and thereafter immunofluorescence-stained as described 182 
earlier. Cells were mounted in mounting medium containing DAPI (ProLong Gold antifade 183 
reagent with DAPI; Invitrogen). Fluorescence microscopy was performed as described earlier.  184 
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In vitro growth inhibition assay  185 
In vitro growth inhibition assays with P. falciparum strains 3d7, 7G8, D6, W2mef, and K1 186 
were conducted essentially as described (60). Each culture was set up in triplicate in 96-well 187 
flat-bottom culture plates. Viable parasites were stained with hydroethidine and analyzed in a 188 
FACScan flow cytometer (Becton Dickinson, San Jose, CA) using CellQuest software. A 189 
total of 30,000 cells per sample were analyzed. Percent inhibition was calculated from the 190 
mean parasitemia of triplicate test and control wells as follows: percent inhibition = (control – 191 
test)/(control/100).  192 
In vivo growth inhibition assay  193 
Abs were tested in the murine P. falciparum model essentially as described (65). The only 194 
modification implemented was that daily human blood injections (0.75 ml) were administered 195 
by the i.v. route instead of the i.p. route. Once parasitemia reached .0.5%, mice received a 196 
single dose of 0.5, 2.5, or 5 mg mAb in PBS by i.v. injection. Thereafter, parasitemia was 197 
measured for the next 5 d. To monitor serum levels of administered Abs, serum samples were 198 
taken just before, 1 d, and 5 d after mAb injection.  199 
For the transfer experiment, blood cells of mice having previously received 2.5 mg anti- 200 
CyRPA mAb c12 were washed with 0.9% NaCl and used to infect naive human erythrocyte 201 
engrafted NOD-scid IL2Rgnull mice.  202 
ELISA  203 
Detection of CyRPA-specific and MSP-1–specific Abs in human sera by ELISA. Human 204 
serum samples were derived from healthy Swiss adults with no history of malaria exposure 205 
(66) and from healthy individuals between 5 and 20 y of age living in the malaria endemic 206 
(67) Kassena-Nankana District in northern Ghana. ELISA plates (Maxisorp; Nunc) were 207 
coated with 10 mg/ml purified recombinant CyRPA protein produced in HEK cells or purified 208 
recombinant MSP-1 (aa 34–595) or MSP-1 (aa 1250– 1563) produced in Escherichia coli 209 
(68). After blocking, plates were incubated with dilutions of human serum. Alkaline 210 
phosphatase-conjugated goat anti-human IgG F(ab9)2 (Jackson ImmunoResearch 211 
Laboratories) was used as secondary Ab and p-nitrophenyl phosphate was used as substrate 212 
(Sigma). The OD of the reaction product was recorded at 405 nm with a microplate 213 
absorbance reader (Sunrise Absorbance Reader; Tecan).  214 
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Ab competition ELISA. Plates were coated with 10 mg/ml purified recombinant CyRPA 215 
protein produced in E. coli. After blocking, plates were incubated with 10 mg/ml, 1 mg/ml, or 216 
0 mg/ml of different anti-CyRPA mAbs (c02, c04, c05, c06, c08, c09, c10, c12, c13). After 30 217 
min, different biotinylated anti-CyRPA mAbs (c02, c04, c05, c06, c08, c09, c10, c12, c13) 218 
were added to each well resulting in a concentration of 1 mg/ml of labeled Abs. HRP- 219 
conjugated streptavidin (GenScript) was used as detecting agent, and tetramethylbenzidine 220 
substrate (Pierce Western Blotting Substrate; Pierce) was used for development. The reaction 221 
was stopped with 0.5 M H2SO4, and the OD was measured at 450 nm.  222 
Culture of eukaryotic cells  223 
The human embryonic kidney cell line 293 HEK was obtained from the American Type 224 
Culture Collection (ATCC CRL-1573). 293 HEK cells were cultured in IMDM supplemented 225 
with 10% FCS, glutamine, and penicillin/ streptomycin at 37 ̊C in a humidified incubator.  226 
Expression of CyRPA protein fragments on HEK cell surface  227 
DNA sequences that encode fragments of CyRPA protein were amplified by PCR from a 228 
plasmid containing the codon-optimized sequence of PFD1130w. Primers used for 229 
amplification were as follows: Fr26-251, 3910 (59-CCAATgctagcGGCATAAATTG-39) and 230 
3913 (59-ATAAGAATgcggccgcTTTCACATTATTGATGTTGTCTCCA-39); Fr127-352, 231 
3912 (59-ATACTAgctagcCGTAAGAAGGATATGACTTGTCACAG-39) and 3905 (59- 232 
TCGGTACCTCGCGAATGC-39); Fr26-142, 3910 and 3911 (59- 233 
ATAAGATAgcggccgcCTTACCGTCATTTGAATAGAACCT-39); Fr127-251, 3912 and 234 
3913; Fr236-352, 3886 (59-gctagcGACCTGTCCTTTCACTTTTATGTTG-39) and 3887 (59- 235 
gcggccgcGTTGTAAATGCCCTGGGATG-39); Fr26-181, 3910 and 3939 (59- 236 
ATAAGAATgcggccgcCCCGCAGATGAGGAAGTAC-39); Fr74-181, 3938 (59- 237 
ATACTAgctagcGAGACCCATATCTACGTGCAG-39) and 3939; Fr74-251, 3938 and 3913. 238 
Amplifications were performed using FIREPol DNA polymerase (Solis Biodyne) according 239 
to the manufacturer’s protocol with the following profile: 5 min, 95 ̊C; 30 3 (30 s, 95 ̊C; 30 s, 240 
60 ̊C; 2 min, 72 ̊C); 6 min, 72 ̊C. The amplicons were digested with restriction endonucleases 241 
NheI and NotI (New England Biolabs) and then ligated into a pcDNA3.1-based expression 242 
vector (56). This expression vector allows surface expression of a protein of interest. It 243 
contains the secretion signal of bee-venom melittin, a cloning site for the  244 
protein of interest, a FLAG tag, a transmembrane domain of mouse glycophorin-A, and a 245 
hexa-his tag. The 293 HEK cells were transfected with the different expression vectors using 246 
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JetPEI transfection reagent (PolyPlus) according to the manufacturer’s protocol. One to two 247 
days later, transient transfectants were used for Western blot analysis or immunofluorescence 248 
staining  249 
Immunofluorescence staining of living transfected HEK cells  250 
Immunofluorescence staining of live HEK cells was performed in chamber slides (8-well 251 
chamber-slide, Lab-Tek; Nunc). HEK cells (12,000 cells/ well) were seeded and 4 d later 252 
transfected with different expression vectors. The following day, immunofluorescence 253 
stainings were performed by incubating the wells with 100 mg/ml anti-CyRPA mAb diluted 254 
in IMDM for 30 min on ice. After washing, cells were fixed for 30 min with 4% 255 
formaldehyde in PBS. After washing, cells were incubated for 30 min with Cy3-labeled goat 256 
anti-mouse IgG F(ab9)2 (Jackson ImmunoResearch Laboratories) diluted in PBS and washed 257 
four times with PBS. Slides were mounted with mounting solution containing DAPI (ProLong 258 
Gold antifade reagent with DAPI; Invitrogen). Stainings were assessed by fluorescence 259 
microscopy as described earlier.  260 
Bacterial strains and media  261 
E. coli strain Top10 (TOP10 Chemically Competent E. coli Cells; Invitrogen) was used for 262 
the amplification of plasmids. E. coli strain BL 21 Star (DE3) (Invitrogen) was used for 263 
recombinant expression of CyRPA protein. Bacteria were grown in lysogen broth medium 264 
containing 100 mg/ ml ampicillin.  265 
Recombinant protein expression and purification  266 
CyRPA (aa 26–352) was recombinantly expressed in E. coli using the pET28a expression 267 
system (Novagen, modified to contain an ampicillin selection cassette). Briefly, a PCR 268 
product of CyRPA was generated from a plasmid containing the sequence of PFD1130w 269 
using primer 59-ATGCCATGGGCATAAATTGTGACAGCC-39 and 59- 270 
CCGCTCGAGGTTGTAAATGCCCTGGGA-39. The amplicon was digested with restriction 271 
endonucleases NcoI and XhoI (New England Biolabs) and cloned into NcoI and XhoI sites of 272 
pET28a. Protein expression in E. coli BL 21 Star (DE3) (Invitrogen) was induced by addition 273 
of 1 mM isopropyl thiogalactoside (Calbiochem) for 2 h at 37 ̊C. The recombinant protein 274 
was purified from inclusion bodies using denaturing conditions (8 M urea, 500 mM NaCl, 20 275 
mM Tris-HCl, 5 mM imidazole) by Ni-NTA chromatography. The purity and integrity of the 276 
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purified protein was analyzed by SDS-PAGE, and the protein concentration was determined 277 
by measuring OD280. The purified recombinant protein was identified as the expected 278 
CyRPA protein by Western blot analysis with CyRPA-specific mAbs.  279 
Hexa-his–tagged recombinant proteins corresponding to aa 34–595 and aa 1250–1563 of 280 
MSP-1 of P. falciparum MAD20 were a kind gift of Bela Takacs (Pharma Research Basel, F. 281 
Hoffmann-La Roche, Basel, Switzerland [retired]). Proteins were produced in E. coli and 282 
purified by Ni-NTA chromatography (68).  283 
CyRPA was recombinantly expressed in HEK cells. The codon-optimized sequence of 284 
PFD1130w corresponding to aa 22–362 was cloned into a pcDNA3.1-based expression 285 
vector. This expression vector allows secretion of the protein of interest. It contains the 286 
secretion signal of bee-venom melittin, a cloning site for the protein of interest, and a C- 287 
terminal hexa-his tag. 293 HEK cells were stably transfected with the expression vector using 288 
JetPEI transfection reagent (PolyPlus) according to the manufacturer’s protocol, and clones 289 
were generated by limiting dilution. For recombinant protein production, transfected cells 290 
were cultured in serum-free medium (Panserin 293A; PAN Biotech). The recombinant protein 291 
was purified from culture supernatant by Ni-NTA chromatography. The purity and integrity 292 
of the purified protein was analyzed by SDS-PAGE. The purified recombinant protein was 293 
identified as the expected CyRPA protein by Western blot analysis with CyRPA-specific 294 
mAbs.  295 
Analysis for binding of soluble CyRPA to RBCs by flow cytometry  296 
Human RBCs were incubated with 100, 20, 4, or 0 mg/ml purified recombinant CyRPA 297 
(produced in HEK cells) diluted in PBS, 1% BSA. Surface-bound protein was detected by 298 
incubating cells with 100 mg/ml anti–hexa-his tag mAb 6/9 (56) and subsequently with Alexa 299 
Fluor 568 donkey anti-mouse IgG (H+L) conjugate. FACS analysis was performed on a 300 
FACScan (Becton Dickinson) using CellQuest software (Becton Dickinson), and 30,000 301 
events were collected for each sample.  302 
Analysis for binding of human RBCs to CyRPA expressed on HEK cells  303 
Human RBCs were incubated with 50% confluent stably transfected HEK cells expressing 304 
recombinant CyRPA on the cell surface (56) for 2 or 24 h. After repeated washing with 305 
culture medium, RBCs attached to HEK cells were assessed by microscopy.  306 
Surface plasmon resonance analysis of anti-CyRPA mAb– CyRPA interaction  307 
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The affinities of the anti-CyRPA mAbs for CyRPA were determined with an optical biosensor 308 
using the real-time surface plasmon resonance (SPR) technology (BIAcore 3000; Pharmacia 309 
Biacore) at 35 ̊C. About 2000 response units of goat anti-mouse IgG (H+L) (Jackson 310 
ImmunoResearch) were coupled to CM5 sensor chip by using N-hydroxysuccinimide and 1- 311 
ethyl-3-(3-dimethylaminopropyl)-carbodiimide. Approximately 350 response units of anti- 312 
CyRPA mAbs in PBS were captured onto the surface. The purified recombinant CyRPA 313 
produced in HEK cells at concentrations ranging from 400 to 3.1 nM was injected for 2 min 314 
using a flow rate of 50 ml/min. Dissociation of bound Ag in PBS was followed for 5 min. The 315 
surfaces were regenerated after each cycle. Equilibrium dissociation constant (KD) was 316 
calculated from the ratio of the dissociation and association rate constants obtained with the 317 
BIAevaluation 2.1 software using a 1:1 binding model with mass transfer.  318 
Sequencing the CyRPA gene of different strains  319 
Genomic DNA was prepared from P. falciparum strains 3D7, MAD20, FC27, RFCR3, 320 
W2met, Hb3, Ro-33, 7G8, K1 FCR3, ITG2F6, FVO, IFA4, IFA6, IFA10, IFA12, IFA18, and 321 
IFA19 and used for PCR amplification of PFD1130w. PFD1130w was amplified in three 322 
overlapping fragments with the following primer combinations: 5’- 323 
AAAATTTTGTAGGAAATGTTGAGAA-3’ and 5’-AAAACGATGACAAGTCATATCCT 324 
TC-3’; 5’-TGTTCCTTGTATTCGTGATATGTTTT-3’ and 5’-TCATCATTTAATGTAGAA  325 
ACATCTTGA-3’; 5’-TGACAATTACAAATTAGGTGTGCAA-3’ and 5’-CAAATATGAT 326 
GATTGTTGAATGGTT-3’. Amplifications were performed using DreamTaq DNA 327 
polymerase (Fermentas Life Sciences) according to the manufacturer’s protocol with the 328 
following profile: 5 min, 95 ̊C; 35 3 (30 s, 95 ̊C; 30 s, 60 ̊C; 2 min, 72 ̊C); 6 min, 72 ̊C. 329 
Amplicons were purified and subjected to direct sequencing (Macrogen, Seoul, South Korea). 330 
Sequences were analyzed using AutoAssembler 1.4.0 software (Applied Biosystems, 331 
PerkinElmer).  332 
Accession numbers for all genes and proteins mentioned in this study  333 
Sequences of genes and proteins mentioned in this study can be found on PlasmoDB 334 
(http://plasmodb.org/plasmo/) with the following accession numbers: P. falciparum CyRPA 335 
(PFD1130w), P. vivax CyRPA (PVX_090240), P. knowlesi CyRPA (PKH_052740), P. 336 
falciparum MSP-1 (PFI1475w), P. falciparum MSP-2 (PFB0300c), P. falciparum MSP-3 337 
(PF10_0345), P. falciparum MSP-4 (PFB0310c), P. falciparum MSP-5 (PFB0305c), P. 338 
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falciparum AMA-1 (PF11_0344), P. falciparum EBA-175 (MAL7P1.176), P. falciparum 339 
GLURP (PF10_0344), P. falciparum SERA5 (PFB0340c), P. falciparum RH4 (PFD1150c), 340 
P. falciparum RH5 (PFD1145c), P. falciparum SURFIN4.2 (PFD1160c), P. falciparum 341 
GAPM2 (PFD1110w), P. falciparum PSOP12 (PFE0680), and P. falciparum GAPDH 342 
(PF14_0598).  343 
  344 
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Results 345 
Sequence analysis of P. falciparum CyRPA  346 
pfd1130w/cyrpa is 1188 bp long with a 99-bp intron and is localized in the subtelomeric 347 
region of chromosome 4 in close proximity to genes encoding proteins known to be involved 348 
in RBC invasion, such as RH4 and RH5, SURFIN4.2, and GAPM2 (Fig. 1) (52–55).  349 
 350 
 351 
 352 
FIGURE 1. The CyRPA encoding gene (dark gray) is positioned in the subtelomeric region of chromosome 4. ORFs in close 353 
proximity include genes encoding GAPM2, RH4 and RH5, and SURFIN4.2. These proteins are known or presumed to be 354 
involved in merozoite invasion (52–55). Positional data were obtained from PlasmoDB (http://www.plasmoDB.org).  355 
The hypothetical protein encoded by pfd1130w is predicted to contain an N-terminal secretion 356 
signal peptide. Orthologs of CyRPA are only present in the genomes of P. knowlesi 357 
(PKH_052740) and P. vivax (PVX_090240) and are absent in Plasmodium species infecting 358 
rodents. Comparison of these protein sequences revealed conservation with 36% and 38% 359 
identity of P. falciparum CyRPA with the P. knowlesi and the P. vivax orthologs, 360 
respectively. Furthermore, cysteine residues in the orthologs are positionally conserved (Fig. 361 
2). BLAST search identified the mosquito-stage protein PSOP12 (PFE0680) as paralog of 362 
CyRPA (69). This protein shares nine positionally conserved cysteine residues in the 363 
homologous N-terminal part, but additionally has a 6-cysteine-protein domain at the C 364 
terminus (70).  365 
CyRPA is nonpolymorphic  366 
To assess potential sequence diversity of the CyRPA protein, cyrpa genes of 12 P. falciparum 367 
standard strains from different geographical origin (3D7, K1, MAD20, FC27, FCR3, RFCR3, 368 
W2met, Hb3, Ro-33, 7G8, ITG2F6, and FVO) and six field isolates from Tanzania (IFA4, 369 
IFA6, IFA10, IFA12, IFA18, and IFA19) were amplified by PCR and sequenced. Apart from 370 
one nonsynonymous single nucleotide polymorphism (SNP) at base pair position 1116 in P. 371 
falciparum strains K1, FCR3, ITG2F6, and FVO, all sequences obtained were identical to the 372 
P. falciparum 3D7 reference sequence. In the protein sequence, this SNP results in an 373 
arginine/serine dimorphism at amino acid position 339 (Fig. 2).  374 
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 375 
 376 
FIGURE 2. Amino acid sequence alignment of P. falciparum CyRPA with orthologs in P. knowlesi and P. vivax. Full- 377 
length putative orthologs of P. falciparum CyRPA are only found in the genomes of P. vivax (PVX_090240) and P. knowlesi 378 
(PKH_052740). Sequence identities are 38 and 36%, respectively. Asterisk (*), identical; colon (:), conservation between 379 
groups of strongly similar properties; period (.), conservation between groups of weakly similar properties substitution. Ten 380 
of twelve cysteine residues are positionally conserved (shaded in gray). Amino acid residues of the predicted secretion signal 381 
sequences are indicated in boldface. DNA-sequencing of the cyrpa gene of a set of P. falciparum strains revealed one 382 
nonsynonymous SNP at base pair position 1116. Hence, at amino acid residue 339 (framed), the strains 3D7 (airport 383 
malaria), MAD20 (PNG), FC27 (PNG), RFCR3 (The Gambia), W2met (Indochina), Hb3 (Honduras), Ro-33 (Ghana), 7G8 384 
(Brazil), IFA4 (Tanzania), IFA6 (Tanzania), IFA10 (Tanzania), IFA12 (Tanzania), IFA18 (Tanzania), and IFA19 (Tanzania) 385 
encode an arginine residue, whereas strains K1 (Thailand), FCR3 (The Gambia), ITG2F6 (Brazil), and FVO (Vietnam) 386 
encode a serine residue.  387 
  388 
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Stage-specific expression of CyRPA in schizonts and free merozoites  389 
The PFD1130w gene encodes a 362-aa-long protein with a predicted molecular mass of 42.8 390 
kDa. Using highly synchronized asexual blood-stage parasite cultures, we assessed the 391 
expression profile of CyRPA in P. falciparum across the intraerythrocytic developmental 392 
cycle at the protein level by Western blot analysis with CyRPA-specific mAbs at 8-h 393 
intervals. A discrete band of 36 kDa was detected in schizont stages, free merozoites, and 394 
very early ring stages but not in late ring and early trophozoite stages (Fig. 3A). Stage- 395 
specific expression of CyRPA in schizont stages and free merozoites was affirmed by indirect 396 
immunofluorescence staining of synchronized blood-stage parasites with anti-CyRPA mAbs 397 
(Fig. 3B). These results are in agreement with transcriptional data for PFD1130w, showing 398 
elevated transcript levels in late stages of the asexual blood cycle of P. falciparum with 399 
maximal expression measured at 40 to 48 h postinvasion (46, 47, 71). Additionally, mass 400 
spectrometry-based evidence for expression of PFD1130w was reported in schizont stages 401 
(72).  402 
 403 
 404 
FIGURE 3. Stage-specific expression of CyRPA in late asexual blood-stage parasites. (A) Western blot analysis with lysates 405 
of tightly synchronized P. falciparum 3D7 blood-stage parasites with anti-CyRPA mAb c12 (upper panel). The blot was 406 
probed for equal loading with an anti-GAPDH mAb (lower panel). 1-4, 4-12, 12-20, 20-28, 28-36, 36-44, 44-52: hours 407 
postinvasion. M: free merozoites. (B) Indirect immunofluorescence stainings of asexual blood-stage parasites confirmed 408 
stage-specific expression in schizont stages and free merozoites. Methanol/acetone fixed P. falciparum 3D7 parasites were 409 
probed with anti-CyRPA mAb c06 (red) and anti-GAPDH mAb (green). Exposure times were identical for all pictures of the 410 
same channel. Nuclei were stained with DAPI (blue). Original magnification 31008.  411 
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CyRPA is localized at the merozoite apex  412 
CyRPA has a putative N-terminal secretion signal sequence and is cysteine-rich (Fig. 2). In 413 
contrast to fixed merozoites, CyRPA could not be stained with specific mAbs in live 414 
merozoites, indicating that the Ag is located intracellularly in free merozoites (Supplemental 415 
Fig. 1). To determine the localization of CyRPA in schizont stages and free merozoites more 416 
accurately, we performed colocalization studies using Abs specific for the cytosol (GAPDH), 417 
the micronemes (AMA-1) (73), the rhoptry bulb (RAP-1) (74), and the merozoite surface 418 
[MSP-1 (75) and MSP-5 (64)] (Fig. 4). The pattern of CyRPA staining in free merozoites 419 
included a dot toward the merozoite apical end and a weaker staining dispersed over the 420 
anterior pole of the merozoite. The apical dot did not colocalize with micronemes or rhoptry 421 
bulbs. But stainings of CyRPA resembled MSP-5–specific stainings. Apical dots of MSP-5 422 
and CyRPA largely overlayed, but the degree of additional faint staining of the merozoite 423 
body differed, being spread over the anterior part for CyRPA and just at the apical pole for 424 
MSP-5. Accordingly, schizonts were stained by CyRPA-specific mAbs in a patchy to dotty 425 
manner, not colocalizing with rhoptry bulbs or micronemes. CyRPA-specific and MSP-5– 426 
specific stainings showed a relatively similar pattern. Hence, CyRPA localizes to an apical 427 
structure distinct from rhoptry bulbs and micronemes.  428 
 429 
 430 
FIGURE 4. Localization of CyRPA to the merozoite apex by immunofluorescence staining. P. falciparum 3D7 merozoites 431 
(A) or schizont stages (B) were coimmunostained with anti-CyRPA mAb c06 (red) and anti-GAPDH Abs (marker for 432 
cytosol), AMA-1 (marker for micronemes), RAP-1 (marker for rhoptry bulbs), MSP-1 (marker for merozoite surface), or 433 
MSP-5 (green). Nuclei were stained with DAPI (blue). Original magnification 31008.  434 
  435 
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Anti-CyRPA mAbs inhibit merozoite invasion in vitro  436 
Considering the apical localization of CyRPA, and as CyRPA was predicted to be implicated 437 
in merozoite invasion (48), we assessed anti-CyRPA mAbs for in vitro parasite growth 438 
inhibitory activity. Growth inhibition assays were conducted for two cycles of merozoite 439 
invasion. Of the anti-CyRPA mAbs tested, seven out of nine consistently inhibited growth of 440 
all five tested P. falciparum strains in a concentration-dependent manner (Fig. 5A, 441 
Supplemental Fig. 2). At a concentration of 1000 mg/ml, the anti-CyRPA mAb c12 inhibited 442 
parasite growth by 58.0 6 2.8%. In contrast, anti-CyRPA mAb c05 had no effect on parasite 443 
growth, and anti-CyRPA mAb c13 exerted only marginal growth inhibitory activity even at 444 
high concentrations (Fig. 5A). All mAbs tested were produced and purified in parallel in the 445 
same manner, and results were reproducible with independent mAb production batches (data 446 
not shown).  447 
To identify the step at which the anti-CyRPA mAbs exert their effect, parasite growth was 448 
compared in the presence or absence of inhibitory mAbs during one blood-stage cycle of 449 
highly synchronized parasites. Anti-CyRPA mAb c12 (250 mg/ml) was added to early ring 450 
stages, and parasitemia was monitored after 13, 27, and 31 h by flow cytometry. No 451 
significant difference in the development of trophozoites from ring stages was observed at 452 
any time point compared with the PBS control (Fig. 5C). When the anti-CyRPA mAb c12 453 
was added to a synchronized parasite culture at the schizont stage and parasitemia was 454 
monitored during development into new ring and subsequently into trophozoite stages, a 455 
significant reduction in parasitemia compared with the PBS control was measured (Fig. 5C). 456 
This reduction emerged as soon as the parasitized erythrocytes had ruptured and the released 457 
merozoites had infected new erythrocytes (p = 0.0283 for the difference in parasitemia of PBS 458 
versus anti-CyRPA mAb samples at time point +15 h; two-sided t test). In contrast, the 459 
subsequent development of the intraerythrocytic parasites from ring stages into trophozoites 460 
was not affected by the mAbs. These results verify that the parasite growth inhibitory activity 461 
of anti-CyRPA mAbs is not due to inhibition of intracellular parasite development but due to 462 
specific inhibition of merozoite invasion.  463 
 464 
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 466 
FIGURE 5. CyRPA-specific mAbs inhibit parasite growth in vitro. (A) Synchronized P. falciparum 3D7 blood-stage 467 
parasites were cultured for two cycles in the presence of different concentrations of purified anti-CyRPA mAbs c05, c10, 468 
c12, and c13. Percent parasite growth inhibition was calculated against the parasitemia of PBS control wells. Anti–hexa-his 469 
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tag mAb was used as negative control mAb. Each symbol represents the mean of a triplicate experiment, and error bars 470 
indicate the SD. (B) Synchronized P. falciparum 3D7 blood-stage parasites were cultured for two cycles in the presence of 471 
various combinations of different anti-CyRPA mAbs. Percent parasite growth inhibition was calculated against the 472 
parasitemia of PBS control wells. Anti-6xHis tag mAb was used as negative control mAb. Each symbol represents the mean 473 
of a triplicate experiment, and error bars indicate the SD. (C) Left: Anti-CyRPA mAb c12 (circles) was added to highly 474 
synchronous early ring stages, and parasitemia was monitored during development into trophozoite stages and compared with 475 
PBS controls (squares). Parasitemia was measured after 0, 13, 21, and 37 h. Right: Anti-CyRPA mAb c12 (circles) was 476 
added to highly synchronous schizont stages, and parasitemia was monitored during the infection of new erythrocytes and the 477 
development into ring and trophozoite stages and compared with the PBS control (squares). Parasitemia was measured after 478 
0, 15, 24, 39, and 48 h. Each symbol represents the mean of a duplicate experiment, and error bars indicate the SD. Black 479 
symbols, total parasitemia; gray symbols, ring stages; white symbols, trophozoite stages. Asterisks indicate significant 480 
differences in total parasitemia between Ab-treated cultures and control cultures (unpaired t test); *p , 0.05, **p , 0.05.  481 
Anti-CyRPA mAbs inhibit parasite growth in vivo  482 
CyRPA has no orthologs in the rodent malarial species and therefore cannot be studied with 483 
conventional mouse models with rodent parasites. Therefore, we evaluated the in vivo parasite 484 
inhibitory activity of anti-CyRPA mAbs in a P. falciparum SCID mouse model. This model 485 
uses nonmyelodepleted NOD-scid IL2Rgnull mice engrafted with human erythrocytes to allow 486 
the growth of P. falciparum (65). Groups of three mice with a parasitemia of 0.87 6 0.12% 487 
were injected once with 0.5, 2.5, or 5 mg anti-CyRPA mAb c12, respectively. The control 488 
group received 2.5 mg subclass-matched control mAb (hexa-his tag-specific). Parasitemia of 489 
all mice was monitored for the next 5 d (Fig. 6A). In mice that had received the control mAb, 490 
a sigmoidal increase in parasitemia was measured, reaching 21.0 6 3.6% on day 6. 491 
Parasitemia in mice having received 2.5 mg anti-CyRPA mAb 13, which has shown a very 492 
weak in vitro growth inhibitory effect, increased similarly. In contrast, parasitemia of mice 493 
having received 2.5 or 5 mg anti-CyRPA mAb c12 increased only marginally, reaching 3.5 6 494 
1.2% and 3.7 6 1.1% on day 6. The difference in parasitemia on day 6 in mice receiving 2.5 495 
mg mAb c12 compared with the negative control group was highly significant (two-sided t 496 
test; p = 0.0013). Also, a five times lower dose of mAb c12 (0.5 mg) still reduced parasite 497 
growth (15.0 6 1.2% parasitemia on day 6). Titration of mAbs in the circulation of the 498 
passively protected mice by ELISA showed that Ab levels remained high over the entire 499 
study period, ranging from 57 to 117% on day 6 compared with day 2, and 500 
immunofluorescence staining of persisting parasites showed that they still expressed CyRPA 501 
(data not shown).  502 
On day 6, blood cells of mice having received 2.5 mg anti-CyRPA mAb c12 were used in a 503 
follow-up experiment to infect three naive groups of NOD-scid IL2Rgnull mice engrafted with 504 
human erythrocytes (Fig. 6B). A rapid and continuous increase in parasitemia indicated good 505 
viability of the transferred parasites (14.7 6 1.3% parasitemia on day 6 in the untreated 506 
group). To assess if parasites growing in anti-CyRPA mAb c12-treated mice (Fig. 6A) have 507 
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developed resistance to Ab inhibition, recipient mice were treated with a single i.v. injection 508 
of 2.5 mg anti-CyRPA mAb c12 (Fig. 6B). Again, parasitemia was significantly reduced in 509 
comparison with mice treated with an isotype-matched control mAb (two-sided t test day 6, p 510 
= 0.0001).  511 
 512 
 513 
 514 
FIGURE 6. CyRPA-specific mAbs inhibit parasite growth in the NOD-scid IL2Rgnull mouse model. (A) P. falciparum- 515 
infected NOD-scid IL2Rgnull mice received purified anti-CyRPA mAbs or isotype/subclass-matched control mAbs by i.v. 516 
injection. The arrow indicates the day of mAb injection, and values are the mean parasitemia in peripheral blood of three 517 
mice per group. Data are means 6 SD. (B) On day 6, blood cells of mice having received 2.5 mg anti-CyRPA mAb c12 were 518 
used to infect fresh NOD-scid IL2Rgnull mice. Once parasitemia exceeded 0.5%, mice received a single dose of 2.5 mg anti- 519 
CyRPA mAb c12 or control mAb by i.v. injection. Parasitemia was monitored over the next 5 d. Data are mean parasitemia 520 
of three mice per group 6 SD.  521 
  522 
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Fine specificity of anti-CyRPA mAbs  523 
Of nine CyRPA-specific mAbs analyzed, two (c05 and c13) showed no or borderline growth 524 
inhibitory effect, and seven (c02, c04, c06, c08, c09, c10, and c12) showed inhibitory activity. 525 
To explain these differences in biological activity, affinities as well as fine specificities of the 526 
anti-CyRPA mAbs were assessed.  527 
SPR with immobilized anti-CyRPA mAbs and recombinant CyRPA injected at various 528 
concentrations was used to analyze binding association and dissociation (Supplemental Fig. 529 
3). All mAbs showed similar on-rates and slightly varying off-rates resulting in KDs ranging 530 
from low nanomolar to low picomolar. However, no correlation between affinity and growth 531 
inhibitory activity was observed.  532 
Additionally, the fine specificities of the different mAbs were analyzed. First, Ab–Ab 533 
competition experiments were performed by ELISA using plates coated with recombinant 534 
CyRPA protein expressed in E. coli (Table I). mAbs c02, c04, c06, c08, c09, and c12 535 
competed against each other. These mAbs did not compete with and were not competed by 536 
mAbs c05, c10, and c13. Whereas mAbs c05 and c13 competed with each other, mAb c10 did 537 
not compete with and was not competed by any of the other anti-CyRPA mAbs. According to 538 
these results, the nine mAbs were grouped into three epitope groups (I, II, III), with the two 539 
non-inhibitory mAbs forming epitope group III.  540 
Second, the anti-CyRPA mAbs were tested for their reactivity with overlapping protein 541 
fragments of CyRPA. For this purpose, HEK cells transiently transfected with expression 542 
plasmids encoding fragments of CyRPA comprising aa 26–352, 26–251, 26– 181, 127–352, 543 
236–352, 74–251, 74–181, 26–142, and 127–251 were analyzed by Western blot analysis and 544 
life cell staining. In Western blot analysis, CyRPA-specific mAbs bound to fragments 26– 545 
181, 26–251, and 26–352 but not to the two overlapping subfragments 26–141 and 74–181. 546 
This indicates that all nine mAbs recognize conformational epitopes that are present in 547 
fragment 26–181 but not formed in subfragments 26–141 and 74–181 (Supplemental Fig. 4 548 
and data not shown). Live cell staining of HEK cells expressing the protein fragments on their 549 
cell surface with different anti-CyRPA mAbs revealed five distinctive reactivity patterns (A, 550 
B, C, D, E) (Table I). When combining results from Ab–Ab competition experiments and 551 
epitope mapping, the seven growth inhibitory anti-CyRPA mAbs were classified into three 552 
fine specificity groups. These were distinctive from the fine specificities of the two 553 
noninhibitory mAbs c05 and c13, which were the only mAbs reacting with the N-terminally 554 
truncated fragment comprising aa 74–251 (Table I). The identified dimorphism at amino acid 555 
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position 339 does not lie within the sequence stretch aa 26–181 relevant for binding of the 556 
analyzed anti-CyRPA mAbs (Table I). Accordingly, anti-CyRPA mAb 12 inhibited growth of 557 
P. falciparum strains expressing either variant (3D7 versus K1) (Supplemental Fig. 2B).  558 
 559 
TABLE 1. Fine specificity of anti-CyRPA mAbs.  560 
 561 
 Anti-CyRPA mAb c10 c02 c06 c08 c09 c12 c04 c05 c13 
 Parasite growth inhibition yes yes yes yes yes yes yes no no 
A Antibody-antibody competition ELISA 
  Detecting anti-CyRPA mAb 
 Competing anti-CyRPA mAb c10 c02 c06 c08 c09 c12 c04 c05 c13 
 c10 x − − − − − − − − 
 c02 − x x x x x x − − 
 c06 − x x x x x x − − 
 c08 − x x x x x x − − 
 c09 − x x x x x x − − 
 c12 − x x x x x x − − 
 c04 − x x x x x x − − 
 c05 − − − − − − − x x 
 c13 − − − − − − − x x 
 epitope group I II II II II II II III III 
B Reactivity of anti-CyRRPA mAbs with CyRPA fragments 
  Anti-CyRPA mAb 
 CyRPA fragment  C10 c02 c06 c08 c09 c12 c04 c05 c13 
 
 x x x x x x x x x 
 
 − x x x x x x x x 
 
 − x x x x x x x x 
 
 − − − − − − x* − − 
 
 − − − − − − x* − − 
 
 − − − − − − − x* x* 
 
 − − − − − − − − x* 
 
 − − − − − − − − − 
 
 − − − − − − − − − 
 epitope group A B B B B B C D E 
 562 
(A) Ab–Ab competition ELISA results of nine anti-CyRPA mAbs. According to their competition pattern, mAbs were 563 
assigned to epitope groups I, II, or III. x, Ab competition; 2, no Ab competition.  564 
(B) Capability of nine anti-CyRPA mAbs to bind to fragments of CyRPA expressed on the cell surface of HEK cells assessed 565 
by live-cell immunofluorescence staining. According to their reactivity pattern, mAbs were assigned to epitope groups A, B, 566 
C, D, or E. x, Staining; 2, no staining.  567 
aNo reactivity in Western blot analysis of HEK cell lysates (data not shown).  568 
  569 
26 352 
2 251 
26 18
127 352 
23 352 
74 251 
74 181 
26 142 
127 251 
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Synergistic inhibitory activity of anti-CyRPA mAbs  570 
In vitro growth inhibition assays with combinations of anti-CyRPA mAbs were performed to 571 
assess whether different mAbs functionally interfere with each other (Fig. 5B). The functional 572 
activity of inhibitory anti-CyRPA mAbs was not affected by the addition of the noninhibitory 573 
anti-CyRPA mAb c05 or a malaria-unrelated control mAb. A synergistic inhibitory activity 574 
was measured when combining two inhibitory anti-CyRPA mAbs, which bind to distinct 575 
epitopes: 46.0 6 1.1% and 52.1 6 3.4% growth inhibition was measured for 500 mg/ml of 576 
anti-CyRPA mAb c10 or c12, respectively, but combining 250 mg/ml of either mAb inhibited 577 
parasite growth by 81.6 6 0.3%. In contrast, when combining two inhibitory anti-CyRPA 578 
mAbs with the same fine specificity, only an additive but no synergistic inhibitory effect was 579 
observed.  580 
Natural immunogenicity of CyRPA  581 
To examine if natural exposure to P. falciparum leads to the development of anti-CyRPA 582 
Abs, human sera were analyzed by ELISA for their reactivity with purified recombinant 583 
CyRPA expressed in HEK cells (Fig. 7). Sera were collected from healthy individuals 584 
between 5 and 20 y of age living in the Kassena-Nankana District in northern Ghana where P. 585 
falciparum is highly endemic (67). Sera from healthy Swiss adults without any history of 586 
malaria served as negative control. Whereas sera from malaria-exposed individuals readily 587 
contained IgG specific for two MSP-1–derived recombinant protein fragments (mean OD 588 
0.61 6 0.03 and mean OD 0.50 6 0.02, respectively, at 1:200 serum dilution), basically no 589 
CyRPA-specific IgG was measured (mean OD 0.07 6 0.00 at 1:200 serum dilution).  590 
 591 
 592 
 593 
 594 
 595 
 596 
 597 
 598 
 599 
 600 
 601 
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 602 
FIGURE 7. Analysis of serum from malaria-exposed individuals for presence of CyRPA-specific IgG. Reactivity of human 603 
sera from healthy European adults with no history of malaria exposure or from healthy individuals between 5 and 20 y of age 604 
living in the Kassena-Nankana District in northern Ghana (malaria exposed) with recombinant CyRPA and two recombinant 605 
MSP-1 fragments assessed by ELISA. Shown are IgG levels expressed as OD at 405 nm of serum samples diluted 1:200. 606 
Horizontal lines designate means and SDs of responses.  607 
  608 
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Discussion 609 
With the release of the fully annotated genome of P. falciparum in 2002, genome-wide 610 
searches for potential vaccine candidate Ags have become possible (44, 45). On the basis of 611 
published transcriptome and proteome data, suggesting expression in extracel 612 
lular stages and surface localization, we have selected sets of uncharacterized ORFs for 613 
evaluation of their potential as vaccine candidate Ags (Refs. 46–48, 51, 56 and A. Dreyer, G. 614 
Pluschke, unpublished observations). Among the proteins characterized, CyRPA exhibited 615 
outstanding properties, demonstrating the utility of systematic genome-wide approaches for 616 
vaccine Ag selection. However, for each individual Ag, detailed evaluations, including 617 
functional assays, remain indispensable to evaluate its potential as a vaccine candidate.  618 
One major problem in the development of a malaria asexual blood-stage vaccine is the lack of 619 
functional assays with proven predictive potential. Established assays only assess certain 620 
potential Ab-mediated effector functions against blood-stage parasites (18, 76–78); that is, 621 
growth inhibition by Abs alone or Ab-dependent cellular inhibition. Still, these assays can 622 
provide valuable information on the protein function. Abs against CyRPA on its own showed 623 
a strong parasite growth inhibitory activity. This activity targeted the process of merozoite 624 
invasion into RBCs but not the development of intraerythrocytic stages. These results point 625 
toward a complement- and leukocyte-independent mode of action, such as blocking of 626 
molecular interactions involved in merozoite invasion (26, 28).  627 
Plasmodium in vitro cultures are very sensitive to physiological changes. Thus, the in vitro 628 
growth inhibition assay is criticized for being very sensitive to impurities of Ab preparations 629 
tested. We addressed this by testing more than one independently produced batch of the 630 
individual mAbs and obtained consistent results. Importantly, the mouse in vivo model offers 631 
the advantage of a constant physiological environment given that factors like nutrient supply, 632 
electrolyte balance, and pH are very well controlled by the animal (79). Because P. 633 
falciparum cannot infect rodent erythrocytes and rodent malaria parasites lack many Ags of P. 634 
falciparum, including CyRPA, nonhuman primates or SCID-mice engrafted with human 635 
erythrocytes are the only in vivo models available to study growth inhibitory effects of 636 
CyRPA-specific Abs. It was previously shown that the P. falciparum model in NOD-SCID 637 
mice genetically deficient in IL-2R g-chain (NOD-scid IL2Rgnull) engrafted with human 638 
erythrocytes is a reliable test system for drug evaluation in vivo (65, 80). Also in our hands, 639 
parasite growth in infected NOD-scid IL2Rgnull mice was very consistent and reproducible. 640 
However, this model has never been used previously for passive immunization studies. Anti- 641 
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CyRPA mAbs administered at the beginning of the exponential growth phase exerted a 642 
strong, dose-dependent parasite growth inhibitory effect. To the best of our knowledge, our 643 
study describes the first Ig transfer assay using a P. falciparum murine model in which a 644 
dose-response relationship has been reported. In contrast to the previously described model 645 
(79), this system therefore permits comparison of the relative inhibitory potency of malaria- 646 
specific Abs in vivo. Thus, we propose this model as a reliable in vivo model to test protective 647 
efficacy of vaccine Ags against P. falciparum blood stages.  648 
The NOD/scid-IL2Rgnull mouse model is restricted to passive immunization as mice lack the 649 
adaptive immune system and additionally have deficiencies in the innate immune system (83, 650 
84). However, besides passive immunization with Abs, adoptive transfer of specific effector 651 
immune cells may potentially be studied in this model. Another question left unanswered is 652 
whether this model can be used for the assessment of the other Ab-mediated effector 653 
mechanisms apart from plain neutralization that have been described for blood-stage-specific 654 
Abs (26, 27, 29–32, 81, 82). Such studies may shed light into the relevance of different Ab- 655 
mediated effector mechanisms for in vivo protection.  656 
Growth inhibitory capacities of different anti-CyRPA mAbs assessed in the in vivo model 657 
correlate with the results obtained in the in vitro assays, strengthening credibility of both 658 
systems. The inhibitory effect of CyRPA-specific Abs seen in vivo can well be ascribed to the 659 
same effector mechanisms as in vitro; namely, blocking of invasion-relevant processes. Yet, 660 
we cannot exclude involvement of additional immune effector mechanisms. NOD-scid 661 
IL2Rgnull mice are incapable of mounting adaptive immune responses and additionally lack a 662 
functional common IL-2R g-chain, which is required for high-affinity binding of IL-2, IL-4, 663 
IL-7, IL-9, IL-15, and IL-21 to their receptor (83). As a consequence, NOD-scid IL2Rgnull 664 
mice have no NK cells and show additional defects in innate immunity. Involvement of 665 
complement or cellular effector mechanisms in the observed protection is nevertheless 666 
possible, as in these mice the percentage of macrophages/monocytes and granulocytes is 667 
normal or even increased (84).  668 
Although it has been demonstrated that very high titers of specific Abs can be induced by 669 
appropriate vaccine formulations (85), the high Ab concentration required for in vivo 670 
protection may represent a hurdle for the development of a CyRPA-based vaccine. However, 671 
a substantial synergistic growth inhibitory effect was observed when combining two 672 
inhibitory anti-CyRPA mAbs with different fine specificity. Hence, stronger inhibitory 673 
activities may be achieved if active immunizations with CyRPA induce Abs specific for more 674 
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than one inhibitory epitope. If so, lower titers of total CyRPA-specific Abs may be required to 675 
confer protection.  676 
Anti-CyRPA mAbs inhibited, but did not completely block, parasite growth. The 677 
multiplication rate in vivo was much reduced but remained above one, leading to a very slow 678 
rise in parasitemia. Increasing the applied dose from 2.5 to 5 mg per mouse did not reduce 679 
multiplication further, indicating a saturation of the inhibitory mechanism. From our 680 
functional data, we deduce that anti-CyRPA mAbs reduce parasite growth by partially 681 
inhibiting some processes crucial for invasion of erythrocytes by merozoites, be it a specific 682 
protein interaction or processing of invasion-relevant proteins. However, RBCs did not bind 683 
to HEK cells that express CyRPA on their cell surface, and purified recombinant CyRPA did 684 
not specifically bind to the erythrocyte surface (data not shown). These results indicate that 685 
CyRPA, at least on its own, is no ligand for erythrocyte surface receptors.  686 
P. falciparum merozoites are described to use alternative invasion pathways to evade Ab- 687 
mediated immunity (86). Use of a CyRPA-independent invasion pathway of limited 688 
efficiency could explain persistence of infection associated with a reduced multiplication rate. 689 
Because parasites that survived treatment with anti-CyRPA mAb showed normal 690 
multiplication rates when transferred into naive mice and remained sensitive to re-exposure to 691 
anti-CyRPA mAbs, no rigid switch to an alternative invasion pathway seems to occur. The 692 
fact that, at least over a short time period, no CyRPA-Ab–resistant parasites were selected is 693 
of importance when considering the inclusion of CyRPA into a malaria subunit vaccine.  694 
Notably, among a set of nine mAbs specific for CyRPA, seven mAbs showed a parasite 695 
growth inhibiting effect whereas two did not. The growth inhibitory activity of the Abs was 696 
not determined by their affinity for the target Ag, but by their fine specificity. No confined 697 
CyRPA sequence stretch could be defined as epitope, as all mAbs seem to recognize 698 
conformational epitopes not present in short CyRPA sequence stretches. However, the fine 699 
specificity of inhibitory anti-CyRPA mAbs was distinct from the fine specificity of 700 
noninhibitory anti-CyRPA mAbs. The fact that only anti-CyRPA Abs of a certain fine 701 
specificity showed invasion inhibitory activity demonstrates once more the shortcoming of 702 
assessing immunity or vaccine potential of Ags by solely measuring Ab titers by ELISA. 703 
Besides CyRPA, a range of other blood-stage Ags, including AMA-1 and MSP-1, were 704 
shown to induce inhibitory as well as noninhibitory or even inhibition-blocking Abs (87, 88). 705 
ELISA cannot differentiate between functional and nonfunctional Abs. For the same reason, it 706 
is favorable to perform passive immunoprotection experiments with mAbs in animal models 707 
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to identify novel vaccine targets rather than using active immunization. MAbs represent 708 
highly defined agents with a distinct fine specificity and affinity, whereas immunization 709 
induces Abs with a wide range of binding properties. Hence, functional assays with 710 
polyclonal Abs pose the risk of generating misleading results due to interference or masking 711 
of functional by nonfunctional Abs.  712 
Most merozoite Ags associated with protection identified to date are located on the merozoite 713 
surface or within apical organelles. From a gene interaction network associated with invasion 714 
constructed from gene coexpression, sequence homology, domain– domain, and yeast two- 715 
hybrid data, CyRPA was selected as one of the genes to be expressed as a GFP-fusion protein 716 
to validate functional annotations (48). In that study, expression of CyRPA as a GFP-fusion 717 
protein in transgenic parasites was shown to result in a predominantly apical distribution. 718 
Consistent with this finding, we showed by indirect immunofluorescence staining with 719 
CyRPA-specific mAbs that CyRPA localizes intracellularly at the merozoite apex. 720 
Additionally, we could show that CyRPA does not localize to micronemes or rhoptry bulbs. 721 
The CyRPA-specific staining showed similarity to the staining of MSP-5, possibly indicating 722 
that CyRPA shares the same subcellular localization as MSP-5, a protein considered as a 723 
blood-stage vaccine candidate (89, 90). Although MSP-5 is described as a merozoite surface 724 
protein, its exact localization is sparsely characterized, and immunofluorescence staining of 725 
schizonts with MSP-5–specific Abs was shown previously to result in a rather dotty staining 726 
pattern (64, 91). The exact subcellular structure at the merozoite apex to which CyRPA 727 
localizes and how this structure is implicated in merozoite invasion remain to be investigated.  728 
P. falciparum is a highly polymorphic organism. This is particularly the case for many 729 
surface Ags as a result of natural selective pressure by the human immune responses (92). 730 
Most of the asexual blood-stage vaccine candidates evaluated to date, including AMA-1, 731 
MSP-1, and MSP-2, therefore have substantial polymorphisms (39–42). Immunodominance 732 
of the polymorphic and variant epitopes may explain the need for repeated exposure over 733 
several years to achieve clinical immunity against the natural polymorphic parasite 734 
populations (93). Malaria vaccines based on polymorphic Ags run the risk of compromised 735 
efficacy due to selection of vaccine-resistant variants (8). Therefore, it may be desirable to 736 
focus on Ags and protein domains with limited polymorphism. Sera of malaria-exposed adults 737 
tested here basically contained no CyRPA-specific Abs; natural immunogenicity of CyRPA 738 
thus appears to be very low. Our sequence analysis indicates that CyRPA has no substantial 739 
sequence polymorphisms. Only a single nonsynonymous SNP was detected among a range of 740 
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P. falciparum isolates. This, together with the low immunogenicity, is an indication that 741 
CyRPA is not a major target of naturally acquired immune responses. A possible explanation 742 
tor the low immunogenicity of CyRPA may be the intracellular localization of CyRPA in 743 
released merozoites. Hence, CyRPA may only be accessible to the humoral immune 744 
surveillance during the short period of invasion. Other reasons may be a critical function of 745 
CyRPA prohibiting variation or hindered accessibility of CyRPA in its native context.  746 
Furthermore, we could demonstrate that the identified SNP-associated amino acid 747 
dimorphism is not located within the epitope of the growth inhibitory anti-CyRPA mAbs and 748 
that parasites harboring sequence variants are likewise affected by growth inhibitory anti- 749 
CyRPA mAbs, indicating that this dimorphism is of no functional importance. From these 750 
results, we deduce that the protection-associated epitopes of CyRPA are likely to be free of 751 
sequence polymorphisms, suggesting that a CyRPA-based vaccine would target the entire P. 752 
falciparum population. This represents a clear advantage compared with polymorphic vaccine 753 
Ags like AMA-1, where several studies showed significant allele specificity in the inhibitory 754 
activity of anti–AMA-1 Abs (94–96).  755 
Our data show that CyRPA clearly fulfills three key criteria applied to select asexual blood- 756 
stage Ags as vaccine candidates (97): 1) the protein is conserved; 2) Abs against the Ag 757 
inhibit parasite growth in vitro and 3) are protective in animal models. To validate further 758 
CyRPA as a blood-stage vaccine Ag, one ought to demonstrate that 1) CyRPA is essential for 759 
parasite survival, 2) growth inhibitory anti-CyRPA Abs can be induced by active 760 
immunization with recombinant CyRPA, 3) immunization is safe, and 4) growth inhibitory 761 
anti-CyRPA Abs confer protection against clinical malaria in humans.  762 
In summary, we have identified a conserved merozoite protein that induces Abs that inhibit 763 
parasite growth in vitro and in vivo. We suggest evaluating its suitability as a candidate Ag for 764 
inclusion into a multivalent malaria subunit vaccine. In addition, we adopted the improved P. 765 
falciparum mouse model based on NOD-scid IL2Rgnull mice for functional analysis of malaria 766 
blood-stage– specific Abs. This model now allows a more systematic and quantitative 767 
comparison of the in vivo functionality of malaria Ag-specific Abs.  768 
 769 
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Supplementary Material 1094 
 1095 
 1096 
Supplementary Figure 1. CyRPA resides intracellular in free merozoites. 1097 
Indirect immunofluorescence staining of fixed (left) and un-fixed /right) merozoites with mAbs specific for GAPDH (green), 1098 
MSP-1 (green) and CyRPA (red). Nuclei were stained with DAPI. 1099 
 1100 
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  1101 
Supplementary Figure 2. Some, but not all anti-CyRPA mAbs inhibit parasite growth of various strains. 1102 
(A) Synchronous P. falciparum 3D7 blood stage parasites were cultured for two cycles in the presence of different 1103 
concentrations of different purified anti-CyRPA mAbs. Percent parasite growth inhibition was calculated against the 1104 
parasitemia of PBS control wells. Anti-6xHis-tag mAb was used as negative control mAb. Each symbol represents the mean 1105 
of a triplicate experiment, and error bars indicate the standard deviation.  1106 
(B) Synchronous blood stage parasites of P. falciparum strain 3D7, 7G8, D6, W2mef and K1 were cultured for two cycles in 1107 
the presence of different concentrations of purified anti-CyRPA mAb c12 or c05. Percent parasite growth inhibition was 1108 
calculated against the parasitemia of PBS control wells. Anti-6xHis-tag mAb was used as negative control mAb. Each 1109 
symbol represents the mean of a triplicate experiment, and error bars indicate the standard deviation. 1110 
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 1111 
Supplementary Figure 3. Surface Plasmon Resonance analysis of CyRPA binding to anti-CyPRA mAbs. 1112 
(A) SPR sensograms showing binding kinetics of CyRPA anti-CyRPA mABs. A CM5 chip with immobilized anti-mouse 1113 
IgG Abs was used to capture anti-CyRPA mAbs. Purified recombinant CyRPA was injected at concentrations of 400, 200, 1114 
100, 50, 25, 12.5, 6.25 and 3.13 nM (coloured lines, from top to bottom). Fitted curves for a 1:1 binding model is 1115 
superimposed in black. RU, response units. (B) Summary of affinity constants for anti-CyRPA mAbs. Ka: on-rate, kd: off- 1116 
rate, Rmax: response at complete saturation, KA: association constant, KD: dissociation constant. No fit could be obtained 1117 
for mAb c13. 1118 
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Supplementary Table 2. Primer sequences. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Primer Name Sequence (5’ to 3’) 
3888 AAAATTTTGTAGGAAATGTTGAGAA 
3899 AAAACGATGACAAGTCATATCCTTC 
3896 TGTTCCTTGTATTCGTGATATGTTTT 
3903 TCATCATTTAATGTAGAAACATCTTGA 
3900 TGACAATTACAAATTAGGTGTGCAA 
3891 CAAATATGATGATTGTTGAATGGTT 
3910 CCAATGCTAGCGGCATAAATTG 
3911 ATAAGATAGCGGCCGCCTTACCGTCATTTGAATAGAACCT 
3912 ATACTAGCTAGCCGTAAGAAGGATATGACTTGTCACAG 
3913 ATAAGAATGCGGCCGCTTTCACATTATTGATGTTGTCTCCA 
3886 GCTAGCGACCTGTCCTTTCACTTTTATGTTG 
3887 GCGGCCGCGTTGTAAATGCCCTGGGATG 
3905 TCGGTACCTCGCGAATGC 
3938 ATACTAGCTAGCGAGACCCATATCTACGTGCAG 
3939 ATAAGAATGCGGCCGCCCCGCAGATGAGGAAGTAC 
3986 ATGCCATGGGCATAAATTGTGACAGCC 
3941 CCGCTCGAGGTTGTAAATGCCCTGGGA 
3987 CCGCTCGAGCCCGCAGATGAGGAA 
 1119 
Supplementary Figure 4. Reactivity pattern of anti-CyRPA mAb c12 with fragments of the target antigen. 1120 
Lysates of HEK cells transiently transfected with expression plasmids encoding different CyRPA protein fragments were 1121 
probed with anti-CyRPA mAbs. All nine mAbs recognized fragment 26-352 (dark pink), and all except mAb c10 recognized 1122 
fragment 26-251 and fragment 26-181 (light pink). As an example, Western blots with anti-CyRPA mAb c12 are shown in 1123 
the middle and right panel. As positive control lysates were probed with anti-6xHis-tag mAb (left panel). Relative molecular 1124 
masses in kDa are indicated on the left. 1125 
Supplementary Table 1. Oligonucleotide sequence of used primers. 1126 
 1127 
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Abstract  27 
Background 28 
The pathogenesis of malaria is primarily associated with blood-stage infection and there is 29 
strong evidence that antibodies specific for parasite blood-stage antigens can control 30 
parasitaemia. This provides a strong rationale for incorporation of asexual blood-stage antigen 31 
components into an effective multivalent malaria subunit vaccine., Previously uncharacterized 32 
Plasmodium falciparum open reading frames, coding for new blood stage vaccine candidates, 33 
were selected on the basis of available genome-wide transcriptomic and proteomic data. This 34 
has led to the identification of the Cysteine-Rich Protective Antigen (PfCyRPA), which forms 35 
together with PfRH5 and PfRipr a multiprotein complex that is crucial for erythrocyte 36 
invasion.  37 
Methods 38 
Glycosylated and non-glycosylated variants of recombinant PfCyRPA were expressed and 39 
produced as secreted protein in mammalian cells. Adjuvanted formulations of purified 40 
PfCyRPA were tested to assess whether they can effectively elicit parasite inhibitory 41 
antibodies, and investigate whether or not the glycosylation status affects antibody binding. 42 
For this purpose, two sets of PfCyRPA-specific mouse monoclonal antibodies (mAbs) have 43 
been raised and evaluated for functional activity. 44 
Results 45 
Generated PfCyRPA-specific mAbs, irrespective of the immunogen’s glycosylation status, 46 
showed substantial parasite in vitro growth-inhibitory activity due to inhibition of erythrocyte 47 
invasion by merozoites. Furthermore, passive immunization experiments in P. falciparum 48 
infected NOD-scid IL2Rγnull mice engrafted with human erythrocytes demonstrated potent in 49 
vivo growth-inhibitory activity of generated mAbs. 50 
Conclusions 51 
Recombinantly expressed PfCyRPA tested as adjuvanted vaccine formulations in mice 52 
elicited antibodies that significantly inhibit P. falciparum asexual blood stage parasite growth 53 
both in vitro and in vivo. These findings render PfCyRPA a promising blood-stage candidate 54 
antigen for inclusion into a multicomponent malaria subunit vaccine.  55 
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Background  56 
The World malaria report 2015 reported the reduction of malaria mortality rates by an 57 
impressive 48% between 2000 and 2015 as a result of a major scale-up of vector control 58 
interventions, diagnostic testing, and treatment with artemisinin‐based combination therapy 59 
[1]. Despite these tremendous achievements, an estimated 214 million cases of malaria 60 
occurred globally in 2015, and the disease led to 438,000 deaths, mostly those of children 61 
under five years of age in Africa [1]. Limited efficacy achieved by subunit vaccine 62 
candidates, emerging anti-malarial drug resistances, along with reported insecticide 63 
resistances, underline the need of new tools to control and prevent malaria [2,3]. In this 64 
perspective, the development of an effective malaria vaccine is recognized as one of the most 65 
promising approaches to conquer the disease. Despite decades of research, an effective 66 
vaccine against malaria has remained elusive. Anti-malarial vaccines can break the parasite 67 
life cycle at different stages: infection-blocking vaccines targeting hepatic stages, anti- 68 
morbidity vaccines targeting the asexual blood stages, and transmission-blocking vaccines 69 
targeting the sexual stages. To achieve effective protection, the ideal malaria vaccine is 70 
thought to target several steps of the parasite life-cycle in a multistage combination vaccine 71 
[4].  72 
 73 
Clinical and experimental data support the feasibility of developing an effective malaria 74 
vaccine. Adults living in malaria endemic areas rarely experience malaria episodes: partial 75 
protection of adults is mediated by naturally acquired immunity, and protects against 76 
symptomatic disease and high‐density parasitaemia, but is not effective in offering sterile 77 
immunity [5]. Also, passive transfer of γ-globulin from semi-immune adults to malaria 78 
patients conferred a significant reduction of parasitaemia and recovery from clinical 79 
symptoms [6]. Those studies showed that immunity can be naturally acquired with exposure 80 
and indicated antibodies as crucial components of the protective immune response against 81 
asexual blood stage parasites. In this perspective, a multi-stage malaria vaccine should contain 82 
as one component antigen(s) that elicit antibody responses upon parasite presentation, leading 83 
to clearance of asexual blood stage parasites, and thus reducing the clinical symptoms.  84 
 85 
Currently, with a total 25 projects in the pipeline [7], three candidate vaccines are in Phase 2B 86 
clinical trials and one, the pre-erythrocytic subunit vaccine RTS,S/AS01, has completed 87 
Phase 3 [8]. In infants aged 6-12 weeks at first vaccination with four doses of RTS,S reduced 88 
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the number of cases of clinical malaria by 26% to the end of the study over an follow-up of 38 89 
months. Blood-stage vaccines, designed to elicit anti-invasion and anti-disease responses [9], 90 
are traditionally mainly based on a few protein candidate antigens: Apical Membrane Antigen 91 
1 (AMA1) [10–12], Erythrocyte-Binding Antigen-175 (EBA-175) [13], Glutamate-Rich 92 
Protein (GLURP) [14,15], Merozoite Surface Protein (MSP) 1 [16], MSP2 [17,18] and MSP3 93 
[19,20] and Serine Repeat Antigen 5 (SERA5) [21,22]. These immunodominant antigens, 94 
highly expressed on merozoites surface or within apical organelles, are involved in the 95 
invasion process. Unfortunately, AMA1 and MSP1, the most advanced blood-stage vaccines, 96 
have not demonstrated effective protection in African children [10,16,23], probably due to 97 
their highly polymorphic nature [24]. Genetic variability, extensive polymorphism and 98 
antigenic complexity in immunodominant antigens represent major obstacles in the 99 
development of an effective blood-stage malaria vaccine [25–27]. Identifying and designing 100 
antigens able to induce strain-transcending immune responses, which cover antigenic 101 
diversity remains a critical issue to be addressed. Since the Plasmodium falciparum genome 102 
was sequenced and annotated in 2002 [28], reverse vaccinology represents the most attractive 103 
strategy to rationally identify novel malaria vaccine candidates [29,30]. On the basis of the 104 
large-scale genomic, transcriptomic, proteomic and comparative data from Plasmodium spp. 105 
that have become available, new antigens with great potential as blood-stage vaccine 106 
candidates have been discovered [31].  107 
 108 
Among the newly characterized proteins, the Cysteine Rich Protective Antigen (PfCyRPA) 109 
exhibited remarkable properties: PfCyRPA (i) elicits Abs that inhibit parasite growth in vitro 110 
and in vivo [32], (ii) is highly conserved among P. falciparum isolates [32], (iii) has limited 111 
natural immunogenicity, and (iv) forms together with the Reticulocyte-binding Homolog 5 112 
(PfRH5) and the PfRH5-interacting Protein (PfRipr) a multiprotein complex crucial for P. 113 
falciparum erythrocyte invasion [33]. PfRH5 is currently regarded another leading blood- 114 
stage malaria vaccine candidate: it has been shown to induce invasion-inhibitory antibodies 115 
that are effective across common PfRH5 genetic variants and PfRH5-based vaccines can 116 
protect Aotus monkeys against virulent vaccine-heterologous P. falciparum challenges [34– 117 
37]. The PfCyRPA encoding gene PFD1130w is located in the subtelomeric region of 118 
chromosome 4 in close proximity to other genes playing a crucial role in the erythrocytes 119 
invasion, including PFD1145c that encodes for PfRH5 [36]. PfCyRPA is a 362-aa-long 120 
protein with a predicted molecular mass of 42.8 kDa, an N-terminal signal peptide, a C- 121 
terminal GPI-anchor motif and twelve cysteine residues, potentially involved in the formation 122 
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of six disulfide bridges. PfCyRPA was identified as a promising blood-stage malaria vaccine 123 
candidate exploiting a cell-based approach that utilizes antigens expressed on the surface of 124 
mammalian cells for mouse immunization [38]. Since antigen-loaded cells are not suitable for 125 
human immunization, we investigated whether invasion inhibitory anti-PfCyRPA antibodies 126 
could be raised by active immunization with purified recombinant PfCyRPA protein. In the 127 
present study, PfCyRPA was recombinantly-expressed in mammalian cells and adjuvanted 128 
vaccine formulations of purified PfCyRPA were tested for their potential to elicit antibodies 129 
that inhibit P. falciparum parasite growth in vitro and in vivo. 130 
  131 
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Methods 132 
Bacterial strains and media 133 
Escherichia coli strain Top10 (Life Technologies) was used for the amplification of plasmids. 134 
Bacteria were grown in LB medium containing 100 µg/ml ampicillin at 37°C. 135 
Construction of expression plasmids 136 
The expression vector which allows for the secretion of the recombinant PfCyRPA protein (aa 137 
22-362) was generated by PCR-based mutagenesis [39–42] using the 138 
BVM_PFD1130W_FLAG_GP_His plasmid as template [38]. Briefly, a PCR product 139 
encompassing the bee-venom melittin secretion signal (BVM) and PfCyRPA aa 26-352 140 
codon-optimized sequence, was amplified using GeneAmp® High Fidelity PCR System (Life 141 
Technologies) and primer 4325 (5’-CAACTCCGCCCCATTGACGCA-3’) and 4326 (5’- 142 
GGTGTGGATGTTGTAAATGCCCTGGGA-3’). The hexa-his tag was amplified with 143 
primers 4329 (5’-GAGGAATTCCATCACCATCACCATCACTGATAA-3’) and 4330 (5’- 144 
AGGGCGATGGCCCACTACGT-3’). A double-stranded oligonucleotide encoding for 145 
PfCyRPA aa 353-362 was generated by oligos-annealing employing the complementary 146 
oligonucleotides 4327 (5’-ATTTACAACATCCACACCATCTACTACGCCAACTACGAG 147 
GAATTCCATCACCAT-3’) and 4328 (5’-ATGGTGATGGAATTCCTCGTAGTTGGCGTA 148 
GTAGATGGTGTGGATGTTGTAAAT-3’). In a second step, a ligation PCR was performed 149 
with the outermost primer pair (4325 and 4330) using a mixture of the three previously 150 
generated PCR amplicons. Eventually, the recombined PCR product was recloned by NheI 151 
and XhoI (New England Biolabs) resulting in plasmid pcDNA3.1_BVM_CyRPA(26- 152 
362)_6xHis. This expression vector allows the expression of PfCyRPA with a hexa-His tag as 153 
secreted protein via the BVM signal peptide (designated G-CyRPA). It contains the secretion 154 
signal of bee-venom melittin, the coding sequence of the protein of interest and a hexa-His 155 
tag. 156 
The expression vector coding for the non-glycosylated PfCyRPA (N-CyRPA) was generated 157 
by site-directed mutagenesis (GenScript) resulting in the expression plasmid 158 
pcDNA3.1_BMV_CyRPA(26-362/N145Q-N322Q-N338Q)_6xHis. 159 
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Culture of eukaryotic cells 161 
FreeStyle 293-F cells (Thermo Fisher), a variant of human embryonic kidney cell line HEK 162 
cells, were cultured in suspension in serum-free medium (FreeStyle™ 293 Expression 163 
Medium, Thermo Fisher) at 37°C in a humidified incubator with 5% CO2. Shake flask 164 
cultures were run in 1 L shake flasks (Corning, 120 rpm, 5 cm diameter) and 10 L cultures 165 
were performed in fully instrumented Wave bioreactors (Sartorius, Melsungen) under 166 
controlled conditions (30 rpm, pH 7.2, 30% DO). 167 
Recombinant protein expression and purification 168 
FreeStyle 293-F cells were transfected with pcDNA3.1_BVM_CyRPA(26-362)_6xHis and 169 
pcDNA3.1_BMV_CyRPA(26-362/N145Q-N322Q-N338Q)_6xHis plasmids using a riDOM- 170 
based transfection system [43]. Prior to transfection at 1.2 x 106 cells/ml, cells were diluted 171 
1:2 with fresh culture medium and transfected with 0.4 mg/l expression plasmids and 172 
transfection reagents. Cell supernatants containing secreted proteins were typically harvested 173 
72-96 hours post-transfection. Histidine-tagged proteins were purified by immobilized metal 174 
ion affinity chromatography (IMAC). The purity and integrity of the purified proteins were 175 
analysed by RP-HPLC on an Agilent 1290 Series with a Poroshell 300SB-C8, 1x75 mm 176 
column (Agilent). Chromatography was performed with a non-linear (H2O + 0.01% TFA / 177 
Acetonitrile + 0.08% TFA) gradient system. The protein concentration was determined by 178 
measuring the OD280 (1 Abs = 1 mg/ml). The purified recombinant proteins were identified as 179 
the expected G-CyRPA and N-CyRPA proteins by Western blot analysis with PfCyRPA- 180 
specific mAbs [32]. 181 
Expression of PfCyRPA fragments on the surface of HEK cells  182 
293 HEK cells expressing PfCyRPA fragments on the cell surface were generated essentially 183 
as described previously by Dreyer et al. [32]. Briefly, DNA sequences coding for the 184 
fragments of PfCyRPA were amplified by PCR from a plasmid containing the full length and 185 
codon-optimized sequence of PfCyRPA. The amplicons were digested with restriction 186 
endonucleases NheI and NotI (New England Biolabs) and then ligated into a pcDNA3.1- 187 
based expression vector [38]. This expression vector allows to anchor the protein of interest 188 
on the cell surface via the transmembrane domain of mouse glycophorin-A. In addition it 189 
contains the secretion signal of bee-venom melittin, a FLAG tag located extracellularly, and a 190 
hexa-His tag located in the cytosol. The 293 HEK cells were transfected with the different 191 
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expression vectors using JetPEI transfection reagent (PolyPlus) according to the 192 
manufacturer’s instructions. Transient transfectants were harvested 48 hours post- 193 
transfection; cell lysates were generated as described below and used for Western blot 194 
analysis. 195 
Immunization of mice  196 
All procedures involving living animals were performed in strict accordance with the Rules 197 
and Regulations for the Protection of Animal Rights (Tierschutzverordnung) of the Swiss 198 
Federal Food Safety and Veterinary Office. The protocol was granted ethical approval by the 199 
Veterinary Office of the county of Basel-Stadt, Switzerland (Permit Numbers: 2375 and 200 
2303). Specific pathogen-free HsdWin:NMRI outbred mice were purchased from Harlan 201 
Laboratories B.V. (The Netherlands) and used for immunizations studies. Sixteen mice were 202 
immunized intraperitoneally with 20 µg/injection of recombinant protein emulsified in 203 
aluminum hydroxide gel (Alhydrogel-2%, Brenntag Biosector) containing CpG ODN as 204 
immune enhancer [44]. The animals received three booster injections at two weeks intervals 205 
with the same antigen preparation. Two weeks after the last boost, blood was collected and 206 
the serum was tested for the presence of PfCyRPA-specific antibodies by ELISA and Western 207 
blot analysis. 208 
Fusion and cell-based selection 209 
The best immune responders were selected for fusion. These mice received an intravenous 210 
(i.v.) injection of 20 µg of antigen dissolved in PBS two days before the fusion. Mice were 211 
sacrificed and the spleen was removed. Splenocytes were fused to the myeloma cell partner 212 
(PAI mouse myeloma cells, derived from SP-20, Institute of Immunology, Basel) using 213 
polyethylene glycol 1500 (Roche Diagnostics). The fusion mix was plated into 96-well 214 
culture plates and hybridomas were selected by growing in HAT-medium supplemented with 215 
culture supernatant of mouse macrophages P388. Wells were screened for IgG production two 216 
weeks post-fusion by ELISA as described previously [38]. IgG-producing hybrids were 217 
further screened for PfCyRPA-specific IgG production by ELISA on recombinant PfCyRPA. 218 
Positive wells were cloned in HT-medium by limiting dilution to obtain monoclonal 219 
populations. 220 
 221 
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Antibody production and characterization 222 
Identification of antibody subclasses was performed using a Mouse Monoclonal Antibody 223 
Isotyping Kit (ISO2, Sigma). For large-scale mAb production hybridoma cell lines were 224 
cultured in 500 ml roller-bottles (Corning). Monoclonal antibodies were purified by affinity 225 
chromatography using Protein A Sepharose (GE Healthcare). 226 
Plasmodium falciparum blood stage culture 227 
Plasmodium falciparum strain 3D7 was cultured essentially as described previously [45]. The 228 
culture medium was supplemented with 0.5% AlbuMAX (Life Technologies) as a substitute 229 
for human serum [46]. Cultures were synchronized by sorbitol treatment [47]. Erythrocytes 230 
for passages were obtained from the Swiss Red Cross (Switzerland). Plasmodium falciparum 231 
merozoites were mechanically released from mature schizonts as previously described [48]. 232 
Briefly, late-stage parasites (40-46 h post-invasion) were purified by Percoll density gradient 233 
[49] and incubated with 10 µM E-64 inhibitor (Sigma). After 6-8 h incubation, mature 234 
schizonts were filtered through 1.2 µm filters to release merozoites mechanically. Then, 235 
merozoites were resuspended PBS and stored at -80 °C until further use. 236 
ELISA  237 
Detection of PfCyRPA-specific Abs in mouse sera by ELISA 238 
ELISA Maxisorp plates (Nunc) were coated with 10 µg/ml purified recombinant G-CyRPA or 239 
MUL3720 proteins. After blocking, plates were incubated with dilutions of mouse serum. 240 
Horseradish Peroxidase (HRP) conjugated goat anti-mouse γ-chain specific 241 
(SouthernBiotech) was used as secondary antibody and tetramethylbenzidine substrate was 242 
used as substrate (KPL). The reaction was stopped with 0.5M H2SO4 and the absorbance at 243 
450 nm was measured using the Sunrise Absorbance Reader (Tecan). The cut-off value for 244 
calculation of endpoints titers was defined for each immunization group as: 245 𝐴𝑣𝑒𝑟𝑎𝑔𝑒	𝑂𝐷	𝑣𝑎𝑙𝑢𝑒	𝑐𝑜𝑛𝑡𝑟𝑜𝑙 + (2𝑥	𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑑	𝐷𝑒𝑣𝑖𝑎𝑡𝑖𝑜𝑛	𝑐𝑜𝑛𝑡𝑟𝑜𝑙)  246 
Serum IgG endpoint titers were calculated as reciprocal values of the last dilution factor 247 
yielding an OD value higher than the cut-off. Data were processed and analysed using 248 
GraphPad Prism 6.0 (GraphPad). 249 
 250 
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Ab competition ELISA 251 
Plates were coated with 10 µg/ml purified recombinant G-CyRPA protein; after blocking, 252 
plates were incubated with 10 µg/ml, 1 µg/ml, or 0 µg/ml of different anti-PfCyRPA mAbs. 253 
After 30 min, different biotinylated anti-PfCyRPA mAbs were added to each well resulting in 254 
a concentration of 1 µg/ml of labelled mAb. As the two antibodies compete for the same 255 
binding site, the signal is reduced because less biotinylated detection antibody is able to bind 256 
to PfCyRPA. Alkaline phosphatase-conjugated streptavidin (Southern Biotech) was used as 257 
detecting agent, and p-nitrophenyl phosphate substrate (Sigma) was used for development. 258 
The OD of the reaction product was measured at 405 nm. Anti-PfCyRPA antibodies with a 259 
signal reduction higher than 30% (compared to the absence of competitor) were considered as 260 
competing. 261 
Western blotting analysis 262 
Blood stage parasite lysates were prepared essentially as described previously by saponin 263 
lysis of P. falciparum 3D7-infected erythrocytes [45]. In brief, cultured parasites were washed 264 
once with PBS. Pelleted infected red blood cells were lysed in 20 volumes of 0.06% (w/v) 265 
saponin in PBS and incubated on ice for 20 min. Parasites were washed and the final pellet 266 
was resuspended in three volumes of PBS and stored at -80 °C until further use. RIPA-lysates 267 
were prepared by resuspending saponin pellets in three volumes of complete lysis buffer (1% 268 
NP40, 0.25% DOC, 10% glycerol, 2 mM EDTA, 137 mM NaCl, 20 mM Tris HCl pH 8.0, 269 
Protease Inhibitors) for 10 min on ice. The lysates were cleared by centrifugation at 15,000g 270 
for 10 min and the supernatant kept at -80°C until use. HEK cell lysate were prepared at 107 271 
cells/ml in Complete Lysis Buffer as described above. For SDS-PAGE, recombinant 272 
PfCyRPA, cell- or parasite lysates were resolved on precast 4-12% gradient gels (NuPAGE® 273 
Novex 4-12% Bis-Tris Gel, Life Technologies) with MES running buffer according to the 274 
manufacturer’s directions. For analyses under reducing conditions, samples were reduced 275 
with 50mMf dithiothreitol (DTT) and heated to a temperature of 70°C for 10 minute prior to 276 
loading. The proteins were electrophoretically transferred to nitrocellulose membrane using a 277 
dry-blotting system (iBlot, Life Technologies). After blocking the membrane, specific 278 
proteins were detected with appropriate dilutions of mAbs followed by HRP-conjugated goat 279 
anti-mouse IgG Abs (SouthernBiotech). Blots were developed using the ECL Western 280 
blotting detection reagents (Pierce). 281 
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Immunofluorescence staining of infected erythrocytes and free merozoites 282 
For indirect immunofluorescence microscopy, smears of infected red blood cells or free 283 
merozoites were fixed in 60% methanol and 40% acetone for 2 min at -20°C, air-dried and 284 
blocked with 3% BSA in PBS. Parasites were probed with the following antibodies: biotin- 285 
labelled anti-PfCyRPA mAb SB3.3b and Alexa 568-labelled streptavidin (Invitrogen), Alexa 286 
488-labelled mouse anti-GAPDH 1.4a mAb [50]. The slides were mounted in mounting 287 
medium containing DAPI (ProLong Gold antifade reagent with DAPI, Life Technologies). 288 
Fluorescence microscopy was performed on a Leica DM-5000B using a 60x oil immersion 289 
objective lens and documented with a Leica DFC345FX digital camera system. Images were 290 
processed using Leica Application Suite V4 (Leica) and Adobe Photoshop® CS6. 291 
In vitro growth inhibition assay 292 
In vitro growth inhibition assays with P. falciparum strain 3D7 were conducted essentially as 293 
described [51]. Each culture was set up in triplicate in 96-well flat-bottomed culture plates. 294 
The cells were analysed in a FACSscan flow cytometer (Becton Dickinson) using CellQuest 295 
software. A total of 30,000 cells per sample were analysed. Percent inhibition was calculated 296 
from the mean parasitaemia of triplicate test and control wells as follows:  297 
Percent inhibition (%) = 9:;<=:>?<@A<(BCDEFCG HII)  298 
In vivo growth inhibition assay 299 
Monoclonal antibodies were tested in the murine P. falciparum model essentially as described 300 [32,52]. Human blood (0.75 ml) was administered daily by the i.v. or i.p. route. Mice 301 
received a single dose of mAbs formulation by i.v. injection. The following day, mice were 302 
infected with 3x107 parasitized erythrocytes. Parasitaemia was monitored daily by flow 303 
cytometry over six days (day four to nine after mAb injection). To measure serum levels of 304 
administered mAbs, serum samples were taken one and eight days after injection. 305 
. 306 
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Results  307 
Recombinant expression of PfCyRPA 308 
For the production of correctly folded recombinant secreted PfCyRPA (aa. 26-362), we 309 
removed the GPI-anchor motif from the coding sequence of PFD1130w and expressed the 310 
ORF as hexa-Histidine (His-tag) fusion protein in the human embryonic kidney cell line 311 
FreeStyle 293-F cells. While the predicted molecular mass of the recombinant protein, 312 
designated G-CyRPA, was 40.9 kDa, a discrete band of about 48 kDa was detected both in 313 
SDS-PAGE and Western Blot analyses with a PfCyRPA-specific mAb (Fig. 1a and b). When 314 
analysed for the presence of N-glycosylation sites (NetNGlyc 1.0 Server) [53], three 315 
asparagine residues were predicted as potential sites for N-glycosylation (N145, N322 and 316 
N338) in human cells. Recombinant G-CyRPA was then treated with PNGase F, which 317 
enzymatically removes N-linked carbohydrate residues from proteins. As expected, this 318 
treatment reduced the size of G-CyRPA by about 8 kDa (see Additional file 1). 319 
 The shift in molecular mass after PNGase F treatment suggests that G-CyRPA is indeed N- 320 
glycosylated when recombinantly expressed in HEK cells. Therefore, a non-glycosylated 321 
variant of PfCyRPA, designated N-CyRPA, was generated by replacing the three asparagine 322 
residue potentially implicated in N-glycosylation with glutamine residues (N145Q, N322Q, 323 
N338Q). As expected, N-CyRPA expressed in HEK cells migrated, both in SDS-PAGE and 324 
Western Blot analyses with a PfCyRPA-specific mAb, as a discrete band of about 41 kDa 325 
(Fig. 1a and b, and Additional file 2). 326 
 327 
Fig. 1 Expression of recombinant PfCyRPA. Glycosylated (G) and non-glycosylated (N) recombinant PfCyRPA were 328 
expressed as His-tagged proteins in HEK cells and purified by affinity chromatography. The proteins were analyzed by 329 
denaturing/reducing gel electrophoresis (SDS-PAGE) and stained with Coomassie blue (a), and identified by Western blot 330 
analysis with the PfCyRPA-specific mAb Q8IF12 (b). 331 
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Immunogenicity of recombinant PfCyRPA and generation of PfCyRPA-specific mAbs 332 
Mice were immunized three times with 20µg of recombinant G-CyRPA or N-CyRPA 333 
emulsified in aluminium hydroxide containing CpG ODN as immune enhancer [44]. After the 334 
third immunization, PfCyRPA-specific serum IgG endpoint titers were determined by indirect 335 
ELISA. All mice raised antibody responses against recombinant PfCyRPA, irrespective of the 336 
immunogen’s glycosylation state (p = 0.9591, Mann-Withney test, 95% confidence interval, 337 
two-tailed p value). As expected, mice raised also marginal antibody responses against the 338 
hexa-His tag, as indicated by a low antibody titer against the hexa-His tagged irrelevant 339 
protein MUL_3720 (Fig. 2a). Also, all immunized mice raised immune responses cross- 340 
reactive with P. falciparum endogenous PfCyRPA, as shown by Western blot analyses on late 341 
blood-stage parasite lysates (Fig. 2b).  342 
Hybridoma cell lines producing PfCyRPA-specific mAbs were generated by fusing 343 
splenocytes of immunized mice with myeloma cells. Based on reactivity to recombinant 344 
PfCyRPA in ELISA, a panel of 11 anti-PfCyRPA mAbs was generated and tested for 345 
reactivity on recombinant and P. falciparum expressed PfCyRPA by Western blot analyses. 346 
8/11 anti-PfCyRPA mAbs stained the recombinant PfCyRPA band and ten of them also 347 
stained either strongly (mAbs SB1.6, SB2.1, SB2.3, SB3.3 and SB3.9) or weakly (SB1.5, 348 
SB2.4, SB2.5, SB3.8 and SB3.8) a band of the size expected for PfCyRPA in P. falciparum 349 
schizont-stage lysate (Fig. 3, Table 1). In indirect immunofluorescence staining of asexual 350 
blood stage parasites, 9/11 mAbs were positive. mAb SB2.2 was positive in ELISA with 351 
recombinant PfCyRPA, but negative both in Western blot analysis and in IFA (Table 1). With 352 
the exception of mAb SB3.8, which in ELISA was reacting only to recombinant G-CyRPA, 353 
no general differences in binding properties, between anti-PfCyRPA mAbs produced against 354 
glycosylated or non-glycosylated recombinant PfCyRPA, were observed (Table 1). In indirect 355 
immunofluorescence and Western blotting analyses mAbs stained asexual blood stage 356 
parasites stage-specifically (Fig. 4, Table 1), since PfCyRPA is only expressed by schizonts 357 
and free merozoites [32]. As expected, the generated mAbs showed the characteristic pattern 358 
[32] consisting of a small spot toward the merozoite apical pole (see Additional file 3). 359 
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 360 
Fig.  2 Anti-PfCyRPA IgG responses in outbred NMRI mice. Anti-PfCyRPA IgG immune responses were determined two 361 
weeks after the third immunization. Mice were immunized either with glycosylated (G-) or non-glycosylated (N-) 362 
recombinant PfCyRPA. (a) Serum IgG endpoint titers were measured using ELISA plates coated with recombinant G- 363 
CyRPA. As control, serum IgG endpoint titers were also measured using ELISA plates coated with an unrelated hexa-His 364 
tagged protein (MUL_3720). Horizontal lines designate geometric means and each data point represents one animal. Data 365 
were processed and analysed using GraphPad Prism 6.0 (GraphPad). (b) Pre-immune (upper panel) and immune (lower 366 
panel) serum samples of individual mice were tested by Western-blotting analysis on P. falciparum 3D7 schizont-stage 367 
parasites under non-reducing conditions. The anti-PfCyRPA mAb c12 and the anti-GAPDH mAb 1.4a were used as positive 368 
control [32,50]; the secondary antibody without primary antibody served as negative control. 369 
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  370 
 371 
Fig.  3 Western blotting analysis of anti-PfCyRPA mAbs. Anti-PfCyRPA mAbs were tested by Western-blotting analysis 372 
on (a) recombinant G-CyRPA and (b) N-CyRPA (both sample were analysed under reducing conditions). Anti-PfCyRPA 373 
mAbs were also tested on P. falciparum 3D7 schizont-stage parasites under non-reducing (c) and reducing conditions (d). 374 
The anti-PfCyRPA mAb c12 and the anti-GAPDH mAb 1.4a were used as positive control [32,50]; the secondary antibody 375 
without primary antibody served as negative control. 376 
 377 
Table 1 Summary of anti-PfCyRPA mAbs characterization 378 
 379 
Anti-PfCyRPA mAbs were characterized by ELISA (x, OD value higher than control anti-6xHis mAb HIS-6/9; –, OD value 380 
≤ control mAb), Western blotting analyses (x, staining; –, no staining; cf. Fig. 3), immunofluorescence assays (x, staining; –, 381 
no staining), growth inhibition assays (yes, GIA ≥ 40%; no, GIA ≤ 20%) and categorized into distinct epitope groups by 382 
epitope mapping experiments (cf. Table 2). G-CyRPA designates recombinant glycosylated PfCyRPA whereas N-CyRPA 383 
designates non-glycosylated recombinant PfCyRPA.  384 
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 385 
Fig.  4 Stage specific expression of PfCyRPA in late asexual blood stage parasites 386 
(a) Indirect immunofluorescence staining of synchronized asexual blood stage parasites showed stage specific expression of 387 
PfCyRPA in schizont stages and free merozoites. Methanol/acetone fixed P. falciparum 3D7 parasites were probed with the 388 
anti-GAPDH mAb (green) and the anti-PfCyRPA mAb SB3.3 (red) as representative example. Nuclei were stained with 389 
DAPI (blue). Exposure times were identical for all pictures of the same channel. (b) Western blot analysis with lysates of 390 
tightly synchronized P. falciparum 3D7 blood-stage parasites with anti-PfCyRPA mAb SB1.6 (upper panel). The blot was 391 
probed for equal loading with an anti-GAPDH 1.4a mAb (lower panel). 4, 12, 20, 28, 36, 44: hours post-invasion; M: free 392 
merozoites.  393 
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Vaccine elicited anti-PfCyRPA mAbs inhibit parasite growth in vitro 394 
For the analysis of the growth inhibitory activity of mAbs generated against the purified 395 
recombinant PfCyRPA, parasites were cultured for two cycles of merozoite invasion in the 396 
presence of anti-PfCyRPA mAbs at concentrations of 500, 250, and 125 µg/ml. Anti- 397 
PfCyRPA mAbs with parasite growth inhibitory activity higher than 40% at the concentration 398 
of 500 µg/ml were classified as inhibitory and those with an inhibitory effect ranging between 399 
20 and 40%, were classified as partially inhibitory. Among the four inhibitory mAbs (SB1.6, 400 
SB2.1, SB2.3, and SB3.3), SB1.6 showed the highest activity by reducing parasite growth by 401 
64 ± 3.2% when tested at a concentration of 500 µg/ml (Fig. 5, Table 1). Another four anti- 402 
PfCyRPA mAbs inhibited parasite growth partially, whereas three mAbs showed no 403 
inhibitory effect (Fig. 5, Table 1). All tested mAbs were produced and purified in the same 404 
way and results were reproducible in independent experiments and with independent mAb 405 
production batches (see Additional file 4). 406 
 407 
 408 
Fig 5. Vaccine elicited anti-PfCyRPA mAbs inhibit parasite growth in vitro 409 
Synchronized P. falciparum 3D7 parasites were cultivated for 96 h in the presence of anti-PfCyRPA mAbs. The percentage 410 
of growth inhibition was calculated against the parasitaemia of PBS control wells. Each bar represents the mean of a 411 
triplicate experiment, and error bars indicate the SD. Anti-PfCyRPA mAbs SB1.6, SB2.3, SB2.1 and SB3.3 are growth 412 
inhibitory mAbs, mAb SB1.5 is shown as an example for a partially inhibitory mAb, and mAb SB3.8 as an example for a 413 
non-inhibitory mAb. The anti-cortisol mAb CORTI-4/16 was used as negative control and the anti-PfCyRPA mAb c12, 414 
which was produced after immunization with mammalian cells expressing recombinant PfCyRPA on their cell surface, as 415 
positive control [32]. 416 
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Vaccine elicited anti-PfCyRPA mAbs inhibit parasite growth in vivo 417 
The in vivo parasite inhibitory activity of the generated anti-PfCyRPA mAbs was evaluated in 418 
the P. falciparum SCID murine model [52] that employs non-myelodepleted NOD-scid 419 
IL2Rγnull mice engrafted with human erythrocytes. Groups of three mice received 2.5 or 0.5 420 
mg of PfCyRPA-specific mAbs, either mAb SB1.6 generated here, or the previously 421 
described [32] invasion-inhibitory mAb c12, by i.v. injection. The control group received the 422 
same volume of PBS. Mice were infected with parasitized erythrocytes one day after the 423 
antibody transfer and parasitaemia of all mice was monitored for six days (Fig. 6). In the 424 
control group, parasitaemia reached 22.9 ± 1.7% on day nine. Parasitaemia in mice having 425 
received 2.5 mg anti-PfCyRPA mAbs SB1.6 or c12 increased only marginally, reaching 2.2 ± 426 
1.4% and 1.5 ± 0.6% on day nine after mAb injection, respectively. At the lower dose of 0.5 427 
mg anti-PfCyRPA mAbs SB1.6 or c12 inhibited parasite growth to 10% ± 1,6% and 12.8% ± 428 
5.8% parasitaemia, respectively (Fig. 6). Titration of administered mAbs in the serum of the 429 
passively immunized mice by ELISA showed that antibodies, although at reduced level, 430 
persisted over the entire study period. One day after mAb injection (2.5 mg dose), when mice 431 
were infected, PfCyRPA-specific mAb concentrations were estimated to be 295 ± 0.3 % and 432 
389 ± 0.1 % µg/ml of serum, for SB1.6 and c12, respectively. Eight days after mAb injection, 433 
at the end of the experiment, antibody concentrations had dropped down to 74 ± 0.1 % and 83 434 
± 0.2 % µg/ml, for SB1.6 and c12 respectively (see Additional file 5). 435 
 436 
 437 
 438 
Fig.  6 Vaccine elicited anti-PfCyRPA mAbs inhibit parasite growth in vivo. NOD-scid IL2Rγnull mice received purified 439 
anti-PfCyRPA mAbs by i.v. injection. Mice were then infected with P. falciparum 3D7 and parasitaemia was monitored over 440 
six days. Values are the mean parasitaemia in human erythrocytes in peripheral blood of three mice per group. Error bars 441 
indicate the SD. PBS was used as negative control, the anti-PfCyRPA mAb c12 as positive control [32]. 442 
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Fine specificities of anti-CyRPA mAbs 443 
The fine specificities of the generated anti-PfCyRPA mAbs were analysed by Ab-Ab 444 
competition ELISA on recombinant PfCyRPA. The in vitro growth-inhibitory anti-PfCyRPA 445 
mAbs SB1.6, SB2.1, SB2.3, and SB3.3 competed against each other for their antigen binding 446 
site (Table 2 A). These four mAbs did neither compete with the partially inhibitory mAbs 447 
SB2.5 and SB3.7 nor with the previously described parasite inhibitory anti-PfCyRPA mAb 448 
c12. Additionally, the reactivity of anti-PfCyRPA mAbs with overlapping protein fragments 449 
of PfCyRPA [32] was tested by Western blotting analysis (Figs. 7, 8b). With the exception of 450 
SB2.5, all tested anti-PfCyRPA mAbs reacted with fragment 26-251. All four inhibitory anti- 451 
PfCyRPA mAbs SB1.6, SB2.1, SB2.3, and SB3.3 recognized the same fragments, i. e. bound 452 
to fragment 74-251, but not to the truncated sub-fragments 26-142, 74-181, and 127-251, 453 
indicating that they recognize a conformational epitope present in fragment 74-251. 454 
Furthermore, the partially inhibitory mAbs SB3.7 and the control mAb c12 showed the same 455 
reactivity pattern. Based on the complementary results of both epitope classification assays 456 
we assigned the anti-PfCyRPA mAbs to four distinct epitope groups (Fig. 8b, c). 457 
 458 
 459 
 460 
Fig.  7 Reactivity pattern of anti-PfCyRPA mAbs with recombinant PfCyRPA fragments. Anti-PfCyRPA mAbs were 461 
tested by Western blot analysis on lysates of HEK cells expressing recombinant PfCyRPA fragments. A lysate HEK cells 462 
transfected with empty plasmids served as negative control. Both samples were analysed under reducing conditions. (a) 463 
Reactivity pattern of anti-6xHis mAb HIS-6/9 as positive control for expression. (b) Reactivity pattern of anti-PfCyRPA 464 
mAb SB 3.7 as a representative example. 465 
 466 
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 467 
Fig. 8 Epitope specificities of anti-PfCyRPA mAbs. (a) Anti-PfCyRPA mAbs were tested in an Ab–Ab competition 468 
ELISA. x Ab competition (signal reduction higher than 30 %; measured values: min. 34 %, max. 91 % reduction), − no Ab 469 
competition (measured values: min. −10 %, max. 21 % reduction. (b) Reactivity of anti-PfCyRPA mAbs with recombinant 470 
PfCyRPA fragments were investigated by western blotting analyses performed on lysates of HEK cells expressing 471 
recombinant PfCyRPA fragments. x staining, − no staining (an example of the reactivity pattern is reported in Fig. 7b). (c) 472 
Anti-PfCyRPA mAbs were assigned to different epitope groups according to the results from the Ab–Ab competition ELISA 473 
and the epitope mapping experiment. (d) P. falciparum in vitro growth inhibition activity of mAbs. 474 
 475 
476 
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Discussion  477 
On the basis of available genome-wide transcriptomic and proteomic data, Dreyer et al. [38] 478 
have selected uncharacterized surface proteins, with specific expression in extracellular 479 
parasite stages, to evaluate their potential as blood stage vaccine candidate antigens. A panel 480 
of candidates was characterized (e.g. abundance, distribution and parasite growth inhibitory 481 
potential) using antigen-specific mAbs, which were generated exploiting a cell-based 482 
approach that utilizes antigen-expressing living cells for mouse immunization. This strategy 483 
has led to the identification of PfCyRPA as promising blood-stage malaria vaccine candidate: 484 
generated anti-PfCyRPA mAbs showed parasite in vitro and in vivo growth-inhibitory 485 
activity due to inhibition of merozoite invasion [32]. Since antigen-loaded mammalian cells 486 
are not suitable for human immunization, here it was investigated whether growth inhibitory 487 
anti-PfCyRPA Abs could be raised by active immunization with adjuvanted purified 488 
recombinant PfCyRPA protein. The expression of Plasmodium antigens in heterologous hosts 489 
as stable recombinant protein can be challenging. Since PfCyRPA is a cysteine-rich protein, 490 
disulfide bonds play an important role in its folding. Aiming at the production of a properly 491 
folded recombinant protein, a eukaryotic rather than a prokaryotic expression system was 492 
used. Since PfCyRPA was successfully expressed in a native conformation on the surface of 493 
HEK cells and raised parasites-cross reactive mAbs [32], the same mammalian expression 494 
platform was exploited for the production of secreted PfCyRPA. For this purpose, the 495 
expression plasmid coding for PfCyRPA was modified to produce the secreted version of the 496 
protein by removing the sequence coding for the transmembrane domain artificially used to 497 
display the protein on the cell surface. PfCyRPA was expressed and secreted into the 498 
cultivation medium in good quality and quantity (ca.18 mg/l), and the glycosylated 499 
recombinant protein was easily purified via the hexa-His tag. Since the protein glycosylation 500 
status may influence immunogenicity, we also produced a non-glycosylated version of 501 
PfCyRPA, but did not find a marked difference between the two proteins with respect to their 502 
immunogenicity. To dissect and characterize the properties of the elicited anti-PfCyRPA 503 
antibody response, mice immunized with either the glycosylated or the non-glycosylated 504 
recombinant protein were employed to generate a panel of eleven IgG mAbs reactive with 505 
recombinant PfCyRPA in ELISA. Nine of the generated mAbs were cross-reacting in indirect 506 
immunofluorescence analysis with P. falciparum asexual blood stage parasites, yielding a 507 
dotted staining pattern characteristic for PfCyRPA and ten of them stained a band of the size 508 
expected for PfCyRPA in Western blotting analysis with P. falciparum schizont stage lysate. 509 
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Four mAbs showed strong and another four partial parasite blood stage in vitro growth 510 
inhibitory activity. The parasite inhibitory activity of mAb SB1.6 showing the strongest in 511 
vitro activity was comparable to that of the previously described anti-PfCyRPA mAb c12 512 
which was produced after immunization with mammalian cells expressing recombinant 513 
PfCyRPA on their cell surface [32]. The strongly growth inhibitory mAbs c12 and SB1.6 do 514 
not compete for antigen binding (Table 2), confirming that PfCyRPA harbours more than one 515 
target epitope for inhibitory antibodies, as already suggested by Dreyer et al. [32]. Structural 516 
analyses with antigen-antibody complexes are required to gain deeper insight into the targets 517 
and mode of action of these antibodies. Since orthologs of PfCyRPA are only present in the 518 
human malaria parasite Plasmodium vivax and the primate pathogens Plasmodium knowlesi, 519 
Plasmodium cynomolgi, and Plasmodium reichenowi [54–56], but are absent in Plasmodium 520 
species infecting rodents, conventional mouse models with rodent parasites cannot be used to 521 
evaluate the in vivo growth inhibitory activity of anti-PfCyRPA mAbs. Therefore, passive 522 
immunization experiments were performed exploiting an innovative P. falciparum SCID 523 
mouse model [32,52].  524 
Non myelo-depleted NOD-scid IL2Rγnull mice, engrafted with human erythrocytes to allow 525 
the growth of P. falciparum, received a single dose of anti-PfCyRPA mAbs via the i.v. route 526 
and were infected with P. falciparum 3D7 parasites on the subsequent day. In mice receiving 527 
SB1.6 mAb, a strong, dose-dependent parasite growth inhibitory effect was observed, 528 
reducing parasite’s growth by about 90% (2.5 mg dose). The concentration of mAb SB1.6 in 529 
the circulation of the passively immunized mice which received the higher dose, was 530 
estimated to be 300 µg/ml and 80 µg/ml one and eight days after injection, respectively. Since 531 
SCID mice lack the adaptive immune system and have deficiencies in the innate immune 532 
system [57,58], the injected mAbs were the only circulating IgG, and this may enhance their 533 
clearance from the circulation. However, the measured serum concentration of PfCyRPA- 534 
specific antibody fall in the range of specific Abs that can be induced by appropriate vaccine 535 
formulations [8,37]. In this context, it should also be taken into account that immunizations 536 
with recombinant PfCyRPA (both antigen-loaded cells and adjuvanted purified proteins) 537 
generated anti-PfCyRPA mAbs with different fine specificity [32].  538 
Hence, stronger inhibitory activities may be achieved in the context of active immunizations, 539 
where Abs specific for more than one inhibitory epitope are induced, and lower titers of total 540 
PfCyRPA-specific Abs may be required to confer substantial protection. As already described 541 
[32], anti-PfCyRPA mAbs reduce, but do not completely block, parasite growth by inhibiting 542 
a crucial invasion pathway of erythrocytes by merozoites. Invasion of host erythrocytes is a 543 
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complex and critical step in the life cycle of malaria parasites, and P. falciparum has evolved 544 
an abundance of antigenically diverse, and probably functionally redundant, merozoite 545 
surface proteins to facilitate parasite escape from host immune detection and ensure invasion 546 
via multiple pathways [59,60]. In this respect, marginal sequence polymorphisms and limited 547 
natural immunogenicity of PfCyRPA [32] suggest a critical function of PfCyRPA in 548 
erythrocytes invasion, which prevents sequence variation and accessibility to the immune 549 
system in the natural context. PfCyRPA has been recently identified as the anchor protein that 550 
tethers PfRH5, and its interacting partner PfRipr, to the surface of merozoites [33]. PfRH5 has 551 
been shown to play a key role in the attachment of merozoites to the erythrocyte surface via 552 
the interaction with the host receptor basigin [61,62]. Interestingly, PfCyRPA and PfRH5 553 
genes are located in close proximity in the genome, have no substantial sequence 554 
polymorphisms, have demonstrated poor natural immunogenicity, and elicit potent and strain- 555 
transcending growth-inhibitory parasite antibodies [32,34]. Anti-PfCyRPA mAb 556 
concentrations required for substantial growth inhibition in GIA were higher than those 557 
reported for anti-basigin (1ug/ml) and anti-PfRH5 (15ug/ml) mAbs, respectively [36]. This 558 
may be in part related to different assay formats, but also to other factors, such as accessibility 559 
of the antigens and kinetic and thermodynamic features of mAb binding. Reddy et al. [33] 560 
also reported a synergistic in vitro inhibitory activity for the combination of polyclonal anti- 561 
PfCyRPA and anti-PfRH5 antibodies. Targeting simultaneously PfCyRPA and PfRH5 seems 562 
to hinder parasite invasion more effectively than when blocking only one component of the 563 
multiprotein invasion complex. Taken together, these findings suggest that additional 564 
investigation are needed for an in depth characterization of the invasion complex, and make 565 
both PfCyRPA and PfRH5 appealing candidates for the development of new anti-malarial 566 
vaccine strategies. 567 
 568 
Conclusions  569 
A vaccine formulation composed of adjuvanted recombinantly expressed PfCyRPA has been 570 
shown to elicit in mice high titers of antibodies that inhibit both in vitro and in vivo P. 571 
falciparum asexual blood stage parasite growth. These findings qualify PfCyRPA, a highly 572 
conserved and poorly immunogenic merozoite protein, as highly suitable candidate antigen 573 
for inclusion into a strain-transcending, multivalent malaria subunit vaccine. 574 
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Additional files 824 
 825 
Additional file 1. PNGase F treatment of recombinant G-CyRPA. 1 mg/ml of native (second lane) or reduced with 50mMf 826 
DTT (third lane) G-CyRPA was subjected for 16 h at room temperature to PNGase F at a final concentration of 0.05 mg/ml, 827 
and analysed by reducing SDS-PAGE (1 µg protein per lane). Lane 1: untreated G-CyRPA; lane 4: PNGase F. 828 
 829 
 830 
 831 
 832 
Additional file 2. Recognition of N-CyRPA by PfCyRPA- and 6xHis-specific mAbs. Reducing (R) and non-reducing (N) 833 
SDS-PAGE of non-glycosylated PfCyRPA (N-CyRPA) detected by Coomassie-staining (blue) and Western blotting with 834 
anti-PfCyRPA mAb c12 and anti-6xHis mAb HIS-6/9 (black). Analyses under non-reducing conditions revealed both a 835 
monomeric and a dimeric form of PfCyRPA. 836 
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 837 
 838 
 839 
Additional file 3. Localization of PfCyRPA in late asexual blood stage parasites. Indirect immunofluorescence staining of P. 840 
falciparum 3D7 schizont stages. Methanol/acetone fixed parasites were co-immunostained with mAbs against PfCyRPA 841 
(red) and AMA-1 (marker for micronemes), RAP-1 (marker for rhoptry bulbs), MSP-1 or MSP-5 (marker for merozoite’s 842 
surface) (green). Parasites were probed with the following primary or secondary antibodies: biotin-labeled anti-PfCyRPA 843 
mAb SB3.3b, Alexa 488-labeled mouse anti–AMA-1 DV5a mAb [51], Alexa 488-labeled mouse anti–RAP-1 5-2 mAb [63], 844 
anti–MSP-1 MC7.2 mAb (G. Pluschke, unpublished), anti–MSP-5 rabbit serum (MRA-320; Malaria Research and Reference 845 
Reagent Resource Center) [64], Alexa 568-labeled streptavidin (Invitrogen), Alexa 488-labeled goat anti-mouse IgG (H+L) 846 
Abs, and Alexa 488-labeled chicken anti-rabbit IgG (H+L) Abs (Invitrogen). Nuclei were stained with DAPI (blue). 847 
Exposure times were identical for all pictures of the same channel. 848 
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 850 
Additional file 4. In vitro parasite growth inhibitory activity of vaccine elicited anti-PfCyRPA mAbs was reproducible in 851 
independent experiments. Different batches of anti-PfCyRPA mAbs were produced and purified in the same way, and tested 852 
in independent in vitro growth inhibition assays. Reported are three independent experiments as representative examples of 853 
obtained results. Anti-PfCyRPA mAbs SB1.6 is shown as an example for an inhibitory mAb, mAb SB1.5 for a partially 854 
inhibitory mAb, and mAb SB3.8 for a non-inhibitory mAb. The anti-cortisol mAb CORTI-4/16 was used as negative control 855 
and the anti-PfCyRPA mAb c12 as positive control [32]. Each bar represents the mean of a triplicate experiment, and error 856 
bars indicate the SD. 857 
 858 
 859 
 860 
 861 
Additional file 5. Titration of administered mAbs in the serum of the passively immunized mice. The concentration of 862 
administered PfCyRPA-specific mAbs SB1.6 and c12 in the circulation was estimated by indirect ELISA on day one and 863 
eight after injection. For the detection of PfCyRPA-specific mAbs and total circulating IgGs, plates were coated with N- 864 
CyRPA or goat anti-mouse IgG (γ-chain specific) mAb (M1397, Sigma), respectively. After blocking, plates were incubated 865 
with dilutions of individual mouse serum. An HRP-conjugated goat anti-mouse IgG (γ-chain specific) Ab (A3673, Sigma) 866 
was used as secondary antibody and TMB as substrate. Standard curves were generated from known dilutions of SB1.6 and 867 
c12 mAbs and fit using a 4-PL logistic equation. Concentration of circulating mAbs was calculated by interpolating the 868 
absorbance values for the test sera from the standard curves. Reported values are means of three mice per group ± SD. 869 
 870 
 871 
 872 
 873 
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Data deposition: The coordinates and structure factors have been deposited in the Protein 32 
Data Bank (accession codes 5ezi, 5ezl, 5ezj, 5ezn, and 5ezo). 33 
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Abstract 35 
Invasion of erythrocytes by Plasmodial merozoites is a composite process involving the 36 
interplay of several proteins. Among them, the Plasmodium falciparum Cysteine-Rich 37 
Protective Antigen (PfCyRPA) is a crucial component of a ternary complex, including 38 
Reticulocyte binding-like Homologous protein 5 (PfRH5) and the RH5-interacting protein 39 
(PfRipr), essential for erythrocyte invasion. Here we present the crystal structures of 40 
PfCyRPA and of complex with the antigen-binding fragment of a parasite growth inhibitory 41 
antibody. PfCyRPA adopts a 6-bladed β-propeller structure with similarity to the classic 42 
sialidase fold, but it has no sialidase activity and fulfills a purely non-enzymatic function. 43 
Characterization of the epitope recognized by protective antibodies may facilitate design of 44 
peptidomimetics to focus vaccine responses on protective epitopes. Both in vitro and in vivo 45 
anti-PfCyRPA and anti-PfRH5 antibodies showed more potent parasite growth inhibitory 46 
activity in combination than on their own, supporting a combined delivery of PfCyRPA and 47 
PfRH5 in vaccines. 48 
 49 
Keywords: CyRPA, Malaria vaccine candidate, sialidase, crystal structure, β-propeller, 50 
invasion inhibitory antibody. 51 
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Introduction 53 
According to the World Health Organization 2015 Malaria Report 54 
(who.int/malaria/publications/world_malaria_report/en), malaria is estimated to have caused 55 
214 million clinical cases and 438,000 deaths in 2015. The disease is transmitted by female 56 
Anopheles mosquitoes and caused by parasitic protozoans of the genus Plasmodium, of which 57 
P. falciparum and P. vivax are the most prevalent and P. falciparum is causing the most often 58 
fatal and medically most severe form of malaria. Debilitating clinical symptoms associated 59 
with the infection are caused by the multiplication of the asexual blood-stage parasites in 60 
erythrocytes. One of the most promising targets for malaria vaccine development is therefore 61 
at the stage where merozoites invade erythrocytes. 62 
Invasion of host erythrocytes by merozoites is a complex process, conceptually divisible into 63 
four phases: (1) initial recognition of and reversible attachment to the erythrocyte membrane 64 
by the merozoite; (2) junction formation leading to irreversible attachment of the merozoite, 65 
parasitophorous vacuole formation, and release of the Plasmodium rhoptry-microneme 66 
secretory organelles are released; (3) invagination of the erythrocyte membrane around the 67 
merozoite, accompanied by the shedding of the merozoite’s surface coat; (4) closing of the 68 
parasitophorous vacuole and resealing of the erythrocyte membrane mark the completion of 69 
merozoite invasion (Pinder et al., 2000). The initial recognition and the active invasion of 70 
erythrocytes depend on specific molecular interactions between parasite ligands and receptors 71 
on the host erythrocyte membrane. Although several ligand-receptor interactions have already 72 
been identified, the entire network of molecular interactions involved in invasion is not yet 73 
fully disentangled. In addition, P. falciparum merozoite proteins are antigenically highly 74 
diverse and in part functionally redundant, to facilitate parasite escape from host immune 75 
surveillance and to ensure erythrocyte invasion via alternative pathways (Cowman et al., 76 
2012). 77 
Most efforts in malaria blood stage vaccine research and development have historically 78 
concentrated on immuno-dominant, polymorphic antigens that contribute to the invasion of 79 
red blood cells by merozoites. Despite major efforts, blood stage vaccines based on merozoite 80 
surface antigens have so far shown limited efficacy in clinical trials (reviewed in (Halbroth 81 
and Draper, 2015)). Extensive antigenic polymorphism represents one major hurdle for the 82 
development of an effective blood-stage malaria vaccine (Takala et al., 2009; Dzikowski and 83 
Deitsch, 2009). Therefore, the identification of new candidate antigens that are able to induce 84 
broad strain-transcending immunity and that are not susceptible to ‘vaccine resistance’ has 85 
become a recent research focus. 86 
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Availability of pathogen genomes is facilitating the discovery of novel vaccine candidate 87 
antigens through ‘reverse vaccinology’ approaches (Rappuoli, 2001; Donati and Rappuoli, 88 
2013). Sequencing and annotation of the P. falciparum genome (Gardner et al., 2002) has 89 
supported the identification of new blood stage vaccine candidate antigens (Conway, 2015; 90 
Proietti and Doolan, 2015), among which the P. falciparum Cysteine-Rich Protective Antigen 91 
(PfCyRPA) has a number of noteworthy properties. While PfCyRPA is highly conserved 92 
among a plethora of P. falciparum isolates, it also is poorly immunogenic in the context of 93 
natural exposure (Dreyer et al., 2012). Moreover, PfCyRPA-specific monoclonal antibodies 94 
(mAb) inhibit parasite growth both in vitro and in vivo by blocking merozoite invasion 95 
(Dreyer et al., 2012; Favuzza et al., 2016). 96 
PfCyRPA is a 42.8 kDa protein of 362 residues with a predicted N-terminal secretion signal. 97 
Orthologs of PfCyRPA have been found in the genomes of the human malaria parasite P. 98 
vivax and the primate pathogens P. knowlesi, P. cynomolgi, and P. reichenowi (Figure 3- 99 
figure supplement 1), but not in the sequenced genomes of other Plasmodium species. P. 100 
falciparum PfCyRPA shares on average 42% sequence identity with its orthologs, but within 101 
different P. falciparum isolates PfCyRPA is highly conserved: just thirteen dimorphic amino 102 
acid positions (highlighted in Figure 3-figure supplement 1) were found in 227 P. falciparum 103 
field isolates (Manske et al., 2012), and only a single variant (Arg399 instead of Ser399) was 104 
found at a frequency of greater than 2%. 105 
PfCyRPA is part of a multi-protein complex (Reddy et al., 2015; Volz et al., 2016) including 106 
also the PfRH5-interacting protein PfRipr and the reticulocyte binding-like homologous 107 
protein PfRH5, which binds to the erythrocyte receptor basigin (Baum et al., 2009; Crosnier 108 
et al., 2011; Chen et al., 2011b; Chen et al., 2014). PfRH5, PfCyRPA and PfRipr colocalize 109 
during parasite invasion at the junction between merozoites and erythrocytes. The complex 110 
seems to be required both for triggering Ca2+ release and establishment of tight junctions 111 
(Volz et al., 2016). While merozoites deficient in PfCyRPA or PfRH5 can still bind to 112 
erythrocytes, they do not attach irreversibly and cannot invade the host cells (Volz et al., 113 
2016). Like PfCyRPA (Dreyer et al., 2012), PfRH5 induces invasion-blocking antibodies that 114 
are effective across common genetic variants (Douglas et al., 2011; Bustamante et al., 2013; 115 
Douglas et al., 2014). 116 
‘Structural vaccinology’, a combination of immunological, structural, and bioinformatics 117 
approaches, is increasingly used for the design of improved vaccine antigens (Dormitzer et 118 
al., 2008; Cozzi et al., 2013; Malito et al., 2015). To this end the crystal structures of PfRH5 119 
in complex with basigin and neutralizing inhibitory mAb have been determined (Chen et al., 120 
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2014; Wright et al., 2014). Here, we describe the crystal structure of the promising vaccine 121 
candidate PfCyRPA alone and in complex with the antigen-binding fragment (Fab) of the 122 
parasite growth inhibitory mAb c12 (Dreyer et al., 2012). The structure of PfCyRPA 123 
represents a step toward elucidating its biological function. Furthermore, definition of the 124 
specific epitope–paratope interactions from the crystal structure of the PfCyRPA/c12 complex 125 
will support rational design of an epitope-focused PfCyRPA-based candidate vaccine. 126 
  127 
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Results 128 
Fine specificities of anti-PfCyRPA antibodies 129 
The finding that PfCyRPA and PfRH5 form a complex essential for parasite invasion 130 
prompted us to investigate the fine specificities of previously generated parasite inhibitory 131 
and non-inhibitory anti-PfCyRPA mAbs. The 16 anti-PfCyRPA mAbs available for analysis 132 
(Dreyer et al., 2012; Favuzza et al., 2016), showed six distinctive reactivity patterns with 133 
seven overlapping recombinant protein fragments of PfCyRPA, assigning them to the epitope 134 
groups A – F, with groups A, B, C and F comprising the parasite inhibitory and groups D and 135 
E the non-inhibitory mAbs (Figure 1). All mAbs bound to the full-length PfCyRPA (without 136 
the signal sequence; fragment 1). mAbs belonging to epitope group A exclusively bound this 137 
fragment, indicating that they recognize conformational epitopes not present in any of the 138 
shorter PfCyRPA sequence stretches. Lack of binding to fragments 2 and 7 indicates that the 139 
epitope may comprise sequences from both ends of the polypeptide chains. Epitope group B 140 
antibodies, including mAb c12, bound only to fragments 1, 2 and 3. Epitope group F mAbs 141 
bound to fragments 1, 2 and 5, but not to fragment 3, indicating that in contrast to group B, 142 
residues located in the sequence stretch between aa 181–251 are required for their binding. 143 
The single mAb c04 constitutes the epitope group C showing binding to fragment 7 (only in 144 
IFA, not confirmed by Western blotting analysis). The non-inhibitory mAbs clustered into the 145 
distinct epitope groups D and E. 146 
  147 
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 148 
Figure 1. Binding of anti-PfCyRPA mAbs to fragments of PfCyRPA 149 
Binding of sixteen mAbs to PfCyRPA fragments (black bars) expressed on the cell surface of HEK cells as assessed by 150 
Western blotting analysis and live-cell immunofluorescence staining. (x) indicates staining and (–) no staining; (a) indicates 151 
no reactivity in Western blot analysis of HEK cell lysates. Expression on the surface of the HEK cells has been demonstrated 152 
for all PfCyRPA fragments by immunofluorescence analysis using anti-Histidine tag HIS-6/9 mAb (Figure 1-figure 153 
supplement 1). For reference, the seventeen residues constituting the epitope on PfCyRPA identified from the complex 154 
crystal structure with the Fab of mAb c12 is shown in all constructs as red bars. According to their reactivity pattern, anti- 155 
PfCyRPA mAbs were assigned to different epitope groups: A: c10, SB2.5; B: c02, c06, c08, c09, c12, SB3.7; C: c04; D: 156 
c05; E: c13, SB3.9; F: SB1.6, SB2.1, SB2.3, SB3.3. 157 
The parasite growth inhibitory activity of anti-PfCyRPA antibodies is enhanced by anti- 158 
PfRH5 antibodies 159 
Since it may prove useful to incorporate a combination of PfCyRPA and PfRH5 in a 160 
multivalent malaria vaccine, we investigated whether mAbs against these two vaccine 161 
candidate antigens have additive or synergistic effects. In a first step, we tested a combination 162 
of inhibitory mAbs against the two antigens in an in vitro parasite growth inhibition assay. 163 
Parasites were cultured for one cycle of merozoite invasion in the presence of the anti- 164 
PfCyRPA c12 mAb with or without the anti-PfRH5 BS1.2 mAb at concentrations of 500, 165 
250, and 125 µg/mL. Either mAbs showed potent inhibitory activity, consistently reducing 166 
parasite growth of all four tested P. falciparum strains in a concentration-dependent manner 167 
and to the same extent as the well characterized inhibitory anti-MSP-1 mAb 12.10 (Blackman 168 
et al., 1990) (Figure 2A and Figure 2-figure supplement 1). When combining the anti- 169 
PfCyRPA c12 mAb with the anti-RH5 BS1.2 mAb, we found a significantly enhanced 170 
inhibitory activity: while mAbs c12 and BS1.2 at a concentration of 250 µg/mL inhibited 171 
growth by 21 ± 2.2% and 31 ± 4.6%, respectively, the combination of both mAbs (250 µg/mL 172 
each) inhibited growth by 59 ± 1.4%; (Figure 2A). The functional activity of both mAbs was 173 
not enhanced by the addition of a malaria-unrelated control mAb. 174 
In a second step the in vivo parasite inhibitory activity of the mAbs was evaluated in the P. 175 
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falciparum SCID murine model that employs non-myelodepleted NODscidIL2Rγnull mice 176 
engrafted with human erythrocytes (Dreyer et al., 2012; Jiménez-Díaz et al., 2009). Groups of 177 
three mice received 2.5 or 0.5 mg of mAbs c12 or BS1.2 or a combination of both mAbs by 178 
i.v. injection. The control groups received either 2.5 mg of an isotype-matched malaria- 179 
unrelated mAb or the same volume of PBS without Ab. Mice were infected with parasitized 180 
erythrocytes one day after the antibody transfer and parasitemia was subsequently monitored 181 
(Figure 2B). In the control groups parasitemia reached 19.6 ± 0.8% on day 9 after mAb 182 
injection. Parasitemia in mice having received 2.5 mg c12 or BS1.2 mAb increased only 183 
marginally, reaching 2.2 ± 0.5 and 2 ± 0.3% on day 9 after mAb injection, respectively. At the 184 
lower dose of 0.5 mg c12 and BS1.2 inhibited parasite growth to 10.1 ± 2.3 and 10.8 ± 6.9% 185 
parasitemia, respectively (Figure 2B). In accord with the in vitro data, parasitemia decreased 186 
significantly (p = 0.0356; unpaired t test, 95% confidence interval, two-tailed) and reached 187 
only 4.8 ± 1.9% on day 9 if mice received 0.5 mg of the anti-PfRH5 BS1.2 mAb in addition 188 
to 0.5 mg of the anti-PfCyRPA c12 mAb. 189 
These results demonstrated that anti-PfCyRPA and anti-PfRH5 antibodies have an additive 190 
parasite growth inhibitory effect, justifying the combination of both antigens in a subunit 191 
vaccine. While the structure of PfRH5 in complex with an inhibitory antibody has been 192 
determined, structural information for PfCyRPA is lacking. We therefore we determined the 193 
crystal structures of PfCyRPA and its complex with the Fab of the growth inhibitory mAb 194 
c12. 195 
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 196 
Figure 2. Anti-PfCyRPA and anti-PfRH5 mAbs have both in vitro and in vivo an additive inhibitory effect on parasite 197 
growth 198 
(A) Growth inhibition in vitro. Synchronized P. falciparum 3D7 blood-stage parasites were cultured for one cycle of 199 
merozoite invasion (48 h) in the presence of anti-PfCyRPA c12 mAb, anti-PfRH5 BS1.2 mAb, and their combinations. An 200 
isotype-matched, malaria-unrelated mAb (NR4.2) (Rose et al., 2016) was used as negative control. Inhibitory and non- 201 
inhibitory anti-MSP-1 mAbs (12.10 and 2F10, respectively) were also included as reference (Blackman et al., 1990; 202 
Blackman et al., 1994). Percent parasite growth inhibition was calculated against the parasitemia of PBS control wells. Each 203 
bar represents the mean of a triplicate experiment, and error bars indicate the standard deviation (SD). Differences in parasite 204 
growth inhibition between mAbs c12 and BS1.2 alone and their combinations are statistically significant (unpaired t test with 205 
Welch’s correction, 95% confidence interval, two-tailed p value). 206 
(B) Growth inhibition in vivo. NODscidIL2Rγnull mice received purified anti-PfCyRPA c12 mAb and/or anti-PfRH5 BS1.2 207 
mAb by i.v. injections. Mice were then infected with P. falciparum 3D7 and parasitemia was monitored over six days. 208 
Values represent the mean parasitemia in human erythrocytes in peripheral blood of three mice per group. Error bars indicate 209 
the SD. PBS and an unrelated control mAb were used as negative control. 210 
Results – Part 3 
 
115 
Biophysical analysis and crystal structure of PfCyRPA 211 
The far-UV CD spectrum of PfCyRPA is consistent with an all-b structure connected by loop 212 
regions and the absence of a-helices (Figure 3-figure supplement 2A). Mass spectrometric 213 
analysis of proteolytic fragments of PfCyRPA revealed at least four disulfide bonds that are 214 
sequential along the sequence (Figure 3-figure supplement 2B). Intrinsic fluorescence showed 215 
that the two Trp residues present in PfCyRPA are buried in the native state. Also, the 216 
disulfide bonds seem to be buried, because addition of 50 mM reducing agent had no 217 
significant effect on the fluorescence of PfCyRPA (Figure 3-figure supplement 2C). Taken 218 
together, these data are consistent with PfCyRPA forming a compact, disulfide-stabilized 219 
molecule of predominantly b-sheet structure. 220 
In order to crystallize PfCyRPA, we needed to pre-treat the protein with Actinase E (Figure 4- 221 
figure supplement 1A). The crystal structure of PfCyRPA, determined to a resolution of 2.5 Å 222 
(detailed in Supplementary file 1), confirmed our biophysical analyses (Figure 3). PfCyRPA 223 
adopts a six-bladed b-propeller structure that buries the disulfide bonds and the Trp residues. 224 
Each blade of the propeller is constructed by a four-stranded anti-parallel b-sheet (Figure 3B). 225 
The five disulfide bonds in PfCyRPA are located within blades 2-6 (Figure 3A), stabilizing 226 
each individual blade. The first blade has no disulfide bond; it is formed by b-strands from the 227 
N- and C-terminal regions of PfCyRPA, potentially enabling conformational changes in 228 
PfCyRPA by opening and closing. A domain alignment search (DALI; (Holm and 229 
Rosenstrom, 2010)) for related structures revealed that PfCyRPA adopts a heavily modified 230 
sialidase/neuraminidase fold. The closest structural relative is the catalytic domain of Vibrio 231 
cholerae sialidase (Moustafa et al., 2004) (Figure 3C). The two proteins have only 9% 232 
sequence identity and the structures have a large root mean square distance (rmsd) of 3.7 Å 233 
over 285 residues, clearly showing that while the overall fold is similar, the structures are 234 
very different with respect to the inclination of the blades (Figure 3C) and the length and 235 
conformations of the surface loops connecting the b-strands (Figure 3D). PfCyRPA also 236 
contains a signature sequence motif for sialidases known as an Asp-box (201-SHDKGETW- 237 
208; conserved residues are underlined) (Roggentin et al., 1989), which serve structural roles 238 
in the b-propellers of sialidases. However, while bacterial sialidases contain between three to 239 
five Asp-boxes, PfCyRPA contains only a single one. 240 
Two molecules of PfCyRPA are present in the asymmetric unit and have conformational 241 
differences in several surface loops, suggesting possible flexibility of these loops in solution 242 
(Figure 3B). From the point of peptidomimetics that could be derived from PfCyRPA for 243 
vaccine development, these surface loops connecting the blades on the back and front of the 244 
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b-propeller are natural candidates. Although some of the loops, e.g. in blade 5 (arrows in 245 
Figure 3B), have significant structural plasticity, it should be possible to stabilize them in a 246 
conformation suitable to raise an immune response. 247 
 248 
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Figure 3. PfCyRPA adopts the neuraminidase fold 249 
(A) Structure-sequence relationship of PfCyRPA. Indicated are an Actinase E cleavage site at Asp189 (red), a sialidase- 250 
typical Asp-box (dotted underlined), the two Trp residues (dotted underlined), and the sequential disulfide bonds (connected 251 
by lines and in same color). b-strands are shown as arrows colored according to the blade they form. The epitope recognized 252 
by mAb c12 is underlined in bold. 253 
(B) Cross-eyed stereo view of the ribbon representation of a superposition of the two PfCyRPA molecules in the asymmetric 254 
unit with the blades numbered 1-6 from the N-terminus and colored individually. Blade 1 is made up of an N-terminal (black) 255 
and three C-terminal b-strands (red). One protomer is shown with white, the other with black loop regions, which may differ 256 
substantially (arrows in blade 5). The Trp and Cys residues are drawn as stick models. 257 
(C) The same orientation of the catalytic domain of Vibrio cholerae sialidase (PDB-ID 1w0o), the next structural homolog of 258 
PfCyRPA with a DALI score of 18 (Z < 5 is structurally dissimilar). Sialic acid and residues in the Vibrio enzyme are 259 
displayed as balls and sticks. Structural Ca2+ ions are marked as magenta spheres. None of the residues necessary for metal 260 
ion binding, substrate binding, or catalysis is present in PfCyRPA. 261 
(D) Superposition of PfCyRPA with the V. cholerae sialidase. While both proteins are 6-bladed b-propellers, the blades have 262 
very different angles, extents, and loop lengths and conformations connecting the b-strands. The four Asp-boxes in the 263 
bacterial sialidase (grey) are colored black. PfCyRPA (orange) has only a single Asp-box connecting the third and fourth b- 264 
strands in blade 3 (colored blue). Other b-strand connections are made by sequences unrelated to the Asp-box motif, in 265 
agreement with poor conservation of the Asp-box in other, e.g. viral, sialidases. The view in (D) is rotated by 180º about the 266 
horizontal axis compared to (B) and (C). 267 
PfCyRPA has no sialidase activity 268 
The sialidase fold of PfCyRPA and the presence of an Asp-box motif raised the question 269 
whether PfCyRPA exhibits sialidase activity. In view of the involvement of viral and 270 
microbial sialidases in the unmasking of cryptic host ligands, host cell adhesion, and invasion 271 
(Lewis and Lewis, 2012; Matrosovich et al., 2015), sialidase activity could make sense for 272 
PfCyRPA-mediated invasion of erythrocytes. We detected no sialidase activity, however, 273 
when we tested recombinant PfCyRPA for neuraminidase activity using a colorimetric assay 274 
(Figure 3-figure supplement 3). The active site of sialidases usually contains a triad of Arg 275 
residues that bind to the substrate, a Glu/Tyr pair where the acid acts as a general base to 276 
activate the Tyr nucleophile, and a hydrophobic pocket with a conserved Trp that 277 
accommodates the acetyl group of sialic acid (Buschiazzo and Alzari, 2008). In addition, 278 
many sialidases bind to Ca2+ ions, of which one is close to the active site and is bound by 279 
three main-chain carbonyl groups and oxygen atoms in the side-chains of Asn, Thr, and Asp. 280 
PfCyRPA contains none of the residues necessary for catalysis, nor does it harbor a Ca2+ 281 
binding site, providing structural correlates of the absence of sialidase activity in PfCyRPA. 282 
PfCyRPA and sialidases may have evolved from a common ancestor, or PfCyRPA could have 283 
evolved from a genuine sialidase to adopt other functionalities. 284 
Characterization of the epitope recognized by the parasite growth inhibitory anti- 285 
PfCyRPA mAb c12 286 
The parasite inhibitory anti-PfCyRPA c12 mAb binds tightly to PfCyRPA with a Kd of ca. 1 287 
nM as determined by surface plasmon resonance analysis (Dreyer et al., 2012). This mAb 288 
recognizes PfCyRPA independent of its glycosylation, as revealed by Western blot analyses 289 
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(Figure 4A). Because of these favorable properties, we chose c12 for epitope mapping by 290 
determining the structure of a PfCyRPA/c12 complex. In a first step, we determined the 291 
crystal structure of c12 in isolation (Figures 4B and 4C). We obtained three different crystal 292 
forms containing a total of four crystallographically independent Fab molecules. 293 
Superposition of the structures showed very little structural plasticity of the CDR loops 294 
(Figure 4C), suggesting that they retain their structures upon epitope binding. 295 
We then purified the PfCyRPA/c12 complex, analyzed it by limited proteolysis, and 296 
crystallized it. Actinase E treatment of the PfCyRPA/c12 complex resulted in the same 297 
proteolysis pattern as observed for PfCyRPA alone (Figure 4-figure supplement 1B), 298 
suggesting that the epitope for mAb c12 is distant from the Actinase E recognition site at 299 
Asp189. Actinase E treatment was not necessary to crystallize the PfCyRPA/c12 complex, 300 
however. We determined the crystal structure of the PfCyRPA/c12 complex at a resolution of 301 
4.0 Å by molecular replacement using the individual high-resolution structures of c12 and 302 
PfCyRPA as search models (Figure 5A). Despite the limited resolution, novel molecular 303 
features were visible in the electron density maps of the complex, providing confidence in the 304 
relative orientation of PfCyRPA and c12 (Figure 5-figure supplement 1). First, the electron 305 
density visible for PfCyRPA after molecular replacement with c12 was used as a search 306 
model for structure determination of PfCyRPA alone (see Methods). This strategy would have 307 
been impossible had the placement of c12 been wrong. Second, a loop region that is absent in 308 
the PfCyRPA search model due to Actinase E proteolysis (see above) exhibits omit electron 309 
density in the PfCyRPA/c12 complex (Figure 4-figure supplement 1). Third, consistent with 310 
the similar conformations of the CDR loops in the individual c12 Fab structures (Figure 4) 311 
there are negligible conformational changes in the c12 CDR loops when bound to PfCyRPA. 312 
Similarly, the epitope conformation in PfCyRPA is very similar in the unbound and 313 
complexed form. Minor adjustments of side-chains were required during rebuilding of the 314 
complex structure. While the resolution of the PfCyRPA/c12 complex is limited and many 315 
side-chains lack clear electron density, as is typical for this resolution, knowledge of the 316 
relative orientation of PfCyRPA with respect to c12 in the complex is sufficient for designing 317 
peptidomimetics to target the immune response to the protective epitope. 318 
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 319 
Figure 4. Recognition of PfCyRPA by the mAb c12 and structure of c12 320 
(A) Reducing SDS-PAGE of glycosylated (left) and non-glycosylated (right) PfCyRPA detected by Coomassie-staining 321 
(blue) and Western blotting with mAb c12 (black). Recognition by c12 is independent of the glycosylation. 322 
(B) Overview of the c12 structure with a glycan located at heavy-chain Asn37. mFo-DFc electron density for the glycan is 323 
shown as a red mesh drawn at the 3 rmsd level. The light and heavy chains are colored light pink and light blue, respectively. 324 
Heavy chain CDR1-3 are colored cyan, magenta, and yellow, and light chain CDR1-3 are drawn in dark blue, pink, and 325 
green. 326 
(C) Comparison of the four c12 structures shows little conformational variability of the CDR loops. The four c12 molecules 327 
superimpose onto their variable VHVL di-domains with an average rmsd of 0.35 Å, which reveals a minor spread of the elbow 328 
angles between 133.1° and 135.8°. The high structural congruence indicates that the CDR conformations are genuine and not 329 
dominated by crystal contacts. The view is from above on top of the CDR loops. 330 
The epitope recognized by mAb c12 is a surface composed of blade 2 and part of blade 3 of 331 
PfCyRPA (Figure 5A). The most frequent amino acid dimorphism of PfCyRPA at position 332 
339 is thus located outside the epitope recognized by mAb c12, consistent with the 333 
observation that mAb c12 binds to P. falciparum independent of the PfCyRPA variant they 334 
express (Dreyer et al., 2012). mAb c12 buries a total surface area of 950 Å2 on PfCyRPA with 335 
the major contributor being the light chain, which buries 520 Å2, while the heavy chain buries 336 
only 430 Å2. The surface complementarity coefficient Sc of the complex is 0.67, a typical 337 
value for antibody-antigen interactions (Lawrence and Colman, 1993); a value of one would 338 
denote perfect complementarity. The light chain also forms more potential hydrogen bonds to 339 
PfCyRPA than the heavy chain (Figure 5B). Seven hydrogen bonds are possible between 340 
PfCyRPA and the c12 light chain. Each side-chain of light chain CDR1 residues 50-RND-52 341 
can form a hydrogen bond with the side-chains of PfCyRPA residues Asp66, Asn45, and 342 
Tyr78, respectively. A particularly large contribution to complex stability may stem from a 343 
salt bridge between PfCyRPA residue Asp66 and CDR1 residue Arg50, which by 344 
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mutagenesis was found to be true (see below), a further confirmation that the PfCyRPA/c12 345 
complex structure is correct. In addition, the heavy chain contributes significantly to antigen 346 
binding. Tyr120 of heavy chain CDR3 can engage in two hydrogen bonds with the side- 347 
chains of PfCyRPA residues Asp92 in blade 2 and Tyr144 in blade 3, thus establishing a 348 
mini-network that bridges blade 2 and 3. Together with heavy chain CDR3 residue Tyr122, 349 
Tyr120 also forms numerous van der Waals interactions with Asn91, Lys95, Glu96, and 350 
Phe136, Tyr144, Asn145, and Asn146 (Figures 5B and 5C). A complete listing of the derived 351 
potential interactions is available in Supplementary file 2, which due to the limited resolution 352 
of the complex structure must remain tentative. What is clear from the structure is that mAb 353 
c12 recognizes a discontinuous epitope that contains at least seventeen residues distributed 354 
over four PfCyRPA sequence stretches (marked in Figure 3A). 355 
 356 
Figure 5. Structure of the PfCyRPA/c12 complex 357 
(A) Overview showing that the majority of the interface is made by interactions between the light chain of c12 and blade 2 of 358 
PfCyRPA. 359 
(B) Details of the interface viewed from top onto the CDR loops. The light and heavy chain surfaces buried by PfCyRPA are 360 
colored pink and blue, respectively. Possible hydrogen bonds and van der Waals interactions are indicated by dashed green 361 
and black lines. The CDR loops are color-coded as in Figure 4. The Asp66-Arg50 salt bridge is circled. 362 
(C) Close-up of (B). 363 
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The epitope extracted from the complex structure matches the binding pattern of mAb c12 to 364 
the PfCyRPA fragments in our epitope analysis (Figure 1): only fragments 1-3 containing all 365 
the seventeen interaction sites were recognized by mAb c12. Furthermore, fragment 4, 366 
lacking three out of these seventeen residues (Tyr144, Asn145 and Asn146) and fragments 5 367 
and 6, lacking four residues (Asn45, Val46, Pro47 and Asp66), were not recognized by mAb 368 
c12. 369 
The PfCyRPA epitope recognized by mAb c12 was further verified by mutagenesis. The 370 
crystal structure suggests that Asp66 forms a salt bridge with Arg50 in the CDR1 loop of the 371 
c12 light chain (Supplementary file 2 and Figure 5-figure supplement 1). When Asp66 was 372 
changed to Lys, a capture ELISA detected significantly weaker binding of the mAb c12 to the 373 
Asp66Lys variant of PfCyRPA (Figure 6A). As expected, the Asp66Lys replacement did not 374 
affect binding of the control mAb SB1.6 (Figure 6B), which belongs to the unrelated epitope 375 
group F and is expected to engage in crucial interactions with PfCyRPA residues located 376 
between residues 181-251 (Figure 1). 377 
 378 
Figure 6. Identification of Asp66 as a key contact residue for PfCyRPA/c12 interaction 379 
mAb binding to purified wild type PfCyRPA and an Asp66Lys single amino acid sequence variant was analyzed by capture- 380 
ELISA experiments. ELISA plates were coated with 10 µg/mL anti-PfCyRPA mAbs and then incubated with serial dilutions 381 
of wild-type PfCyRPA (WT) or an Asp66Lys variant (D66K); HRPO-labeled anti-Histidine tag mAbs were used as detection 382 
antibody. 383 
(A) When compared to wild-type PfCyRPA, the Asp66Lys single amino acid exchange strongly reduced the binding to mAb 384 
c12 mAb (epitope group B; Figure 1). 385 
(B) In contrast, the Asp66Lys amino acid exchange did not affect the binding of the mAb SB1.6, which belongs to epitope 386 
group F. 387 
 388 
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Discussion 389 
PfCyRPA has been identified as a novel malaria blood stage vaccine target in an endeavor to 390 
test predicted P. falciparum open reading frames for the capacity to elicit parasite-inhibitory 391 
mAbs (Dreyer et al., 2010). PfCyRPA is stage-specifically expressed in late schizonts and 392 
elicits mAbs that inhibit parasite growth in vitro and in a P. falciparum experimental infection 393 
model based on NODscidIL2Rγnull mice engrafted with human erythrocytes (Dreyer et al., 394 
2012). Recent studies (Reddy et al., 2015) have placed PfCyRPA in a ternary complex with 395 
PfRH5 and PfRipr that as a whole is essential for erythrocyte invasion (Volz et al., 2016). 396 
Like PfRH5 and PfRipr (Baum et al., 2009; Chen et al., 2011b), PfCyRPA is refractory to 397 
genetic disruption (Reddy et al., 2015), and loss of PfCyRPA or PFRH5 function in 398 
conditionally expressing mutants blocks parasite growth due to the inability of merozoites to 399 
invade erythrocytes (Volz et al., 2016). Here we show that antibodies against PfRH5 and 400 
PfCyRPA have additive parasite growth inhibitory activity. Inclusion of both antigens into a 401 
multivalent subunit vaccine therefore represents an attractive strategy to prevent emergence of 402 
escape mutants. While an ortholog of PfCyRPA is also present in the genome of the human 403 
parasite P. vivax, an ortholog of PfRH5 has only been found so far in the genome of P. 404 
reichenowi, a chimpanzee malaria parasite closely related to P. falciparum (Otto et al., 2014). 405 
This may indicate a function of PfCyRPA beyond its role as a protein-binding platform in the 406 
ternary complex with PfRH5 and PfRipr. While it has been claimed that PfCyRPA anchors 407 
the ternary complex through a GPI anchor to the parasite membrane (Reddy et al., 2015), 408 
recent results are not consistent with this suggestion (Volz et al., 2016). This inconsistency 409 
suggests that additional proteins might be involved in anchoring the complex to the parasite 410 
membrane and that PfCyRPA has an essential function other than that of an anchor. Further 411 
functional studies are required to elucidate the molecular mechanisms how the ternary 412 
complex is involved in the triggering of Ca2+ release and the establishment of tight junctions 413 
between the merozoite and the erythrocytes (Volz et al., 2016). In this context it may be 414 
relevant that the five sequential disulfide bonds of PfCyRPA are in blades 1-5, leaving blade 415 
6 of the b-propeller structure without such a local stabilization. Blade 6 is constructed by b- 416 
strands from the N- and the C-terminus, and in principle could act as a gate to allow 417 
PfCyRPA to undergo substantial conformational changes. 418 
Structural vaccinology defines epitopes from antigen-antibody complex crystal structures and 419 
thus allows the design of surrogate antigens that elicit protective humoral immune responses. 420 
The approach may be of particular use for pathogens that cause chronic infections by 421 
presenting immuno-dominant antigens and epitopes to the immune system, which, however, 422 
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only elicit non-protective antibody responses (Liljeroos et al., 2015; Loomis and Johnson, 423 
2015; Robinson, 2013; Dormitzer et al., 2012). The structural studies of Neisseria 424 
meningitidis adhesin A and factor H binding protein (Malito et al., 2013), as well as of the 425 
Staphylococcus aureus manganese transport protein (Ahuja et al., 2015) represent remarkable 426 
examples in which crystal structure determination of antigens elucidated both the molecular 427 
mechanism of their biological functions and their immunological viability as vaccine 428 
antigens. 429 
For the development of synthetic malaria subunit vaccines, conformationally stabilized and 430 
structurally optimized peptide antigens mimicking conserved protective epitopes (Mueller et 431 
al., 2003; Okitsu et al., 2007; James et al., 2006) may be more suitable components than 432 
entire recombinant proteins containing highly polymorphic immuno-dominant non-protective 433 
surface loops. Both PfCyRPA and PfRH5 elicit protective as well as non-protective 434 
antibodies (Dreyer et al., 2012; Douglas et al., 2011), making them candidates for structure- 435 
based approaches, that aim to focus the immune responses on protective epitopes. 436 
Even at the comparatively moderate resolution of 4 Å, the crystal structure of the protective 437 
mAb c12 bound to PfCyRPA provides an ideal starting point for the design of a 438 
conformationally stabilized PfCyRPA-derived peptide antigen to elicit primarily protective 439 
antibodies. Particle-based antigen delivery systems such as virosomes (Cech et al., 2011; 440 
Pluschke and Tamborrini, 2012) are highly suitable to support, by repetitive epitope display, 441 
the development of strong immune responses against peptidomimetics. The epitope 442 
recognized by mAb c12 is monomorphic and, like PfCyRPA in general, little immunogenic in 443 
the natural context. Focusing the vaccine-induced immune response on this PfCyRPA epitope 444 
may confer a strong protective effect. 445 
Malaria vaccine candidates based on single-antigens have been uniformly unsuccessful and an 446 
effective subunit vaccine will likely have to include antigens from more than one stage of the 447 
parasite life cycle (pre-erythrocytic, liver stage, and blood stage components), as well as 448 
sexual blood-stage gametocyte or mosquito-stage parasite antigens as transmission-blocking 449 
components. The Plasmodium genome contains more than 5,000 open reading frames of 450 
which only < 0.5% have been tested as vaccine candidates, so careful selection of new targets 451 
for an optimized multi-valent vaccine is called for (Proietti and Doolan, 2015; Dups et al., 452 
2014; Longley et al., 2015; Wu et al., 2015). PfCyRPA represents one of the most promising 453 
new blood stage vaccine candidate antigens identified with the support of –omics approaches, 454 
and there is renewed hope that an effective combination and formulation of such rationally 455 
selected antigens can lead to the development of a malaria subunit vaccine that offers high 456 
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level strain-transcending protection (Halbroth and Draper, 2015). With the availability of 457 
structural analyses for both PfCyRPA and PfRH5 in complex with an inhibitory antibody, 458 
structure-based approach is now possible. In view of the observed additive effect of 459 
antibodies, inclusion of immunogens representing both antigens in a subunit vaccine would 460 
make sense, thereby reducing the danger of selection of immune escape mutants. 461 
  462 
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Materials and Methods 463 
Molecular biology 464 
Plasmids were amplified in E. coli strain Top10 (Life Technologies) grown in LB medium 465 
under 100 µg/mL ampicillin selection. The expression vector for secretion of recombinant 466 
PfCyRPA was generated by PCR using the plasmid BVM_PFD1130W_FLAG_GP_His as 467 
template (Dreyer et al., 2010). The resulting expression vector pcDNA3.1_BVM_CyRPA(26- 468 
362)_His6 encodes the bee-venom melittin (BVM) signal sequence to secrete PfCyRPA into 469 
the cultivation medium, and a C-terminal His6-tag. Three asparagine residues (N145, N322, 470 
and N338) were predicted to be potential sites for N-glycosylation of PfCyRPA in 471 
mammalian cells. Since Plasmodium proteins are not glycosylated (Dieckmann-Schuppert et 472 
al., 1992), an expression vector coding for the PfCyRPA triple variant N145Q/N322Q/N338Q 473 
comprising residues 29-362 and containing no N-glycosylation sites was derived from the 474 
first vector by site-directed mutagenesis (GenScript). The expression vector coding for the 475 
PfCyRPA Asp66Lys single amino acid variant (D66K) was also generated by site-directed 476 
mutagenesis (GenScript) resulting in the expression plasmid pcDNA3.1_BMV_CyRPA(29– 477 
362/D66K)_His6. 478 
Monoclonal antibodies 479 
Generation of anti-PfCyRPA mAbs has been described elsewhere (Dreyer et al. 2010; 480 
Favuzza et al. 2016). Anti-PfRH5 antibodies were generated using the same strategy as 481 
described by Dreyer et al. 2010. 482 
Plasmodium falciparum blood stage culture 483 
Plasmodium falciparum strains 3D7, K1, 7G8 and D6 were obtained from the Malaria 484 
Research and Reference Reagent Resource Center (MR4; Manassas, VA, USA) (MRA-102, - 485 
159, -154 and -285, respectively). Parasites were cultured essentially as described previously 486 
(Matile and Pink, 1990). The culture medium was supplemented with 0.5% AlbuMAX (Life 487 
Technologies) as a substitute for human serum (Dorn et al., 1995). Cultures were 488 
synchronized by sorbitol treatment (Lambros and Vanderberg, 1979). Erythrocytes for 489 
passages were obtained from the Swiss Red Cross (Switzerland). 490 
In vitro growth inhibition assay 491 
In vitro growth inhibition assays with P. falciparum strains 3D7, K1, 7G8 and D6 were 492 
conducted essentially as described (Persson et al., 2006). Each culture (trophozoite stage 493 
parasites, 0.5% hematocrit, 2% parasitemia) was set up in triplicate in 96-well flat-bottomed 494 
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culture plates. After 48 hours of incubation (one cycle of merozoite invasion), viable parasites 495 
were stained with hydroethidine and analyzed in a FACSscan flow cytometer (Becton 496 
Dickinson) using CellQuest software. A total of 50,000 cells per sample were analyzed. 497 
Percent inhibition was calculated from the mean parasitemia of triplicate test and control 498 
wells as: 499 
Percent inhibition (%) = control – test / (control / 100) 500 
Parasitemia of control samples was also determined by counting GIEMSA stained parasites. 501 
In vivo growth inhibition assay 502 
All procedures involving living animals were performed in strict accordance with the Rules 503 
and Regulations for the Protection of Animal Rights (Tierschutzverordnung) of the Swiss 504 
Federal Food Safety and Veterinary Office. The protocol was granted ethical approval by the 505 
Veterinary Office of the county of Basel-Stadt, Switzerland (Permit Numbers: 2375 and 506 
2303). Monoclonal antibodies were tested in the murine P. falciparum model essentially as 507 
described (Dreyer et al., 2012; Jiménez-Díaz et al., 2009). Human erythrocytes (hE) were 508 
administered daily (0.75 mL) by the i.v. or i.p. route. Mice received a single dose of mAbs 509 
formulation by i.v. injection. The following day, mice were infected with 3x107 erythrocytes 510 
parasitized by P. falciparum PfNF540230/N3, a strain developed at GlaxoSmithKline (GSK) for 511 
growth in hE engrafted mice (Jiménez-Díaz et al., 2009). Parasitemia was monitored daily by 512 
flow cytometry over six days (day four to nine after mAb injection). 513 
Protein production 514 
FreeStyle 293-F cells (Invitrogen, R790-07), a variant of human embryonic kidney HEK 515 
cells, were cultured in suspension in serum-free medium (FreeStyle™ 293 Expression 516 
Medium, Thermo Fisher Scientific) at 37°C in a humidified incubator with 5% CO2 in 517 
volumes of 1 L shake flasks (Corning; 120 rpm, 5 cm diameter) or 10 L wave bioreactors 518 
(Sartorius; 30 rpm, pH 7.2, 30% dissolved oxygen). Cells were diluted 1:2 with fresh culture 519 
medium and transfected at 1.2·106 cells/mL with 0.4 mg/L expression plasmid using a 520 
riDOM-based transfection system (Quebatte et al., 2014). 72 h post-transfection, cells were 521 
removed by filtration and the supernatant was concentrated with a 10K Pellicon 3 cassette 522 
(Millipore). The His6-tagged recombinant proteins were purified by immobilized metal ion 523 
affinity chromatography on a HisTrap HP column (5 or 10 mL volume; GE-Healthcare) 524 
equilibrated with 50 mM HEPES/NaOH pH 7.2, 500 mM NaCl. After washing the column 525 
with the same buffer containing 20, 40 and 50 mM imidazole, the protein was eluted with a 526 
linear 50-500 mM imidazole gradient over 20 column volumes. The eluate was concentrated 527 
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by ultra-filtration (Amicon Ultra-4 Ultracel 10K) and applied to a HiLoad 16/600 Superdex 528 
200 gel permeation column (GE-Healthcare) equilibrated with 50 mM Tris/HCl pH 7.4, 150 529 
mM NaCl. Homogeneity of PfCyRPA was assessed by reversed-phase chromatography (RP- 530 
HPLC) on a Poroshell 300SB-C8 1x75 mm2 column using a H2O + 0.01% TFA / Acetonitrile 531 
+ 0.08% TFA gradient, and was confirmed by LC/MS intact mass analysis. Protein yields 532 
were 17 mg and 10 mg per liter of culture for the glycosylated and non-glycosylated 533 
PfCyRPA, respectively. 534 
Purified anti-PfCyRPA mAb c12 (Dreyer et al., 2012) was diluted to 0.5 mg/mL in 20 mM 535 
sodium phosphate pH 7.0 and cleaved overnight at 21°C with 0.01 mg/mL papain (Sigma- 536 
Aldrich) in a molar ratio of 1:20. The reaction was stopped with 0.001 mg/mL E64 inhibitor 537 
(Sigma-Aldrich) and the concentrated (Amicon Ultra-4 Ultracel 10K) hydrolysate was applied 538 
to a 1 x 5 cm2 Toyopearl protein A (Tosoh Biosciences) column equilibrated in 20 mM 539 
sodium phosphate pH 7.0. The flow-through containing the Fab was concentrated and 540 
chromatographed on a 21.5 x 60 cm2 TSKgel G3000SW column (Tosoh Bioscience) 541 
equilibrated with 20 mM bis-Tris propane/HCl pH 7.0, 200 mM NaCl. The purity of the Fab 542 
was determined by RP-HPLC as described above. 543 
The complex of PfCyRPA with the Fab of mAb c12 (abbreviated as c12 in the following) was 544 
prepared with a 1.5-fold excess of PfCyRPA, which was incubated for 20 min at 21°C, 545 
concentrated as above and chromatographed via a Superdex 200 Increase 10/300 GL column 546 
(GE-Healthcare) equilibrated with 20 mM bis-Tris propane/HCl pH 7.0, 200 mM NaCl. 547 
Complex-containing fractions were pooled and analyzed for homogeneity by asymmetric flow 548 
field-flow fractionation with static multi-angle light scattering (SEC/AF4-MALS). For the 549 
expression of the Asp66Lys PfCyRPA variant and PfRH5, FreeStyle 293-F cells were 550 
cultured in suspension in serum-free medium (FreeStyle™ 293 Expression Medium, Thermo 551 
Fisher Scientific) at 37°C in a humidified incubator with 5% CO2 in 125 mL shake flasks. 552 
Cells were diluted 1:2 with fresh culture medium and transfected at 106 cells/mL with 0.5 553 
mg/L expression plasmid using the 293fectinTM transfection reagent (Thermo Fisher 554 
Scientific). 72 h post-transfection, cells were removed by centrifugation, and the His6-tagged 555 
recombinant Asp66Lys PfCyRPA variant was purified by immobilized metal ion affinity 556 
chromatography on a HisTrap HP column (1 mL volume; GE-Healthcare) equilibrated with 557 
50 mM Na-phosphate buffer pH 7.2, 500 mM NaCl. After washing the column with the same 558 
buffer containing 20 mM imidazole, the protein was eluted (isocratic elution) with 500 mM 559 
imidazole over 5 column volumes. 560 
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FreeStyle 293-F cells were tested and shown to be free of mycoplasma using MycoAlert 561 
Mycoplasma detection kit (Lonza; LT07-318). Identity of cells was confirmed using STR- 562 
PCR (Qiagen; Investigator Idplex Pkus Kit, 381625) from genomic DNA purified using High 563 
Pure PCR Template Kit (Roche Applied Science 11796828001). The obtained profile was 564 
compared to the database available from DSMZ and found to match the HEK293 profile. 565 
Expression of PfCyRPA fragments on the surface of HEK cells 566 
293 HEK cells (ATCC, CRL-1573) expressing PfCyRPA fragments on the cell surface were 567 
generated essentially as described previously by (Dreyer et al., 2012). Briefly, DNA 568 
sequences coding for the fragments of PfCyRPA were amplified by PCR from the 569 
BVM_PFD1130W_FLAG_GP_His plasmid (Dreyer et al., 2010). These expression vectors 570 
allow the anchoring of the protein of interest on the cell surface via the transmembrane 571 
domain of mouse glycophorin-A (GP). In addition they contain the secretion signal of bee- 572 
venom melittin (BMV), a FLAG tag located extracellularly, and a His6-tag located in the 573 
cytosol. The 293 HEK cells were transfected with the different expression vectors using 574 
JetPEI transfection reagent (PolyPlus) according to the manufacturer’s instructions. Transient 575 
transfectants were harvested 48 h post-transfection. HEK cell lysates were prepared at 107 576 
cells/mL in RIPA-Buffer (1 % NP40, 0.25 % DOC, 10 % glycerol, 2 mM EDTA, 137 mM 577 
NaCl, 20 mM Tris/HCl pH 8.0, plus protease inhibitors) and used for Western blot analysis as 578 
described in (Favuzza et al., 2016).  579 
293 HEK cells were regularly tested by PCR with mycoplasma-specific primer GPO-1 (5'- 580 
ACTCCTACGGGAGGCAGCAGTA-3') and MGSO (5'-TGCACCATCTGTCACTCTGTTA 581 
ACCTC-3') and shown to be mycoplasma-free. 582 
Biophysical characterization of PfCyRPA 583 
To locate the disulfide bonds in PfCyRPA, peptides derived from proteolysis under native 584 
conditions by the endo-proteases LysC, AspN, and trypsin were analyzed by UPLC-tandem 585 
mass spectrometry using a Dionex UltiMate3000 RRLC system (Thermo Scientific) coupled 586 
to a Synapt G2 HDMS mass spectrometer (Waters) with an electrospray ion source and 587 
working in resolution mode under default parameters. 10 µg PfCyRPA was hydrolyzed for 588 
several hours at 37°C with 0.3 µg of LysC, trypsin, or AspN. Peptides were separated on a 589 
Waters BEH130 C18 1.7 µm UPLC column (0.3x150 mm2) by a 5–45% gradient of 590 
acetonitrile in water containing 0.1% HCOOH at a flow rate of 10 µL/min over 90 min and 591 
eluted into the mass spectrometer. Data was analyzed using BiopharmaLynx software Ver. 592 
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1.3 (Waters). The data derived from the proteolysis are summarized in Figure 3-figure 593 
supplement 2. 594 
The secondary structure composition of PfCyRPA was estimated by far-UV circular 595 
dichroism (CD) spectroscopy on a Jasco J-815 spectropolarimeter using 10 µM PfCyRPA in 596 
phosphate buffered saline (PBS) at 20°C. A cell of 1 mm path length was used to record four 597 
spectra between 200 and 320 nm with a step size of 0.1 nm and an integration time of 1 s. The 598 
spectral average was corrected for buffer contributions. 599 
Intrinsic tryptophan fluorescence of a 5 µM PfCyRPA solution under native (PBS) and 600 
denaturing (70°C or PBS with 9 M urea) conditions was measured on an ISS PC-1 photon 601 
counting spectrofluorimeter (ISS, Inc.) at 20°C. Fluorescence emission was excited at 295 nm 602 
with 4.8 nm band width and path length 1 mm. Emission was monitored in 2 nm steps 603 
between 300 and 400 nm with a band width of 16 nm, a path length 5 mm, and an integration 604 
time of and 1 s. 605 
Crystallization and data collection 606 
All crystallization was done at 21°C in the sitting drop vapor diffusion setup using a Mosquito 607 
LCP crystallization robot (TTP Labtech). If not stated otherwise crystals were cryo-protected 608 
with paraffin oil and vitrified in liquid N2. A non-glycosylated variant of PfCyRPA (residues 609 
Asp29–Glu362, N145Q/N322Q/N338Q) did not yield well-diffracting crystals unless pre- 610 
treated with proteases. 1 mg/mL PfCyRPA in 50 mM Tris/HCl pH 7.4, 150 mM NaCl was 611 
diluted 1:1 with 10 mM HEPES/NaOH pH 7.5, 500 mM NaCl, subjected for 16 h to a panel 612 
of twelve proteases (Hampton Research Proti-Ace Kit) at a final concentration of 0.01 613 
mg/mL, and analyzed by reducing SDS-PAGE (Figure 4-figure supplement 1). Of the 614 
proteases that changed the apparent molecular mass of PfCyRPA, subtilisin and proteinase K 615 
produced multiple bands, while Glu-C, elastase, and thermolysin produced a single band of 616 
slightly smaller apparent molecular mass. The thermolysin-treated PfCyRPA was subjected to 617 
crystallization, yielding triclinic crystals upon mixing of 120 nL 7.3 mg/mL PfCyRPA in 50 618 
mM Tris/HCl pH 7.4, 150 mM NaCl with 80 nL of precipitant consisting of 0.2 M LiOAc and 619 
20% (w/v) PEG 3350. These crystals are consistent with four molecules per unit cell but did 620 
not diffract X-rays beyond a resolution of 3.3 Å. Actinase E-treatment of PfCyRPA results in 621 
a different proteolysis pattern with two bands of apparent molecular mass 17 kDa and 20 kDa 622 
(Figure 4-figure supplement 1). Thin, plate-shaped monoclinic crystals diffracting to a 623 
maximum resolution of about 2.5 Å were obtained from mixing of 100 or 140  nL 15 mg/mL 624 
Actinase E-treated PfCyRPA in 50 mM HEPES/NaOH pH 7.5, 150 mM NaCl with 100 nL 625 
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and 60 nL precipitants consisting of 0-0.5 M MgCl2 and 20-25% PEG 3350. Crystals of the 626 
same habit were also obtained from 7.6 mg/mL PfCyRPA mixed with 19 % PEG 3350, 0.3 M 627 
MgCl2 and additional 5 mM CaCl2, SrCl2, and BaCl2. Data collected from crystals grown in 628 
the presence of the heavier cations were tested for anomalous and isomorphous information 629 
content for phasing, which turned out to be negative. 630 
Fab of mAb c12 crystallized from several conditions and its structure was determined in three 631 
crystal settings. Crystals were obtained by mixing of 80 nL 16.6 mg/mL c12 in 20 mM bis- 632 
Tris propane/HCl pH 7.0, 200 mM NaCl with 120 nL of precipitants consisting of 1.6 M 633 
sodium citrate pH 6.5 (hexagonal crystal form) or 0.1 M HEPES/NaOH pH 7.0, 20% w/v 634 
PEG 8000 (monoclinic and orthorhombic crystal forms). Monoclinic crystals were cryo- 635 
protected with reservoir solution supplemented with 20% glycerol. 636 
Needle-shaped crystals of the PfCyRPA/c12 complex were obtained by mixing 120 nL of a 637 
15.1 mg/mL solution in 50 mM Tris/HCl pH 7.4, 150 mM NaCl with 80 nL reservoir 638 
consisting of 0.1 M Sodium citrate pH 5.5, 17 % w/v PEG 5000 MME, 0.2 M NDSB-201 639 
(non-detergent sulfobetaine). Cryo-protection was achieved with reservoir solution 640 
supplemented with 20% ethylene glycol. 641 
Diffraction data were collected at Swiss Light Source beamline PX-II on a Pilatus 6M single 642 
photon counting detector using 1 Å radiation over a total range of at least 180° in fine slicing 643 
mode (Df = 0.25°). Data were indexed, integrated, and scaled with XDS (Kabsch, 2010), 644 
except for data from the hexagonal form of c12, which was integrated with MOSFLM and 645 
scaled with AIMLESS (CCP4, 1994). The high resolution limit was chosen as the shell where 646 
the correlation coefficient for half datasets CC1/2 dropped below 70%. Data sets were tested 647 
for internal symmetry by self-Patterson and self-rotation function analyses (not shown). 648 
Twinning was excluded based on L-values and second moments. Data collection and also 649 
refinement statistics are collected in S1 Table. 650 
Structure determination and refinement 651 
The presence of a short sequence motif in PfCyRPA that is characteristic for sialidases 652 
suggested that a six-bladed b-propeller might serve as a molecular replacement model. 653 
However, all attempts using several hundred b-propeller structures as search models both 654 
with and without loop regions and/or as poly-Ala models were unsuccessful. Sialidases often 655 
contain structural Ca2+ ions, which prompted co-crystallization of PfCyRPA with the earth 656 
alkali cations Ca2+, Sr2+, and Ba2+ for SIRAS phasing, but none of these provided useful 657 
derivatives. Attempts to phase the PfCyRPA diffraction data by sulfur-SAD were also 658 
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unsuccessful. Packing density estimations indicated two molecules of PfCyRPA in the 659 
monoclinic asymmetric unit. The PfCyRPA data could be phased by molecular replacement 660 
using the unexplained electron density of the PfCyRPA/c12 complex (see below) as a search 661 
model. The volume of density was separated using a mask, placed in a large cubic cell, and 662 
back transformed to yield structure factor amplitudes, which were then used in a PHASER 663 
(CCP4, 1994) molecular replacement search for two molecules. The solution had a non- 664 
random log-likelihood gain of LLG = 175 and the orientations of the two entities replicated 665 
the 180° two-fold NCS (non-crystallographic symmetry) estimated from the self-rotation 666 
function. Density averaging using PARROT (CCP4, 1994) and the NCS operator defined by 667 
the two PHASER solutions resulted in manually interpretable electron density maps. The final 668 
model has a discontinuity at Asp189, which is consistent with cleavage of a surface loop by 669 
Actinase E. A symmetry-related PfCyRPA occupies the space liberated by the cleaved loop, 670 
explaining the necessity of the proteolytic pre-treatment for crystal formation in this setting. 671 
The model was refined using automatically generated NCS restraints excluding diverging 672 
surface loop regions. 99.5% of all residues are in the favored regions of the Ramachandran 673 
plot. The hexagonal dataset of c12 (Supplementary file 1) was phased by molecular 674 
replacement using a homology model generated from the c12 sequence in MOE (Chemical 675 
Computing Group) as the search model. Separate searches for the variable and constant parts 676 
of the Fab were performed in PHASER, which, as anticipated, placed the VHVL and CHCL 677 
domain boundaries close to each other to generate a complete Fab. The final model has 99.2% 678 
of all residues in the favored regions of the Ramachandran plot. The monoclinic and 679 
orthorhombic c12 datasets were phased using the refined hexagonal c12 structure as 680 
molecular replacement search model. Both structures have 98% of their main-chain torsion 681 
angles in the favored region of the Ramachandran plot. Elbow angles were calculated with 682 
PHENIX (Adams et al., 2010). 683 
According to the Matthews parameter the 4 Å dataset collected from the PfCyRPA/c12 684 
crystal has enough space per asymmetric unit to harbor a single complex. Molecular 685 
replacement readily placed c12, and initial maps calculated from this partial solution revealed 686 
additional electron density at the tips of the Fab (Figure 5-figure supplement 1), which 687 
occupied a volume large enough to host PfCyRPA. The density resembled a b-propeller but 688 
was not interpretable due to the limited resolution of the data. However, this density provided 689 
enough phasing power to solve the 2.5 Å PfCyRPA structure (see above), showing that the 690 
placement of the Fab was correct. The same arrangement of VHVL and CHCL was obtained 691 
when using the VHVL and CHCL parts of the Fab as separate search models, indicating that the 692 
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elbow angle of c12 does not change upon binding to PfCyRPA. The final model of PfCyRPA 693 
was used to complete the molecular replacement phasing of the PfCyRPA/c12 complex (log- 694 
likelihood gain of >1260), density for which is shown in Figure 5-figure supplement 2. A loop 695 
region not present in the PfCyRPA model could be traced in the electron density of the 696 
complex (Panel B in Figure 5-figure supplement 1), establishing confidence in the correctness 697 
of the molecular replacement solution. The model of the complex was refined according to 698 
established protocols for lower resolution structures (DeLaBarre and Brunger, 2006), i.e. 699 
using simulated annealing, group ADP values, automatically assigned TLS definitions, 700 
secondary structure restraints, and external restraints provided by the higher resolution 701 
individual structures of PfCyRPA and c12. No real-space refinement was applied during 702 
building and refinement of the PfCyRPA/c12 complex. Strong geometric restraints were 703 
applied throughout model building of the PfCyRPA/c12 complex. All models were built with 704 
COOT (Emsley et al., 2010) and refined with PHENIX (Adams et al., 2010). 705 
  706 
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Supplementary data 994 
 995 
Figure 1-figure supplement 1. Cell-surface expression of PfCyRPA fragments on transiently transfected HEK cells  996 
Fluorescence staining of HEK cells expressing PfCyRPA fragments on their surface after staining with (A) anti-His tag HIS- 997 
6/9 mAb or (B) anti-PfCyRPA c12 mAb and FITC-labelled anti-mouse IgG antibodies. Nuclei were stained with DAPI. 998 
Untransfected HEK cells served as negative control. 999 
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 1000 
Figure 2-figure supplement 1. Anti-PfCyRPA and anti-PfRH5 mAbs inhibit parasite growth of various P. falciparum 1001 
strains 1002 
Synchronized P. falciparum 3D7, 7G8, K1 and D6 (A, B, C, and D, respectively) blood-stage parasites were cultured for one 1003 
life cycle in the presence of anti-PfCyRPA c12 mAb, anti-PfRH5 BS1.2 mAb, and their combinations. An isotype-matched, 1004 
malaria-unrelated control mAb (NR4.2 mAb) was used as negative control. Percent parasite growth inhibition was calculated 1005 
against the parasitemia of PBS control wells. Each bar represents the mean of a triplicate experiment, and error bars indicate 1006 
the standard deviation (SD). Differences in parasite growth inhibition between mAbs c12 and BS1.2 alone and their 1007 
combinations are statistically significant (unpaired t test with Welch’s correction, 95% confidence interval, two-tailed p 1008 
value). 1009 
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 1010 
Figure 3-figure supplement 1. Sequence alignment of CyRPA orthologs 1011 
Sequence alignment of CyRPA orthologs from P. falciparum (P. fal.), P. vivax (P. viv.; PVX_090240), P. knowlesi (P. kno.; 1012 
PKNH_0515800), P. cynomolgi (P. cyn.; PCYB_053730), and P. reichenowi (P. rei.; PRCDC_0421000). Full-length protein 1013 
sequences (PlasmoDB; plasmodb.org/plasmo) were aligned with Clustal O (1.2.1). Asterisks indicate conserved positions, 1014 
colons indicate strong biophysical conservation, and periods indicate weak biophysical conservation. Ten of the twelve Cys 1015 
residues are conserved (same color code as in Figure 3). The predicted PfCyRPA secretion signal sequence (M1-C28) is 1016 
indicated in boldface, and the predicted GPI-anchor motif (I353-E362) is underlined. The N-glycosylation sites that are used 1017 
in human cells (N145, N322, and N338) are shown in lowercase and the non-synonymous SNPs (D73, D110, V165, P168, 1018 
R174, F187, D236, N270, V292, N338, R339, L341, N352) are colored in red. 1019 
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 1020 
Figure 3-figure supplement 2. Biophysical analysis of PfCyRPA 1021 
(A) The CD spectrum of PfCyRPA shows a prominent minimum around 215 nm, consistent with a high content of b- 1022 
secondary structure. The minimum is remote from the minima expected for helical (208 nm and 222 nm) and random coil 1023 
(200 nm) structures. 1024 
(B) Identification of disulfide bonds in PfCyRPA. The peptide fragments are labeled K (LysC cleavage), D (AspN cleavage), 1025 
and T (trypsin cleavage). A cut-off of 2 % signal intensity was applied to separate highly populated from less populated 1026 
fragments. Masses that correspond to two proteolytic peptides connected by disulfide bonds were repeatedly found 1027 
(parentheses) when using different proteases. An equal sign (=) signifies a disulfide bond and a minus sign (-) signifies a 1028 
skipped cleavage. For instance, the first disulfide bond between Cys48 and Cys64 was identified four times in the LysC 1029 
hydrolysate: K2=K3 corresponds to the mass of the second and third expected proteolytic fragment linked by a disulfide 1030 
bond. K2=K3-4 is the second expected LysC peptide (K2) disulfide-linked to a larger peptide (K3-K4) that still contains a 1031 
LysC cleavage site but this site was not recognized by the enzyme. The same reasoning applies to K2=K3-5, where two LysC 1032 
cleavage sites were not recognized. An asterisk (*) denotes a disulfide bond in a peptide. The K2-4* fragment has a mass 1033 
corresponding to an un-cleaved and disulfide-linked peptide with two intact LysC cleavage sites that were not recognized. 1034 
The last disulfide bond ion PfCyRPA between Cys303/327 was not identified by any protease, possibly due to low 1035 
abundance of the proteolytic fragments containing it. 1036 
(C) The fluorescence emission spectrum of native PfCyRPA (black) shows a maximum at 326 nm that shifts to 338 nm when 1037 
heated to 70°C (red) or 355 nm when unfolded by 9 M urea (blue). Addition of 50 mM DTT (magenta) has no significant 1038 
effect on the fluorescence, suggesting that the disulfide bonds are not solvent-accessible. The unusual finding that the Trp 1039 
fluorescence quantum yield of the unfolded state is higher than in the native state indicates that the excited state of Trp is 1040 
efficiently quenched by nearby residues in the native structure (Chen and Barkley, 1998). 1041 
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 1042 
Figure 3-figure supplement 3. PfCyRPA lacks detectable sialidase activity in a functional assay 1043 
Sialidase activity was estimated using the Amplex Red Neuraminidase (Sialidase) assay kit (Molecular Probes, Inc.). The 1044 
assay utilizes Amplex Red to detect H2O2 generated by galactose oxidase oxidation of desialiated galactose, the end product 1045 
of sialidase activity. The H2O2 in the presence of HRP reacts with Amplex Red reagent to generate resorufin, the red 1046 
fluorescent oxidation product, which was detected at 570 nm using the Sunrise Absorbance Reader (Tecan). PfCyRPA was 1047 
mixed 1:1 (v/v) with the Amplex Red reagent/HRP/galactose oxidase/fetuin working solution (0.2U/mL HRP, 4U/mL 1048 
galactose oxidase, 500 µg/mL fetuin), and the mixture was incubated at 37°C for 30 min in a light-protected container. 1049 
Sialidase and H2O2 (supplied with the kit) were used as positive controls (Ctrl+); a no-sialidase sample as negative control 1050 
(Ctrl-). 1051 
  1052 
Results – Part 3 
 
145 
 1053 
Figure 4-figure supplement 1. Limited proteolysis of PfCyRPA and the PfCyRPA/c12 complex 1054 
(A) PfCyRPA. (B) PfCyRPA/c12 complex. Proteases are abbreviated as: αC: α-Chymotrypsin; TR: Trypsin; EL: Elastase; 1055 
PA: Papain; SU: Subtilisin; EGC: Endoproteinase Glu-C; PK: Proteinase K; CL: Clostripain; PE: Pepsin; TH: Thermolysin; 1056 
BR: Bromelain; AE: Actinase E. The two bands around 28 kDa in (B) correspond to the Fab. Actinase E affects PfCyRPA 1057 
irrespective of bound c12, yielding two major proteolysis products of apparent molecular weight 17 kDa and 20 kDa. 1058 
  1059 
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 1060 
Figure 5-figure supplement 1. Electron density of the PfCyRPA/c12 complex 1061 
(A) Initial electron density at a resolution of 3.6 Å contoured at the 1 rmsd level for PfCyRPA after molecular replacement 1062 
phasing of the PfCyRPA/c12 complex data with c12 as the search model. The light and heavy chains of c12 are colored pink 1063 
and cyan, respectively. The final model of PfCyRPA (blades colored in the same pattern as in Figure 3A) is superimposed for 1064 
reference but could not be traced using this map. This map fragment was cut out and used as starting model for molecular 1065 
replacement of the PfCyRPA structure. 1066 
(B) Zoom of the loop region 186-KFKDDNK-192. This loop was cut at Asp189 by Actinase E. The loop opened and the 1067 
sequence could not be completely traced in the isolated PfCyRPA structure (yellow). Difference electron density at a 1068 
resolution of 3.6 Å contoured at the 1.8 rmsd level shows that the loop is intact in the PfCyRPA/c12 complex and can be 1069 
traced in the electron density maps. The refined model of the complex (loop colored in cyan) is superimposed for reference. 1070 
(C) Region around Arg50 in the free c12 Fab structure 5ezj. 2mFo-DFc electron density is shown at the 1 rmsd level. Arg50 1071 
binds to nearby Asp52. 1072 
(D) This interaction is lost in the complex with PfCyRPA. Arg50 now binds to PfCyRPA residue Asp66 (light blue). 2mFo- 1073 
DFc electron density is shown at the 0.8 rmsd level. 1074 
(E) Superposition of the structures from panels (C) and (D) shows the large movement of Arg50 in the free c12 Fab 1075 
(magenta) versus its position in the complex with PfCyRPA (pink). By contrast, the conformation of Tyr112 does not change 1076 
much. 1077 
  1078 
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 1079 
Figure 5-figure supplement 2. Electron density of the PfCyRPA/c12 complex at the interface 1080 
The final model of the PfCyRPA/c12 complex is shown. PfCyRPA is at the top, shown as a grey ribbon representation. Fab 1081 
c12 is at the bottom with the light and heavy chain colored magenta and blue, respectively. 2Fo-Fc electron density at 4Å 1082 
resolution is contoured at the 1 rmsd level at a radius of 22Å around the center of the image. The panel on the left-hand side 1083 
shows the electron density after molecular replacement (A), while the panel on the right-hand side depicts the density after 1084 
refinement (B). 1085 
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Abstract 26 
Background 27 
One key challenge for the development of a malaria subunit vaccine lies in the identification 28 
of suitable target antigens. Sequencing and annotation of the Plasmodium falciparum genome 29 
has disclosed the sequence of several thousand potential targets for malaria vaccine 30 
development, and reverse-vaccinology approaches offer the possibility to rationally select 31 
new targets from a large set of so far uncharacterized open reading frames (ORFs). 32 
Methods 33 
On the basis of available genome-wide transcriptomic and proteomic data, we selected 34 
previously uncharacterized Plasmodium falciparum ORFs and evaluated their potential as 35 
novel asexual blood-stage vaccine candidate antigens. For this purpose, we exploited a 36 
mammalian cell-based antigen expression platform for immunization of mice, raised antigen- 37 
specific mouse monoclonal antibodies (mAbs), and evaluated their parasite inhibitory 38 
activity. 39 
Results 40 
This strategy has led us to the identification of PF14_0044 as a potential asexual blood-stage 41 
candidate antigen for inclusion into a multi-component malaria subunit vaccine. While 42 
PF14_0044 -specific mAbs had only marginal parasite growth-inhibitory activity on their 43 
own, they showed a significant synergistic inhibitory activity in combination with previously 44 
described inhibitory anti-PfCyRPA mAbs. 45 
Conclusions 46 
Our findings demonstrate that for the selection of new malaria vaccine candidate antigens 47 
both the direct parasite growth inhibitory activity of target specific antibodies and their 48 
synergy with growth inhibitory antibodies against other antigens should be systematically 49 
evaluated. 50 
 51 
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Introduction 52 
According to the latest estimates, there were about 212 million cases of malaria in 2015 and 53 
an estimated 429,000 deaths, mostly among children under five years of age in Africa [1]. 54 
Despite the remarkable improvements achieved in malaria control, which have led to a drastic 55 
reduction of malaria morbidity and mortality rates in the last decade, the development of an 56 
effective vaccine against malaria is still recognized as a most promising method for 57 
preventing and controlling malaria. However, complexity of the Plasmodium spp. parasite as 58 
well as the host response to the parasite has hindered the development of a highly effective 59 
vaccine until now. In spite of these challenges, field and clinical studies showed that some 60 
degree of clinical immunity can be acquired naturally with age and exposure [2] or induced 61 
by passive [3,4] or active immunization [5]. Those studies support the idea that a malaria 62 
vaccine is feasible and pointed out the importance of antibodies as crucial components of the 63 
immune response against blood stage parasites. Until recently, almost all efforts in malaria 64 
vaccine development have been focused on a selected panel of antigens recognized as 65 
immunodominant in the context of natural infection. These studies have primarily focused on 66 
the Circumsporozoite protein (CSP) for the pre-erythrocytic stage, and Merozoite Surface 67 
Protein-1 (MSP-1) and Apical Membrane Antigen-1 (AMA-1) for the blood stage, and 68 
investigated a variety of vaccine delivery systems [6–10]. However, despite major efforts, 69 
candidate subunit vaccines against malaria have shown limited efficacy in clinical trials [11– 70 
14]. This lack of success in single-antigen subunit based vaccines, led to the recognition that 71 
an effective malaria vaccine will likely need to be a multi-component, multi-stage vaccine 72 
[15]. Indeed, is not unforeseen that single-antigen based vaccines failed to confer effective 73 
immune protection against a parasite with such a complex lifecycle, which expresses 74 
hundreds of stage-specific proteins, and that has evolved under the pressure of the human 75 
immune system for millennia [16]. Recent findings indicate that the search for new candidate 76 
antigens for a multivalent malaria vaccine should target parasite proteins that are not 77 
immunodominant in the context of natural infection [17,18]. For protection from clinical 78 
malaria immune recognition of multiple antigens might be required [15,19–21], suggesting 79 
that only a subunit vaccine incorporating several rationally selected key antigens would be 80 
effective. Since the full genome of Plasmodium falciparum 3D7 was sequenced and annotated 81 
in 2002 [22], major efforts have continued to improve availability of large-scale genomic, 82 
proteomic, transcriptomic and comparative data, including different Plasmodium falciparum 83 
strains and clinical isolates and other Plasmodium species [23]. These extensive data sets 84 
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offer valuable and powerful tools for rational search for new candidate antigens, and have 85 
made reverse vaccinology the most promising strategy for vaccine development [24,25]. We 86 
have identified one of the new most promising asexual blood-stage candidate antigens, the 87 
Plasmodium falciparum Cysteine-Rich Protective Antigen (PfCyRPA), based on a reverse 88 
vaccinology approach selecting so far uncharacterized blood-stage antigens and evaluating 89 
their potential as vaccine components [26]. PfCyRPA is a key component of a crucial 90 
invasion pathway of erythrocytes by merozoites [17,27] and is capable of eliciting antibodies 91 
that inhibit parasite growth in vitro and in vivo [28]. Along this line we have characterized in 92 
the present study the PF14_0044 protein with regard to stage-specific expression, localization 93 
and its potential to elicit parasite inhibitory antibodies.  94 
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Materials & Methods 95 
Bacterial strains and media 96 
Escherichia coli strain Top10 (Thermo Fisher Scientific) was used for the amplification of 97 
plasmids. Bacteria were grown at 37°C in LB medium containing 100 µg/ml ampicillin. 98 
Construction of expression plasmids 99 
Codon optimized synthetic sequence encoding Plasmodium falciparum PF14_0044 gene 100 
(GenScript) was subcloned into pcDNA3.1_BVM_FLAG_GP_His as previously described 101 
[26] resulting in expression plasmid pcDNA3.1_BVM_PF14_0044_FLAG_GP_6xHis. This 102 
expression vector allows for expression of the PF14_0044 as membrane-anchored protein. It 103 
contains the secretion signal of bee-venom melittin (BVM), the coding sequence of the 104 
protein of interest, a FLAG-tag, the mouse glycophorin-A (GP) transmembrane domain (for 105 
membrane anchoring), and a hexa-His tag. The expression vector coding for the recombinant- 106 
secreted version of PF14_0044 was generated by site-directed mutagenesis (GenScript) 107 
resulting in expression plasmid pcDNA3.1_BMV_PF14_0044_6xHis. This expression vector 108 
allows the expression of PF14_0044 as secreted protein via the BVM signal peptide. It 109 
contains the secretion signal of BVM, the coding sequence of the protein of interest and an N- 110 
terminal hexa-His tag. 111 
Culture of eukaryotic cells 112 
FreeStyle 293-F cells (Thermo Fisher Scientific), a variant of human embryonic kidney cell 113 
line HEK cells, were cultured in suspension in serum-free medium (FreeStyle™ 293 114 
Expression Medium, Thermo Fisher Scientific) supplemented with 30 mU Heparin at 37°C in 115 
a humidified incubator with 5% CO2 in volumes of 3 L shake flasks (Corning, 100 rpm, 5 cm 116 
diameter). 117 
Generation of transient HEK cell lines expressing PF14_0044 118 
FreeStyle 293-F cells were transfected with pcDNA3.1_BVM_PF14_0044_FLAG_GP_6xHis 119 
plasmid using a riDOM-based transfection system [29]. Prior to transfection at 1.2 x 106 120 
cells/ml, cells were diluted 1:2 with fresh culture medium and transfected with 0.4 mg/l 121 
expression plasmids and transfection reagents. Cells were harvested 48 hours post- 122 
transfection. 123 
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Immunofluorescence staining of methanol-fixed HEK cells 124 
HEK cells were collected, washed with PBS, spotted on multiwell glass slides (Multitest 125 
slide, 12-well, 7 mm, MP Biomedicals), air-dried and fixed in ice-cold methanol for 10 min. 126 
Immunostaining was performed by incubating the wells with 50 µl of hybridoma culture 127 
supernatant, or an appropriate mAb diluted in 0.1% BSA-PBS, for 20 min in a humid 128 
chamber at 37°C. After washing, 50 µl of 20 µg/ml Alexa488-conjugated rabbit anti-mouse 129 
IgG (H+L) antibody (Thermo Fisher Scientific) diluted in 0.1% BSA-PBS was added and 130 
incubated for 20 min in a humid chamber at 37°C. After the final wash, the slides were 131 
mounted in 50% PBS-glycerol and covered with a coverslip. Stainings were assessed by 132 
fluorescence microscopy on a Zeiss Axioscop fluorescence microscope (Carl Zeiss AG). 133 
Immune complex generation 134 
Transiently transfected HEK cells were collected and washed twice with PBS. Cell lysate 135 
were prepared at 107 cells/ml in complete lysis buffer (1% NP40, 0.25% DOC, 10% glycerol, 136 
2 mM EDTA, 137 mM NaCl, 20 mM Tris-HCl pH 8.0, Protease Inhibitors) for 10 min on ice. 137 
The lysate was cleared by centrifugation at 15,000g for 10 min at 4°C, and the supernatant 138 
kept at -80°C until use. For immune complex preparation, 1 mg of anti-His tag (His-6/9) mAb 139 
[26] was added to 50 ml of cell lysate and incubated over 3 days on an orbital shaker at 4°C. 140 
For immune complex purification, 1 ml of Protein G-coupled Sepharose beads (Sigma- 141 
Aldrich) was added and incubated under rotary agitation overnight at 4°C. The tubes were 142 
then centrifuged, the supernatants removed and the beads washed three times in NP40 Buffer 143 
(1% NP40, 10% glycerol, 2 mM EDTA, 137 mM NaCl, 20 mM Tris-HCl pH 8.0). To elute 144 
the immune complex, the resin was resuspended in 3 ml of Elution-Buffer (0.1M Glycine pH 145 
2.8) containing 0.1% TX100. The eluate was collected by centrifugation and the pH 146 
neutralized with NaHCO3, the buffer was exchanged to PBS-0.1% TX100 and the sample 147 
concentrated to 1 ml. Purified immune complex were kept at -80°C in fractions until use. 148 
Immunization of mice 149 
All procedures involving living animals were performed in strict accordance with the rules 150 
and regulations for the protection of animal rights (Tierschutzverordnung) of the Swiss 151 
Federal Food Safety and Veterinary Office. The protocol was granted ethical approval by the 152 
Veterinary Office of the county of Basel-Stadt, Switzerland (Permit numbers: 2375 and 153 
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2303). Specific pathogenfree HsdWin:NMRI outbred mice were purchased from Harlan 154 
Laboratories B.V. (The Netherlands) and used for immunizations studies. 155 
Living cells immunization 156 
Four Naval Medical Research Institute (NMRI) mice were immunized by intravenous (i.v.) 157 
injections of 106 transiently transfected HEK cells. Cells were thawed, washed and 158 
resuspended in 0.9% NaCl. Injections were accomplished on four consecutive days and, after 159 
two weeks, again on four consecutive days. Two weeks after the boost, blood was collected 160 
and the serum was tested for the presence of PF14_0044-specific antibodies by indirect 161 
Immunofluorescence assay (IFA) on HEK cells and Western blotting analysis on cell lysates. 162 
Immune complex immunization 163 
Four NMRI mice were immunized intraperitoneally (i.p.) with 20 µg / injection of antigen 164 
emulsified in aluminum hydroxide gel (Alhydrogel-2%, Brenntag Biosector) containing CpG 165 
ODN as immune enhancer [30]. The animals received three booster injections at two weeks 166 
intervals with the same antigen preparation. Two weeks after the last boost, blood was 167 
collected and the serum was tested for the presence of PF14_0044-specifc antibodies by IFA 168 
on HEK cells and Western blotting analysis on cell lysates. 169 
Fusion and cell-based selection  170 
The best immune responders were selected for fusion. Mice received two consecutive i.v. 171 
injections of 106 cells or single i.v. injection of 12.5 µl of Immune complex in PBS two days 172 
before the fusion. Mice were sacrificed and spleens were removed. Splenocytes were fused to 173 
the myeloma cell partner (PAI mouse myeloma cells, derived from SP-20, Institute of 174 
Immunology, Basel) using polyethylene glycol 1500 (Roche Diagnostics) [31]. The fusion 175 
mix was plated in four 96-well culture plates at 107 cells/plate (remaining cells were aliquoted 176 
and frozen down as backup fusions) and hybridomas were selected by growing in HAT 177 
medium supplemented with culture supernatant of mouse macrophages P388. Wells were 178 
screened for IgG production two weeks post-fusion by ELISA as described previously [26]. 179 
IgG-producing hybrids were further screened for specific IgG production by IFA on 180 
methanol-fixed cells as described above. IFA-positive wells were cloned in HT medium by 181 
limiting dilution to obtain monoclonal populations. 182 
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Antibodies production and characterization 183 
Identification of antibody subclasses was performed using a Mouse Monoclonal Antibody 184 
Isotyping Kit (ISO2, Sigma-Aldrich). For large-scale mAb production hybridoma cell lines 185 
were cultured in 500 ml roller-bottles (Corning). Antibodies were purified by affinity 186 
chromatography using Protein A Sepharose. 187 
Plasmodium falciparum blood stage culture 188 
Plasmodium falciparum strain 3D7 was cultured essentially as described previously [32]. The 189 
culture medium was supplemented with 0.5% AlbuMAX (Thermo Fisher Scientific) as a 190 
substitute for human serum [33]. Cultures were synchronized by sorbitol treatment [34]. 191 
Erythrocytes for passages were obtained from the Swiss Red Cross (Switzerland). 192 
Plasmodium falciparum merozoites were mechanically released from mature schizonts as 193 
previously described [35]. Briefly, late-stage parasites (40-46 h post-invasion) were purified 194 
by Percoll density gradient [36] and incubated with 10 µM E-64 inhibitor (Sigma-Aldrich). 195 
After 6–8 h incubation, mature schizonts were filtered through 1.2 µm filters to mechanically 196 
release merozoites. Then, merozoites were resuspended PBS and stored at −80 °C until 197 
further use. 198 
Western blotting analysis 199 
Blood stage parasite lysates were prepared essentially as described previously by saponin 200 
lysis of Plasmodium falciparum 3D7-infected erythrocytes [32]. In brief, cultured parasites 201 
were washed once with PBS. Pelleted infected red blood cells were lysed in 20 volumes of 202 
0.06% (w/v) saponin in PBS and incubated on ice for 20 min. Parasites were washed in PBS 203 
and the final pellet was resuspended in 3 volumes of RIPA-Buffer and incubated for 10 min 204 
on ice. The lysate was cleared by centrifugation at 15,000g for 10 min at 4°C and the 205 
supernatant kept at -80°C until use. HEK cells lysate were produced at 107 cells/ml in RIPA- 206 
Buffer as described above. For SDS-PAGE recombinant PF14_0044, cell- or parasite lysates 207 
were resolved on precast 4-12% gradient gels (NuPAGE® Novex 4-12% Bis-Tris Gel, 208 
Thermo Fisher Scientific) with MES running buffer according to the manufacturer’s 209 
directions. All samples were reduced with 50mMf dithiothreitol (DTT) and heated to a 210 
temperature of 70°C for 10 minute prior to loading. The proteins were electrophoretically 211 
transferred to nitrocellulose membrane using a dry-blotting system (iBlot, Thermo Fisher 212 
Scientific). After blocking the membrane, specific proteins were detected with appropriate 213 
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dilutions of mAbs followed by Horseradish Peroxidase (HRP) conjugated goat anti-mouse 214 
IgG mAb (SouthernBiotech). Blots were developed using ECL Western blotting detection 215 
reagents (ECL Western Blotting Substrate, Pierce). 216 
Immunofluorescence staining of infected erythrocytes and free merozoites 217 
For indirect immunofluorescence microscopy, smears of infected red blood cells and isolated 218 
free merozoites were fixed in ice-cold 60% methanol and 40% acetone for 2 min at -20°C, 219 
air-dried and blocked with 3% BSA in PBS. Cells were probed with the following antibodies: 220 
biotinylated anti-PF14_0044 mAb 2/27, Alexa 488-labeled mouse anti-GAPDH 1.4a mAb 221 
[37], Alexa 568-conjugated streptavidin (Thermo Fisher Scientific). The slides were mounted 222 
in mounting medium containing DAPI (ProLong Gold antifade reagent with DAPI, Thermo 223 
Fisher Scientific). Fluorescence microscopy was performed on a Leica DM-5000B using a 224 
60x oil immersion objective lens and documented with a Leica DFC345FX digital camera 225 
system. Images were processed using Leica Application Suite V4 (Leica) and Adobe 226 
Photoshop® CS6. For co-localization studies, cells were probed with the following antibodies: 227 
Alexa 568-labeled mouse anti-PF14_0044 mAb 2/27, Alexa 488-labeled mouse anti-RAP–1 228 
5-2 mAb [38], Alexa 488-labeled mouse anti-AMA–1 DV5a mAb [39]. Fluorescence 229 
microscopy was performed on a API DeltaVision Core using a 100x oil immersion objective 230 
lens and documented with a Photometrics CoolSNAP HQ2, interline transfer CCD. Images 231 
were processed using SoftWorx 4.1.2 and Adobe Photoshop® CS6.  232 
In vitro growth inhibition assay 233 
In vitro growth inhibition assays with Plasmodium falciparum strain 3D7 were conducted 234 
essentially as described [39]. Briefly, synchronous early trophozoites were diluted with fresh 235 
red blood cells to give a parasitemia of 0.5% and mixed with purified and sterile filtered 236 
mAbs. The final hematocrit in cultures was adjusted to 0.5%. Each culture was set up in 237 
triplicate in 96-well flat-bottomed culture plates. The cells were analyzed in a FACSscan flow 238 
cytometer using CellQuest software (Becton Dickinson). A total of 30,000 cells per sample 239 
were analyzed. Percent inhibition was calculated from the mean parasitemia of triplicate test 240 
and control wells as follows:  241 
Percent inhibition (%) = "#$%&#'(%)*%(,-./0-1 233)  242 
Anti-PfCyRPA c12 mAb [17] was used as reference growth-inhibitory antibody. The anti- 243 
PfRON12 (Plasmodium falciparum rhoptry neck protein 12) mAb PF10-1/2, the anti- 244 
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PfSHLP2 (Plasmodium falciparum shewanella-like protein phosphatase 2) mAb PFL-2/30 245 
and a malaria-unrelated anti-cortisol CORTI-4/16 mAb served as control antibodies. 246 
Recombinant protein expression and purification 247 
PF14_0044 (aa 21–290) was recombinantly expressed in mammalian cells employing the 248 
pcDNA3.1_BVM_PF14_0044_6xHis plasmid. When the PF14_0044 protein sequence was 249 
analyzed for the presence of N-glycosylation sites (NetNGlyc 1.0 Server) [Gupta et al. pers. 250 
comm.], one asparagine residue (N261) was predicted to be a potential site for N- 251 
glycosylation in human cells. To prevent the improper addition of glycans, which are absent 252 
from Plasmodium proteins [40], the potential N-linked glycosylation site (N-X-S/T, where X 253 
is not proline) was mutated by replacing the asparagine residue with glutamine (N261Q). The 254 
expression vector allows the secretion of the protein of interest in the cultivation medium: it 255 
contains the secretion signal of bee-venom melittin (BVM), the codon optimized coding 256 
sequence, and a C-terminal hexa-His tag. HEK cells were transfected as previously described 257 
and cell supernatant, containing secreted proteins, was harvested 72 hours post-transfection. 258 
Histidine-tagged proteins were purified by immobilized metal ion affinity chromatography 259 
(IMAC). The purity and integrity of the purified protein was analyzed by RP-HPLC on an 260 
Agilent 1290 Series with a Poroshell 300SB-C8, 1x75 mm column (Agilent). 261 
Chromatography was performed with a non-linear (H2O + 0.01% TFA / Acetonitrile + 0.08% 262 
TFA) gradient system. The protein concentration was determined by measuring the OD280 (1 263 
Abs = 1 mg/ml). The purified recombinant protein was identified as the expected PF14_0044 264 
protein by Western blotting analysis with PF14_0044-specific mAbs. 265 
Detection of PF14_0044-specific Abs in human sera.  266 
Human serum samples were derived from healthy individuals living along the Offin River in 267 
Ghana, a malaria endemic region [41]. ELISA plates (Maxisorp; Nunc) were coated with 1.5 268 
µg/ml purified recombinant PF14_0044 protein produced in HEK cells. After blocking, plates 269 
were incubated with dilutions of human serum. HRPO-conjugated goat anti-human IgG γ 270 
chain specific (SouthernBiotech) was used as secondary Ab and tetramethylbenzidine 271 
substrate (KPL) was used for development. The reaction was stopped with 0.5 M H2SO4, and 272 
the OD was measured at 450 nm with a microplate absorbance reader (Sunrise Absorbance 273 
Reader; Tecan). Selected human serum samples were also tested for specificity by Western 274 
blotting analysis on recombinant PF14_0044; anti-PF14_0044 mAb 2/32 served as positive 275 
control. 276 
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Results 277 
Sequence analysis of PF14_0044 278 
The PF14_0044 encoding gene (GeneID: 811626) is 873 bp long and located in the 279 
subtelomeric region of chromosome 14. Orthologs of PF14_0044 are present in the genomes 280 
of Plasmodium vivax (PVX_086200), Plasmodium knowlesi (PKH_134220), Plasmodium 281 
cynomology (PCYB_135180), Plasmodium reichenowi (PRCDC_1404000), Plasmodium 282 
berghei (PBANKA_103740), Plasmodium chabaudi (PCHAS_103820), and Plasmodium 283 
yoelii (PY17X_1039800) with an average identity of 63.25% (see Additional file 1). To 284 
evaluate the genetic diversity of PF14_0044 in Plasmodium falciparum we analyzed the gene 285 
sequences of 190 isolates (see Additional file 2) available on the plasmodia database 286 
PlasmoDB [42]. All sequences were identical to the Plasmodium falciparum 3D7 reference 287 
sequence with the exception of twelve non-synonymous single nucleotide polymorphism 288 
(SNP) and six deletions distributed along the gene (Fig. 1; see Additional file 2). The 289 
nucleotide diversitya calculated for this population was Pi: 0.00214. 290 
 291 
 292 
Fig.  1 Amino acid sequence of Plasmodium falciparum PF14_0044. Amino acid residues of the predicted secretion signal 293 
sequences are indicated in boldface. Twelve non-synonymous SNPs (shaded in grey) and 6 deletions (underlined) are 294 
indicated. 295 
Generation of anti-PF14_0044 monoclonal antibodies in mice  296 
A HEK cell line expressing Plasmodium falciparum PF14_0044 as transmembrane protein 297 
was established by transient transfection. To ensure expression on the mammalian cell 298 
surface, the PF14_0044 sequence was codon-optimized for expression in human cells and the 299 
endogenous secretion signal sequences (aa. 1-20) was replaced by the secretion signal 300 
sequence of bee-venom melittin. For membrane anchoring the transmembrane domain 301 
encoding sequence of mouse glycophorin-A was used and, to allow expression analysis, a 302 
FLAG tag was inserted N-terminally of the transmembrane domain and a hexa-His tag was 303 
placed at the C-terminus. Expression of recombinant PF14_0044 was confirmed by Western 304 
blotting analysis and immunofluorescence analysis (IFA) using an anti-His tag mAb [26]. The 305 
PF14_0044 expressing cells were used for (i) living cell immunization and (ii) generation of 306 
immune complexes derived from the lysate of the transfected HEK cells with an anti-His tag 307 
pfal3D7|PF14_0044   MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDI 60 
                    KIIANKEYEINCMNNSKVFCPLKDTFINNTNIKLYSPKLHFEIKDITHKGKNAALYYLKI 120 
                    DEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDIT 180 
                    PSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHV 240 
                    QEGDNYISFNVIFGEFKKHFNLTCSLDLSDFQQEPCNLGKTANITFIFSK  290 
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mAb. NMRI mice received intravenous injections of living tranfected HEK cells or 308 
intraperitoneal injections of immune complexes. Development of serum anti-PF14_0044 309 
antibody titers was assessed by Western blotting analysis (Fig. 2). While discrete PF14_0044 310 
bands were detected when lysates of PF14_0044 expressing cells were probed, no specific 311 
staining was observed in the control cell lysates.  312 
 313 
Fig.  2 Development of anti-PF14_0044 IgG response in mice. Western blotting analysis of sera from mice immunized 314 
with living cells (A) and immune complexes (B). Lysates of HEK cells transfected with PF14_0044 (upper panel) and control 315 
cell line (lower panel) were probed with serial dilution of sera from individual mice (S, R, K, KS). Sera were taken two 316 
weeks after second round of immunization. 317 
Also in IFA, transfectants showed strong immunostaining compared to control cell lines. 318 
These data indicated that both formulations were highly immunogenic and that mice had 319 
mounted a strong humoral immune response specific for the recombinant PF14_0044. Spleen 320 
cells of two mice per group of immunization (living cells: R, S; immune complexes: K, R) 321 
were pooled and fused with PAI myeloma cells to generate B cell hybridomas. To identify 322 
hybridoma cells producing  PF14_0044 specific antibodies, a two-step screening procedure 323 
was used. All cell culture wells were tested for IgG production by ELISA: between 80% 324 
(immune complex) and 90% (living cells) of tested wells were IgG-positive. Afterwards, 325 
supernatants of 12 IgG-producing wells were randomly selected from each plate (48 wells in 326 
total) for IFA screening. Transfected and control HEK cells spotted onto multiwell glass 327 
slides were stained with individual hybridoma supernatants and analyzed by fluorescence 328 
microscopy. Each fusion yielded numerous wells containing antibodies strongly reactive with 329 
transfectants but not reactive with control cells. From these wells, altogether eight hybridoma 330 
clones producing anti- PF14_0044 IgG were derived by limiting dilution (Table 1). To 331 
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determine whether the mAbs generated against heterologously expressed PF14_0044 would 332 
bind to the endogenous protein of Plasmodium falciparum parasites, we performed IFA and 333 
Western blotting analysis using cultivated blood-stage parasites (Fig. 3, Table 1). All eight 334 
generated anti-PF14_0044 mAbs stained specifically late blood-stage parasites in IFA, 335 
whereas just one of them (PF14-2/32) was positive in Western blotting analysis on parasite 336 
lysate.  337 
 338 
Table 1. Specificities of generated anti-PF14_0044 mAbs. 339 
 340 
Anti-PF14_0044 mAbs were characterized by Western blotting analyses and immunofluorescence assays performed on HEK 341 
cells expressing recombinant PF14_0044 and Plasmodium falciparum 3D7 schizont stages. 342 
Stage-specific expression and localization of PF14_0044 in schizonts and free merozoites  343 
The PF14_0044 gene encodes a 290-aa-long protein with a predicted molecular mass of 33.3 344 
kDa. Using highly synchronized asexual blood-stage parasite cultures, we assessed the 345 
expression profile of PF14_0044 in Plasmodium falciparum across the intraerythrocytic 346 
developmental cycle (Fig. 3A). In Western blotting analysis, a discrete band of ~40 kDa was 347 
detected in schizonts and free merozoites but not in rings and early trophozoites. Stage- 348 
specific expression in schizont stages and free merozoites was confirmed by indirect 349 
immunofluorescence staining of synchronized blood-stage parasites with the anti-PF14_0044 350 
mAb 2/27 (Fig. 3B). To determine the localization of PF14_0044 in schizont stages more 351 
accurately, we performed co-localization studies using Abs specific for the micronemes 352 
(AMA-1) [43] and the rhoptry bulbs (RAP- 1) [44]. Schizonts showed a dotted staining 353 
pattern with PF14_0044-specific mAbs, neither co-localizing with rhoptry bulbs nor with 354 
micronemes (Fig. 4). 355 
  356 
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 357 
 358 
Fig.  3 Stage specific expression of PF14_0044 in late asexual blood stage parasites. (A) Western blot analysis of lysates 359 
of tightly synchronized Plasmodium falciparum 3D7 asexual blood stage parasites 1, 4, 12, 20, 28, 36, 44 hours post-invasion 360 
and of free merozoites (M) with anti-PF14_0044 mAb 2/32  (upper panel). The blot was probed for equal loading with an 361 
anti-GAPDH mAb (lower panel). (B) Indirect immunofluorescence stainings of tightly synchronized asexual blood stage 362 
parasites confirmed stage specific expression in schizont stages and free merozoites. Methanol/acetone fixed Plasmodium 363 
falciparum 3D7 parasites were probed with anti-PF14_0044 mAb 2/27 (red) and anti-GAPDH mAb (green). Exposure times 364 
were identical for all pictures of the same channel. 365 
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 366 
Fig.  4 Localisation of PF14_0044 to the merozoite apex by immunofluorescence staining 367 
Plasmodium falciparum 3D7 schizont stages were co-immunostained with anti-PF14_0044 mAb 2/27 (red) and AMA-1 368 
(marker for micronemes) or RAP-1 (marker for rhoptry bulbs) (green). Nuclei were stained with DAPI (blue). 369 
  370 
Results – Part 4 
 
165 
Synergistic effect of anti-CyRPA and anti-PF14_0044 mAbs in an in vitro growth 371 
inhibition assay 372 
Considering the expression profile and the apical localization of PF14_0044, we tested anti- 373 
PF14_0044 mAbs for in vitro parasite growth inhibitory activity. Growth inhibition assays 374 
were conducted with Plasmodium falciparum 3D7 parasites for two cycles of merozoite 375 
invasion. None of the anti-PF14_0044 mAbs showed more than marginal growth inhibitory 376 
activity even at a concentration as high as 500 µg/ml (Fig. 5A). However, a significant 377 
synergistic inhibitory activity was measured when combining the growth inhibitory anti- 378 
PfCyRPA mAb c12 [17,26,28] with the anti-PF14_0044 mAb PF14-1/44 (Fig. 5A). This 379 
synergistic effect was observed for all eight generated anti-PF14_0044 mAbs (Fig. 4B), but 380 
with none of the tested control antibodies specific for the Plasmodium falciparum antigens 381 
PfRON12 and PfSHLP2 (PF10-1/2 and PFL-2/30 mAbs, respectively), or malaria-unrelated 382 
anti-cortisol CORTI-4/16 mAb (Fig. 4A). All tested mAbs were produced and purified in the 383 
same way and results were reproducible in independent experiments and with independent 384 
mAb production batches. 385 
 386 
Fig.  5 Synergistic inhibitory activity of anti-CyRPA and anti-PF14_0044 mAbs. (A, B) Synchronized Plasmodium 387 
falciparum 3D7 blood-stage parasites were cultured for two cycles in the presence of combinations of different mAbs. 388 
Percent parasite growth inhibition was calculated against the parasitemia of PBS control wells. Anti-CyRPA Q8IF12 mAb 389 
[17] was used as reference growth-inhibitory antibody; anti-PfRON12 PF10-1/2 mAb, anti-PfSHLP2 PFL-2/30 mAb, and a 390 
malaria-unrelated anti-cortisol CORTI-4/16 mAb served as control antibodies. Each bar represents the mean of a triplicate 391 
experiment, and error bars indicate the SD. Significant differences in parasite growth inhibition are indicated (unpaired t test, 392 
95% confidence interval, two-tailed p value). All mAbs tested were produced and purified in the same manner and results 393 
were reproducible in independent experiment and with independent mAb production batches. 394 
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Natural immunogenicity of PF14_0044 395 
To examine if natural exposure to Plasmodium falciparum leads to the development of anti- 396 
PF14_0044 Abs, human sera were analyzed by ELISA for their reactivity with purified 397 
recombinant PF14_0044 (Fig. 6A). Selected samples were further analyzed for specificity by 398 
Western blotting analysis (Fig. 6B). Sera were collected from healthy individuals living along 399 
the Offin River in Ghana, where Plasmodium falciparum is highly endemic [1,41]. Among 81 400 
randomly tested sera, 21 (25.9 %) showed the presence of IgG specific for recombinant 401 
PF14_0044 protein (Fig. 5A). Selected samples among ELISA-positive and negative samples, 402 
were further analyzed by Western blotting on recombinant PF14_0044 confirming the 403 
specificity of the serological response (Fig. 6B). In similar analyses >60% of sere were 404 
positive for AMA-1 and MSP-3, reflecting the strong exposure of the population to 405 
Plasmodium falciparum [41]. 406 
 407 
 408 
Fig.  6 Analysis of serum from malaria-exposed individuals for presence of PF14_0044-specific IgG. (A) Reactivity of 409 
human sera from 81 randomly selected individuals living along the Offin River in Ghana (malaria exposed) with recombinant 410 
PF14_0044 assessed by ELISA. Shown are IgG levels expressed as OD at 450 nm of serum samples diluted 1:400 (mean 411 
OD450 0.93 ± 0.1 for positive and 0.25 ± 0.01 for negative samples). Horizontal lines designate means and SEM of responses. 412 
(B) Western blot analysis of recombinant PF14_0044 with selected 15 human sera; anti-PF14_0044 mAb 2/32 served as 413 
positive control.  414 
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Discussion 415 
Despite being preventable and treatable, malaria still represents a massive global public health 416 
problem, threatening the lives of 3.2 billion people around the world [45]. Substantial 417 
improvements have been achieved in malaria control over the past decade as result of major 418 
investments in vector control, chemoprevention, diagnostic testing and treatment. To pursue 419 
the goal of reducing malaria case incidence and mortality rates globally by at least 90% in 420 
2030 (compared to 2015) [46], the development and introduction of a malaria vaccine with 421 
protective efficacy of at least 75% would be an important addition to the arsenal of preventive 422 
tools. However, the complexity of the malaria parasite makes the development of an effective 423 
malaria vaccine a very difficult task. Despite many decades of intense research and 424 
development effort, there is currently no malaria vaccine commercially available. A number 425 
of vaccine candidates, with different modes of action and in different formulations, are 426 
currently in various stages of pre-clinical and clinical evaluation [14]. Among them, the most 427 
advanced is the pre-erythrocytic subunit vaccine RTS,S/AS01 which has completed Phase 3 428 
[6]. Although immunodominant antigens induce very strong antibody responses, they 429 
typically vary antigenically to escape immune pressure and therefore possess substantial 430 
polymorphisms. Malaria vaccines based on immunodominant and polymorphic antigens have 431 
the risk of limited efficacy and protection, suggesting that the key protective malarial antigens 432 
might be the non-immunodominant antigens [47,48]. The research for novel malaria vaccine 433 
candidate antigens has received a great incentive from the genome-wide transcriptomic and 434 
proteomic data that have become available since the publication of the Plasmodium 435 
falciparum genome [22]. Since then, major efforts have been invested in the annotation of the 436 
Plasmodium falciparum genome. Nevertheless, the vast majority of the proteins are still not 437 
characterized. Therefore, we used a reverse vaccinology-based strategy to selected 438 
uncharacterized ORFs and evaluate their potential as asexual blood-stage vaccine candidate 439 
antigens [26]. Among the characterized proteins, PfCyRPA exhibited outstanding properties, 440 
demonstrating the utility of systematic genome-wide approaches for vaccine antigen selection 441 
[17,28]. Antibodies specific for PfCyRPA showed a strong parasite growth inhibitory activity 442 
by targeting the process of merozoite invasion into RBCs. Indeed, PfCyRPA has recently 443 
been identified as the key component of an essential complex on the surface of invading 444 
merozoites: PfCyRPA interacts with the RH5-interacting protein (PfRipr) and the 445 
Reticulocyte binding-like Homologous protein 5 (PfRH5), which binds the basigin receptor 446 
on the erythrocyte surface [27]. Anti-PfCyRPA and anti-PfRH5 mAbs inhibit, but do not 447 
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completely block, parasite growth by interfering with a crucial pathway for invasion of 448 
erythrocytes by merozoites [17,28,49]. Plasmodium falciparum merozoites are described to 449 
use alternative invasion pathways to evade Ab-mediated immunity [50] and the use of a 450 
PfCyRPA/PfRH5-independent invasion pathway of limited efficiency could explain 451 
persistence of infection associated with a reduced multiplication rate. In addition to the great 452 
potential shown by PfCyRPA and PfRH5 as vaccine candidate on their own [17,18,28], a 453 
synergistic in vitro inhibitory activity has also been reported for the combination of 454 
polyclonal anti-PfCyRPA and anti-PfRH5 antibodies [27]. Hence, it remains essential to 455 
identify next-generation vaccine candidate antigens and systematically assess their potential 456 
to induce antibodies that act synergistically when administered in multi-antigen formulations. 457 
To identify novel target antigens for protective immune responses, available genome-wide 458 
transcriptomic and proteomic data of the intra-erythrocytic stages of Plasmodium falciparum 459 
[2] were analyzed to pick out additional antigens potentially implicated in erythrocyte 460 
invasion. Candidate antigens were selected according to four main criteria: (i) expression 461 
peak in schizont and merozoite stages [51,52], (ii) mass spectrometry evidence for expression 462 
in detectable amounts, (iii) predicted signal peptide and/or a single transmembrane 463 
domain/GPI anchor attachment site (secreted and cell surface exposed proteins) [53–55], (iii) 464 
suitability for recombinant expression (molecular mass below 100 kDa and devoid of long 465 
stretches of repetitive amino acids). Although heterologous protein production has now 466 
become relatively easy and successful for proteins of diverse origins, the functional 467 
expression of plasmodial proteins has remained problematic [56]. The plasmodial proteome is 468 
enriched in proteins with high molecular weight (> 50 kDa), basic isoelectric point (pI > 6), 469 
and presence of low complexity regions [57]. For the expression, characterization and 470 
functional analysis of membrane-associated plasmodial proteins we favored an eukaryotic 471 
expression platform and expressed them on the surface of transfected mammalian cells, 472 
bypassing any need for purification of the recombinant proteins [26]. For the characterization 473 
of selected candidate antigens we (I) generated mammalian cell lines expressing high levels 474 
of the target antigen as His-tagged, transmembrane proteins; (II) used the transfected living 475 
cells, or immune complexes derived from them, for immunization of mice; (III) generated B 476 
cell hybridoma cell lines for the production of target antigen-specific mAbs. Among three 477 
recently investigated antigens (PF10_0166, PFL0300c, PF14_0044), PF14_0044 showed 478 
interesting features. A panel of eight mAbs was generated and employed to assess localization 479 
and stage-specific expression pattern of PF14_0044 in blood-stage parasites. In agreement 480 
with available transcriptional data, showing elevated transcript levels in late stages of the 481 
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asexual blood cycle of Plasmodium falciparum with maximal expression measured at 40 to 482 
48h post invasion [51,52,58], we observed for PF14_0044 a stage-specific expression in 483 
schizonts and free merozoites. Similarly to PfCyRPA, it localized to a merozoites apical 484 
structure distinct from rhoptry bulbs and micronemes. However, in contrast to many anti- 485 
PfCyRPA antibodies, none of the anti-PF14_0044 mAbs significantly inhibited the growth of 486 
Plasmodium falciparum 3D7, but showed even at high concentrations only marginal growth 487 
inhibitory activity. However, a strong synergistic effect was observed when anti-PF14_0044 488 
mAbs were combined with parasite growth inhibitory anti-PfCyRPA mAbs (Fig. 5). Here a 489 
greater inhibitory activity was observed than dose-wise additivity (unpaired t test, 95% 490 
confidence interval, two-tailed p value). To further investigate the detected synergy, for each 491 
combination of antibodies we also calculated the predicted GIA that would be achieved by the 492 
two components having an independent, additive effect by using the definition of Bliss 493 
additivity [59–61]. The observed growth inhibition was significantly higher than the predicted 494 
values at both concentrations of 250 µg/ml and 125 µg/ml (p < 0.01 and p < 0.03 respectively; 495 
2-way ANOVA with Bonferroni post-hoc testing, 95% confidence interval). Given the 496 
complexity of Plasmodium falciparum erythrocyte invasion mechanisms [62,63], PfCyRPA- 497 
specific and PF14_0044-specific antibodies may exert a synergistic effect by acting ‘in 498 
series’, inhibiting successive stages of invasion or, alternatively, they may act ‘in parallel’, 499 
inhibiting redundant invasion processes [60]. Also, similarly to PfCyRPA, natural 500 
immunogenicity of PF14_0044 appears to be limited (Fig. 6) and, sequence analyses indicate 501 
that PF14_0044 have low nucleotide diversitya and no substantial sequence polymorphisms, 502 
reducing the risk of limited efficacy and protection. It has been shown that relatively high 503 
titers of antigen-specific antibodies are required to achieve protective effects in animal 504 
malaria models [64–67]. Despite the improvements in vaccine delivery systems and adjuvant 505 
formulations [68,69], convincing protective immunity in humans has not been achieved yet. 506 
One of the strategies to achieve effective protection appears to be to assess the potential of 507 
candidate antigens to induce antibodies that act synergistically, lowering the individual titers 508 
needed for parasite neutralization [70]. 509 
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Conclusions 511 
Given the complexity of Plasmodium falciparum erythrocyte invasion mechanism and the 512 
extensive genetic diversity found in many Plasmodial antigens, the identification of new 513 
candidate antigens, able to induce broad strain-transcending immunity, has become an eager 514 
research focus. Here it is shown that PF14_0044-specific mAbs  act synergistically with 515 
PfCyRPA-specific antibodies and thus enhancing the growth inhibitory effect. Our findings 516 
support the concept of rational genome-based selection of next-generation vaccine candidates. 517 
 518 
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Endnotes 544 
aNucleotide diversity, in molecular genetics, measures the degree of polymorphism within a 545 
population. Nei and Li in 1979 [71] introduced a commonly used measure of nucleotide 546 
diversity, defined as the average number of nucleotide differences per site between any two 547 
DNA sequences chosen randomly from the sample population.  548 
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Additional file 1 753 
 754 
Additional file 1. Amino acid sequence alignment of Plasmodium falciparum PF14_0044 with orthologs in P. vivax, P. 755 
knowlesi, P. cynomolgi, P. reichenowi, P. berghei, P. chabaudi and P. yoelii. Full-length putative orthologs of Plasmodium 756 
falciparum PF14_0044 are found in the genomes of Plasmodium vivax (PVX_086200), Plasmodium knowlesi 757 
(PKNH_1353400), Plasmodium cynomolgi (PCYB_135180), Plasmodium reichenowi (PRCDC_1404000), Plasmodium 758 
berghei (PBANKA_1037400), Plasmodium chabaudi (PCHAS_1038200) and Plasmodium yoelii (PY17X_1039800). 759 
Average sequence identity is 63.25%. Asterisk (*), identical; colon (:), conservation between groups of strongly similar 760 
properties; period (.), conservation between groups of weakly similar properties substitution.  761 
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Additional file 2. Plasmodium falciparum strains and isolates analysed for 762 
SNPs evaluation (http://plasmodb.org/plasmo/) 763 
(5.1, 7G8, 7G8_2, CS2, HB3, IT, M113-A, N011-A, N023-A, N071-I, N164-A, N497-C, 764 
SEV2_H5, SalvadorI, T9_94, UGK_674.4, RV_3630, RV_3635, RV_3717, SenT061.09, 765 
SenT104.07, TRIPS_700, 365.1, RV_3695, 707A, Dd2-1, Dd2-2, PS097, SenT190.08, 766 
PS122_G11, SenT022.09, UGK_408.2, UGK_659.1, 309.1, RV_3600, RV_3673, 767 
SenT015.09, SenT090.09, SenT092.08, SenT101.09, SenT119.09, SenT145.08, SenT224.08, 768 
SenT238.08, TRIPS_440, UGK_432.4, 383.1, PS186, TRIPS_373, SenT067.09, TRIPS_433, 769 
UGK_730.2, SenT102.08, RV_3650, PS250, SenT033.08, TRIPS_480, UGK_661.1, 318.1, 770 
UGK_443.2, 377.1, RV_3730, TRIPS_467, TRIPS_470, PS103, G224, H209, M219-D, 771 
M271-D, M312-D, N579-A, O079-B, O141-A, O222-A, O306-A, O314, P164-C, P167-B, 772 
P196J3-C, P237-C, P241-D, SenT097.09, TRIPS_482, PS149, RV_3655, RV_3769, 773 
SenT002.09, SenT140.08, TRIPS_487, TRIPS_708, SenT046.10, SenT064.10, RV_3702, 774 
RV_3729, SenT044.10, SenT197.08, TRIPS_303, PS170, PS206_E11, SenT180.08, 775 
RV_3606, RV_3610, RV_3637, RV_3671, RV_3696, RV_3701, RV_3703, RV_3708, 776 
RV_3735, RV_3736, SenT001.08, SenT024.08, SenT029.09, SenT032.09, SenT033.09, 777 
SenT075.10, SenT094.09, SenT106.08, SenT111.09, SenT123.09, SenT128.08, SenT135.09, 778 
SenT151.09, SenT230.08, TRIPS_301, TRIPS_410, TRIPS_437, TRIPS_456, TRIPS_499, 779 
TRIPS_704, TRIPS_759, RV_3737, RV_3687, SenT127.09, SenT179.08, Pf3D7_14_v3, 780 
SenT112.09, 326.1, 58.1, GB4, RV_3614, RV_3714, RV_3740, RV_3766, SenT002.07, 781 
SenT077.08, SenT113.09, SenT149.09, TRIPS_331, 327.1, UGK_815.1, BM_0008, PS183, 782 
RV_3642, RV_3721, RV_3741, TRIPS_501, SenT047.09, SenT093.09, SenT139.08, 783 
SenT227.08, TRIPS_461, 303.1, 398.1, 366.1, BM_0009, PS189, RV_3672, RV_3731, 784 
RV_3764, TRIPS_504, SenT066.08, SenT110.09, SenT142.09, SenT235.08, TRIPS_474, 785 
UGK_396.1, SenT063.07, TRIPS_490, SenT042.09, SenT090.08, SenT137.09, SenT170.08, 786 
TRIPS_364, TRIPS_355, SenT150.09, SenT137.08, SenT087.08, SenT018.09, SenT001.07, 787 
RV_3739, RV_3675, RV_3611, SenT144.08, SenT175.08, 397.1, P. reichenowi)  788 
 789 
  790 
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 791 
Additional file 2. Amino acid sequence alignment of PF14_0044 in a population of 190 P. falciparum isolates. To evaluate 792 
the sequence diversity of PF14_0044 in a population of P. falciparum we analyze the sequences of 190 isolates provided by 793 
the database Plasmodb (http://plasmodb.org/plasmo/). All sequences obtained were identical to the P. falciparum 3D7 794 
reference sequence with the exception of 12 non-synonymous single nucleotide polymorphism (SNP) and 6 deletions 795 
distributed along to the gene (873bp). 796 
 797 
 798 
CLUSTAL 2.1 MULTIPLE SEQUENCE ALIGNMENT
File: PF14_004.gene_all.ps Date: Mon Nov 16 13:54:37 2015 
Page 1 of 1
                **************:*::*********************************:**.**************.****************** ******************************************** *.**********************::*:********************:*************************  : : ***************** ***********************************: ****:******.     
5.1 MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNIKLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFKQEPCNLGKTANITFIFSK   290
7G8 MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNIKLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFKQEPCNLGKTANITFIFSK   290
7G8_2 MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNIKLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFKQEPCNLGKTANITFIFSK   290
CS2 MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNIKLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFKQEPCNLGKTANITFIFSK   290
HB3 MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNIKLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFKQEPCNLGKTANITFIFSK   290
IT MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNIKLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFKQEPCNLGKTANITFIFSK   290
M113-A MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNIKLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFKQEPCNLGKTANITFIFSK   290
N011-A MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNIKLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFKQEPCNLGKTANITFIFSK   290
N023-A MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNIKLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFKQEPCNLGKTANITFIFSK   290
N071-I MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNIKLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFKQEPCNLGKTANITFIFSK   290
N164-A MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNIKLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFKQEPCNLGKTANITFIFSK   290
N497-C MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNIKLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFKQEPCNLGKTANITFIFSK   290
SEV2_H5 MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNIKLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFKQEPCNLGKTANITFIFSK   290
SalvadorI MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNIKLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFKQEPCNLGKTANITFIFSK   290
T9_94 MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNIKLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFKQEPCNLGKTANITFIFSK   290
UGK_674.4 MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNIKLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFKQEPCNLGKTANITFIFSK   290
RV_3630 MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNINLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTENLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFKQEPCNLGKTANITFIFSK   290
RV_3635 MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNINLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTENLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFKQEPCNLGKTANITFIFSK   290
RV_3717 MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNINLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTENLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFKQEPCNLGKTANITFIFSK   290
SenT061.09 MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNINLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTENLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFKQEPCNLGKTANITFIFSK   290
SenT104.07 MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNINLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTENLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFKQEPCNLGKTANITFIFSK   290
TRIPS_700 MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNINLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTENLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFKQEPCNLGKTANITFIFSK   290
365.1 MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNI-LYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTENLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFKQEPCNLGKTANITFIFSK   289
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707A MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNINLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFKQEPCNLGKTANITFIFSK   290
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H209 MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEHIKIIANKEYEINCMNNSKVFCPLKDTFINNTNIKLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEQEEVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFKQEPCNLGKTANITFIFSK   290
M219-D MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEHIKIIANKEYEINCMNNSKVFCPLKDTFINNTNIKLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEQEEVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFKQEPCNLGKTANITFIFSK   290
M271-D MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEHIKIIANKEYEINCMNNSKVFCPLKDTFINNTNIKLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEQEEVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFKQEPCNLGKTANITFIFSK   290
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P164-C MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEHIKIIANKEYEINCMNNSKVFCPLKDTFINNTNIKLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEQEEVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFKQEPCNLGKTANITFIFSK   290
P167-B MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEHIKIIANKEYEINCMNNSKVFCPLKDTFINNTNIKLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEQEEVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFKQEPCNLGKTANITFIFSK   290
P196J3-C MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEHIKIIANKEYEINCMNNSKVFCPLKDTFINNTNIKLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEQEEVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFKQEPCNLGKTANITFIFSK   290
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TRIPS_708 MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNIKLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEQEEVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFQQEPCNLGKTANITFIFSK   290
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SenT064.10 -MKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNIKLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTENLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFQQEPCNLGKTANITFIFSK   289
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PS170 MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNINLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNKEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFQQEPCNLGKTANITFIFSK   290
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RV_3606 MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNINLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFQQEPCNLGKTANITFIFSK   290
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RV_3696 MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNINLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFQQEPCNLGKTANITFIFSK   290
RV_3701 MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNINLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFQQEPCNLGKTANITFIFSK   290
RV_3703 MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNINLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFQQEPCNLGKTANITFIFSK   290
RV_3708 MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNINLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFQQEPCNLGKTANITFIFSK   290
RV_3735 MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNINLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFQQEPCNLGKTANITFIFSK   290
RV_3736 MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNINLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFQQEPCNLGKTANITFIFSK   290
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SenT024.08 MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNINLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFQQEPCNLGKTANITFIFSK   290
SenT029.09 MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNINLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFQQEPCNLGKTANITFIFSK   290
SenT032.09 MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNINLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFQQEPCNLGKTANITFIFSK   290
SenT033.09 MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNINLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFQQEPCNLGKTANITFIFSK   290
SenT075.10 MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNINLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFQQEPCNLGKTANITFIFSK   290
SenT094.09 MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNINLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFQQEPCNLGKTANITFIFSK   290
SenT106.08 MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNINLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFQQEPCNLGKTANITFIFSK   290
SenT111.09 MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNINLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFQQEPCNLGKTANITFIFSK   290
SenT123.09 MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNINLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFQQEPCNLGKTANITFIFSK   290
SenT128.08 MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNINLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFQQEPCNLGKTANITFIFSK   290
SenT135.09 MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNINLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFQQEPCNLGKTANITFIFSK   290
SenT151.09 MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNINLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFQQEPCNLGKTANITFIFSK   290
SenT230.08 MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNINLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFQQEPCNLGKTANITFIFSK   290
TRIPS_301 MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNINLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFQQEPCNLGKTANITFIFSK   290
TRIPS_410 MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNINLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFQQEPCNLGKTANITFIFSK   290
TRIPS_437 MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNINLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFQQEPCNLGKTANITFIFSK   290
TRIPS_456 MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNINLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFQQEPCNLGKTANITFIFSK   290
TRIPS_499 MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNINLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFQQEPCNLGKTANITFIFSK   290
TRIPS_704 MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNINLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFQQEPCNLGKTANITFIFSK   290
TRIPS_759 MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNINLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFQQEPCNLGKTANITFIFSK   290
RV_3737 MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNI-LYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFQQEPCNLGKTANITFIFSK   289
RV_3687 MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEHIKIIANKEYEINCMNNSKVFCPLKDTFINNTNIKLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFQQEPCNLGKTANITFIFSK   290
SenT127.09 MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEHIKIIANKEYEINCMNNSKVFCPLKDTFINNTNIKLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFQQEPCNLGKTANITFIFSK   290
SenT179.08 MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEHIKIIANKEYEINCMNNSKVFCPLKDTFINNTNINLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFQQEPCNLGKTANITFIFSK   290
Pf3D7_14_v3 MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNIKLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFQQEPCNLGKTANITFIFSK   290
SenT112.09 MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNIKLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFQQEPCNLGKTANIK-----   285
326.1 MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNIKLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFQQEPCNLGKTANITFIFSK   290
58.1 MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNIKLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFQQEPCNLGKTANITFIFSK   290
GB4 MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNIKLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFQQEPCNLGKTANITFIFSK   290
RV_3614 MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNIKLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFQQEPCNLGKTANITFIFSK   290
RV_3714 MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNIKLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFQQEPCNLGKTANITFIFSK   290
RV_3740 MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNIKLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFQQEPCNLGKTANITFIFSK   290
RV_3766 MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNIKLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFQQEPCNLGKTANITFIFSK   290
SenT002.07 MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNIKLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFQQEPCNLGKTANITFIFSK   290
SenT077.08 MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNIKLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFQQEPCNLGKTANITFIFSK   290
SenT113.09 MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNIKLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFQQEPCNLGKTANITFIFSK   290
SenT149.09 MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNIKLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFQQEPCNLGKTANITFIFSK   290
TRIPS_331 MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNIKLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFQQEPCNLGKTANITFIFSK   290
327.1 MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNIKLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFQQEPCNLGKTANITFIFSK   290
UGK_815.1 MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNIKLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQ-SGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFQQEPCNLGKTANITFIFSK   289
BM_0008 MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNIKLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFQQEPCNLGKTANITFIFSK   290
PS183 MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNIKLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFQQEPCNLGKTANITFIFSK   290
RV_3642 MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNIKLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFQQEPCNLGKTANITFIFSK   290
RV_3721 MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNIKLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFQQEPCNLGKTANITFIFSK   290
RV_3741 MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNIKLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFQQEPCNLGKTANITFIFSK   290
TRIPS_501 MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNIKLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFQQEPCNLGKTANITFIFSK   290
SenT047.09 MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNIKLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFQQEPCNLGKTANITFIFSK   290
SenT093.09 MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNIKLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFQQEPCNLGKTANITFIFSK   290
SenT139.08 MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNIKLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFQQEPCNLGKTANITFIFSK   290
SenT227.08 MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNIKLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFQQEPCNLGKTANITFIFSK   290
TRIPS_461 MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNIKLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFQQEPCNLGKTANITFIFSK   290
303.1 MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNIKLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFQQEPCNLGKTANITFIFSK   290
398.1 MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNIKLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKL--ILQKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFQQEPCNLGKTANITFIFSK   288
366.1 MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNIKLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFQQEPCNLGKTANITFIFSK   290
BM_0009 MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNIKLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFQQEPCNLGKTANITFIFSK   290
PS189 MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNIKLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFQQEPCNLGKTANITFIFSK   290
RV_3672 MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNIKLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFQQEPCNLGKTANITFIFSK   290
RV_3731 MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNIKLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFQQEPCNLGKTANITFIFSK   290
RV_3764 MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNIKLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFQQEPCNLGKTANITFIFSK   290
TRIPS_504 MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNIKLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFQQEPCNLGKTANITFIFSK   290
SenT066.08 MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNIKLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFQQEPCNLGKTANITFIFSK   290
SenT110.09 MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNIKLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFQQEPCNLGKTANITFIFSK   290
SenT142.09 MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNIKLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFQQEPCNLGKTANITFIFSK   290
SenT235.08 MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNIKLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFQQEPCNLGKTANITFIFSK   290
TRIPS_474 MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNIKLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFQQEPCNLGKTANITFIFSK   290
UGK_396.1 MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNIKLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFQQEPCNLGKTANITFIFSK   290
SenT063.07 MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNIKLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSALLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFQQEPCNLGKTANITFIFSK   290
TRIPS_490 MIKVLLAVLFILIKLENIIGQNEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNIKLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFQQEPCNLGKTANITFIFSK   290
SenT042.09 MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNIKLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFQQEPCNLGKTANITFIFSK   290
SenT090.08 MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNIKLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFQQEPCNLGKTANITFIFSK   290
SenT137.09 MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNIKLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFQQEPCNLGKTANITFIFSK   290
SenT170.08 MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNIKLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFQQEPCNLGKTANITFIFSK   290
TRIPS_364 MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNIKLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFQQEPCNLGKTANITFIFSK   290
TRIPS_355 MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNIKLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFQQEPCNLGKTANITFIFSK   290
SenT150.09 MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNIKLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFQQEPCNLGKTANITFIFSK   290
SenT137.08 MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNIKLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFQQEPCNLGKTANITFIFSK   290
SenT087.08 MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNIKLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFQQEPCNLGKTANITFIFSK   290
SenT018.09 MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNIKLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFQQEPCNLGKTANITFIFSK   290
SenT001.07 MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNIKLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFQQEPCNLGKTANITFIFSK   290
RV_3739 MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNIKLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFQQEPCNLGKTANITFIFSK   290
RV_3675 MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNIKLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFQQEPCNLGKTANITFIFSK   290
RV_3611 MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNIKLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFQQEPCNLGKTANITFIFSK   290
SenT144.08 MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMTNSKVFCPLKDTFINNTNIKLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFQQEPCNLGKTANITFIFSK   290
SenT175.08 MIKVLLAVLFILIKLENIIGKDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNIKLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFQQEPCNLGKTANITFIFSK   290
397.1 MIKVLLAVLFILIKLENIIGQDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQYGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNIKLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYLKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINF-LKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFQ-EPCNLGKTANITFIFSK   288
Preichenowi MIKVLLAVLFILIKLENIVGEDEKSVKNICVCDFTDKLNFLPLEKTKILCELKPQHGEDIKIIANKEYEINCMNNSKVFCPLKDTFINNTNIKLYSPKLHFEIKDITHKGKNAALYYLKIDEEASDIFFSCSIKPKQVSGLLEGEVRVNLKKHINEEYSIFNEEEDVHVCDFSKGNLDITPSAGFYVKNSRNVSCIYRVIPNKLFLIKLPKLDIVTEKLLPSIVNCLSEFSFINFTLKHVQEGDNYISFNVIFGEFKKHFNLTCSLDLSDFKQEPCNVGKTANITFIFSK   290
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Discussion 
Vaccination represents an elegant approach to induce an adaptive immune response in non-
immune individuals by presenting antigenic determinants of a pathogen to the immune system 
without inducing the adverse effects of disease. Vaccination is one of the most effective 
medical interventions in history and helped to eliminate most of the life-threatening diseases 
that caused millions of deaths and severe morbidity (1, 2). 
The intentional inoculation of healthy people to protect them against the onset of diseases 
dates back to the 16th century, when variolation (blowing powdered smallpox material, 
usually variola scabs, up the nostrils) was practiced in China.  
 
Rational vaccination began in the 18th Century when Edward Jenner protected humans from 
smallpox by administering material from humans infected with cowpox (3). In the 19th 
Century, Pasteur, Koch, Ramon and Mérieux pioneered the development of live-attenuated or 
killed vaccines as well as inactivated toxins to protect against rabies, cholera, plague and 
typhoid. Additional major vaccine developments in the 20th Century provided protection 
against diphtheria, tetanus, pertussis, polio, meningococci and pneumococci hepatitis and 
influenza. 
 
In the 21st Century vaccination continues to play a crucial role in global public health system 
(Tab. 1). Nevertheless, many important infections are not yet preventable by vaccination, 
including, respiratory syncytial virus (RSV), human immunodeficiency virus (HIV), malaria, 
tuberculosis and ebola.  
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Table 1 – Outline of the development of human vaccines 
 
Adapted from Plotkin S. 2014 (2) 
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Towards an effective malaria vaccine 
Research for malaria vaccine development started in the middle of the 20th century, based on 
the observation that (I) partially protective immune responses eventually develop in people 
who experience and survive repeated malaria episodes during early childhood (4), and that 
(II) passive transfer of purified immunoglobulins from semi-immune adults can protect 
malaria-naïve children (5). 
The first success in malaria vaccine development was achieved in 1973, when Clyde et al. 
reported that immunization with radiation-attenuated sporozoites could protect humans 
against challenge with fully infectious sporozoites (6), demonstrating the feasibility of 
developing a malaria vaccine capable to induce sterile protective immunity. Since then, 
progress toward developing malaria vaccines has moved forward as result of major advances 
in science and vaccine technologies (Tab. 2). 
Table 2 – Major steps towards subunit and whole parasite malaria vaccines (6–20) 
 
Adapted from Anders 2011 (21) 
Today, the malaria vaccine development field is a dynamic and fertile ground of scientific 
endeavor. Increased funding and research are driving the discovery of new antigens and 
vaccine technologies, and many more malaria vaccine candidates are moving through the 
development pipeline (Tab. 3) (22). 
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Among them, the most advanced vaccine, the pre-erythrocytic subunit vaccine RTS,S/AS01, 
has completed a Phase III clinical trial but only limited clinical efficacy has been reported 
(23). To improve RTS,S efficacy, alternative vaccination regimens and adjuvants systems are 
being explored (i.e. NCT02207816 - booster doses of the vaccine using AS01E as adjuvant 
system, and Tab. 3). 
 
Table 3 – Malaria vaccine clinical trials pipeline (24–43) 
 
Adapted from Moreno & Joyner. 2015 (44) 
Although efficacy and durability of the pre-erythrocytic RTS,S vaccine are far from ideal, the 
information gathered in 30 years of research efforts has paved the way for the progress of 
second generation malaria vaccines and has provided continued support for the development 
of novel subunit vaccines against Plasmodium. 
Nonetheless, more research is needed for realizing the goals set by the WHO in the context of 
the Malaria Vaccine Technology Roadmap (45), which establishes the vision of licensing, by 
2030, a vaccine against both P. falciparum and P. vivax with (I) protective efficacy of at least 
75% against clinical malaria and (II) transmission-blocking effects. 
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Key hurdles to achieving an effective malaria vaccine include (I) antigenic diversity and 
variability of Plasmodial parasites, (II) lack of reliable and predictive animal models, and (III) 
limited availability of safe and efficient antigen delivery systems / adjuvants. 
Subunit vaccines: implication for malaria vaccine development 
Clinical immunity to malaria develops slowly and is short lived. This is mainly due to the 
extensive diversity found in Plasmodium antigens, which provides a mechanism to escape 
host immune detection and drug treatments (46). The antigenic diversity in P. falciparum 
arises from three main mechanisms: (I) classical antigenic variation that allows a clonal 
lineage of P. falciparum to express successive alternate forms of an antigen on the surface of 
the infected RBCs, (II) allelic polymorphisms that arose from host immune selection, and (III) 
phenotypic variation in which different strains express different combinations of functional 
ligands that bind to specific receptors on the erythrocyte surface. Besides, not all antigens are 
immunologically equivalent and P. falciparum, like many other pathogens, seems to hide 
from immune surveillance functionally essential and conserved domains while leading host’s 
immune responses toward immunodominant hyper-variable epitopes (47). 
Such an antigenic complexity is the major reason why progress towards a highly effective 
subunit vaccine has been so slow. Several merozoite surface proteins, and numerous proteins 
released from the merozoite apical organelles, have been described for having roles in the 
process of erythrocyte invasion (48). All these proteins represent potential vaccine candidates 
to elicit anti-invasion and anti-disease responses (49), but only few of them have reached the 
stage of clinical trials evaluation.  
Until recently, almost all efforts in malaria vaccine development have been focused on a 
confined panel of antigens recognized as immunodominant in the context of natural infection. 
These studies have primarily focused on the Circumsporozoite protein (CSP) for the pre-
erythrocytic stage, and Merozoite Surface Protein-1 (MSP-1) and Apical Membrane Antigen-
1 (AMA-1) for the blood stage, and investigated a variety of vaccine delivery systems (23, 42, 
50–53). However, despite major efforts, candidate subunit vaccines against malaria have 
shown limited efficacy in clinical trials, contributing to some discouragement with the 
recombinant protein subunit approach (54–56). 
Although immunodominant antigens induce very strong antibody responses, they are favored 
to vary antigenically to escape immune pressure and therefore possess substantial 
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polymorphisms. Hardly surprising, extensive polymorphism has been observed for both 
MSP1 and AMA1 (57, 58), which might explain the limited efficacy reported in clinical trials. 
Approaches to overcome the problem of antigenic diversity in recombinant protein vaccines 
against P. falciparum include the (I) combination of several unrelated antigens or (II) multiple 
allelic forms of an antigen, (III) use of chimeric proteins or (III) mutagenized antigens. 
Also, out of many potential vaccine antigens identified in P. falciparum some are much less 
polymorphic than MSP1 and AMA1, and could induce a more broadly protective immune 
response (59–61). Therefore, a promising strategy to overcome the risk of limited efficacy 
and protection, associated with antigenic diversity, may rely on non-immunodominant and 
more conserved vaccine antigens (62, 63). 
The research for novel protective malarial antigens has received a great incentive from the 
genome-wide transcriptomic (64–67) and proteomic data (68–72) that have become available 
since the publication of the P. falciparum genome (73).  
These extensive datasets offer valuable and powerful tools for rational search for new 
candidate antigens (74), and uncharacterized proteins with great potential as blood-stage 
vaccine candidates have been discovered (75). 
Among them, the asexual blood-stage vaccine candidate antigen CyRPA, described in this 
thesis, is highly conserved. DNA sequencing of selected P. falciparum strains and field 
isolates from different geographic regions identified only two distinct PfCyRPA haplotypes 
differing by a single amino acid dimorphism of no functional importance. At sequence level, 
the high conservation could indicate that either PfCyRPA is not under strong selective 
pressure or that other evasion strategies, which do not involve diversification, apply for this 
protein. 
Also, natural immunogenicity of PfCyRPA appears to be very moderate - sera of malaria-
exposed adults basically contained no PfCyRPA-specific Abs. In released merozoites, 
PfCyRPA shows an intracellular localization and is thought to be accessible to the host 
immune surveillance for limited time only. Nevertheless, PfCyRPA showed to be accessible 
by inhibitory antibodies during the short period of invasion in both in vitro and in vivo growth 
inhibition assays (GIAs). 
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Developing malaria vaccines in the –omics era 
The sequencing of the first bacterium genome in 1995 (76) had a great impact in pathogen’s 
biology understanding and brought vaccine development into a new era. The concept of 
reverse vaccinology was introduced by Rappuoli in 2000 (77) and is based on the screening of 
the entire pathogenic genome to identify genes encoding proteins with the appealing features 
of potential vaccine targets (i.e., surface-exposed, secreted, highly conserved among strains). 
Once selected, ideal candidates are recombinantly expressed and used to immunize mice for 
evaluating immunogenicity and eventual protective efficacy. This strategy allows for the 
identification of a broad spectrum of vaccine candidates independent of abundance and 
natural immunogenicity. 
The classical strategy, in malaria vaccine development, of inducing robust immune responses 
against a selected panel of antigens recognized as immunodominant in the context of natural 
infection, has been poorly fruitful. Most of the efforts should now be put toward a different 
approach: induce broad immune responses against a large number of parasite antigens, not 
necessarily recognized as immunodominant in the context of natural infection, in order to 
mimic and overtake the immunity induced by the whole parasite. 
Rational genome-based identification of new candidate antigens has developed into a research 
focus (78, 79), and post-genomic tools have already begun to demonstrate their power to 
accelerate and enhance malaria vaccine development through the identification of potential 
novel subunit vaccine candidates (80–85). 
To identify novel target antigens for protective immune responses, we analyzed available 
genome-wide transcriptomic and proteomic data of the intra-erythrocytic stages of P. 
falciparum (86) to pick out additional antigens potentially implicated in erythrocyte invasion. 
Candidate antigens were selected according to four main criteria: (I) expression peak in 
schizont and merozoite stage (65, 87), (II) mass spectrometry evidence, (III) predicted signal 
peptide and/or a single transmembrane domain/GPI anchor attachment site (secreted and cell 
surface exposed proteins) (88–90), (III) suitability for recombinant expression (molecular 
mass below 100 kDa and devoid of long stretches of repetitive amino acids). For the 
expression, characterization and functional analysis of membrane-associated plasmodial 
proteins we favored an eukaryotic expression platform and expressed them on the surface of 
transfected mammalian cells, bypassing any need for purified recombinant protein (91). For 
the characterization of selected candidate antigens we (I) generated mammalian cell lines 
expressing high levels of target antigen as His-tagged, transmembrane proteins; (II) used the 
Discussion 
 
188 
transfected living cells, or immune complexes derived from them, for immunization of mice; 
(III) generated B cell hybridoma cell lines for the production of target antigen-specific mAbs. 
This reverse vaccinology-based strategy (91) led us to the identification of the asexual-blood 
stage malaria vaccine candidate PfCyRPA: PfCyRPA-specific mAbs showed a strong parasite 
in vitro and in vivo growth inhibitory activity by targeting the process of merozoite invasion 
into erythrocytes (92, 93). 
PfCyRPA is part of a multi-protein complex (94, 95) including also the PfRH5-interacting 
protein PfRipr and the reticulocyte binding-like homologous protein PfRH5, which binds to 
the erythrocyte receptor basigin 
Both anti-PfCyRPA and anti-PfRH5 mAbs strongly inhibit, but do not completely impede, 
parasite growth (92, 93, 96). P. falciparum merozoites are described to use alternative 
invasion pathways to evade Ab-mediated immunity (97) and the use of a PfCyRPA/PfRH5-
independent invasion pathway of limited efficiency could explain persistence of parasitemia.  
Reddy et al. (94) reported a synergistic in vitro inhibitory activity for the combination of 
polyclonal anti-PfCyRPA and anti-PfRH5 antibodies, and. we could show that monoclonal 
antibodies specific for PfRH5 and PfCyRPA have both in vitro and in vivo additive parasite 
growth inhibitory activity (98).  
The additive inhibition produced by the combination of PfCyRPA and PfRH5 antibodies 
suggests that blocking two essential molecular interactions within the same invasion pathway 
(i.e. PfRH5-basigin binding and PfRH5/PfCyRPA complex formation) impede parasite 
growth more efficiently than when targeting only a single interaction. Also, in view of the 
observed additive effect, inclusion of both antigens into a multivalent subunit vaccine would 
represent an attractive strategy to prevent emergence of escape mutants. 
Taken together, these findings draw the attention to the identification of additional antigens 
that may exert a synergistic effect by acting ‘in parallel’, inhibiting redundant invasion 
processes, or ‘in series’, inhibiting successive stages of invasion (99). 
Among additional uncharacterized antigens, investigated in the framework of this thesis, 
PF14_0044 showed interesting features: none of the generated anti-PF14_0044 mAbs 
significantly inhibited the growth of P. falciparum 3D7, but a synergistic in vitro inhibitory 
activity was observed when anti-PF14_0044 were combined with anti-PfCyRPA mAbs. 
Given the complexity of P. falciparum erythrocyte invasion mechanism (48, 100), we could 
speculate that anti-PF14_0044 interfere with an invasion pathway of limited efficiency, and 
PfCyRPA- and PF14_0044-specific antibodies act ‘in parallel’ inhibiting redundant invasion 
processes. These fascinating hypotheses wait to be proved in the context of a broader panel of 
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invasion-related antigens. Hence, beside the identification of next-generation vaccine 
candidates, the systematic assessment of their potential to induce antibodies that act 
synergistically when administered in multi-antigen formulations remains essential (101). 
 
Up to date, development of P. vivax vaccines has lagged behind that of P. falciparum owing 
to the knowledge gaps on the biology of this parasite and to the lack of reliable in vitro culture 
system (102, 103). Following the shift from malaria control to elimination and eradication 
(104, 105), P. vivax has been put at the forefront of the malaria research agenda and systems 
biology approaches using high-throughput technologies will greatly support the identification 
of vaccine candidates for P. vivax. 
From reverse to structural vaccinology: a prospective for malaria vaccine 
development 
Despite the improvements in vaccine delivery systems and adjuvant formulations, convincing 
protective immunity in humans has not been achieved yet. Efficacious immune response does 
not require recognition of the entire antigenic protein, but single or multiple selected epitopes 
may be sufficient to induce protective immunity.  
Over the past decade, advances in X-ray crystallography and genetic engineering, have 
inaugurated the era of ‘structural vaccinology’, a combination of immunological, structural 
biology and bioinformatics approaches, in which the insights provided by high resolution 
structural analysis are used to design improved vaccine antigens (106–108). Detailed three-
dimensional (3D) structure, domain organization, and dynamics of surface proteins of 
pathogens offer precious information that can guide the design of effective vaccines.  
The ultimate goal of involving protein crystallography into vaccine research is the structural 
characterization of candidate antigens, either alone or in complexes with Fab (fragment 
antigen-binding) of neutralizing antibodies. The determination of such co-crystal structures 
represents the most powerful technique that allows a visually immediate and highly detailed 
definition of the epitope–paratope interface. Thus, epitope mapping has become one of the 
most relevant applications of protein crystallography in the field of vaccine research. 
The structural studies of Neisseria meningitidis NadA (Neisseria adhesin A) and fHbp (factor 
H binding protein) (109, 110), and Staphylococcus aureus MntC (111) represent remarkable 
examples of crystal structure determination of vaccine antigens that, in turn, provided useful 
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information to elucidate both the molecular mechanism of their biological functions, and their 
immunological properties as vaccine antigens.  
Another important target of structural vaccinology is to present the identified and 
characterized protective determinants in a stabilized and optimized conformation, in order to 
direct the immune response towards the neutralizing epitopes (112). Indeed, epitope-focused 
and scaffold-based vaccines, where neutralizing epitopes are grafted into unrelated scaffold 
proteins for conformational stabilization, have recently demonstrated their concrete 
applicability in HIV and RSV vaccine design and development (113, 114).  
Taken together, these findings have raised hope that the rational design of vaccines for 
impervious pathogens, which have been so far refractory to vaccine development via 
traditional approaches, may become feasible (115). 
In the studies described in this thesis, monoclonal antibodies specific for PfCyRPA were 
generated by immunization of mice with recombinantly expressed protein, either as antigen-
loaded living cells or soluble protein-in-adjuvant. Raised PfCyRPA-specific mAbs inhibit 
merozoite invasion to different extent depending on their unique specificity (92, 93). Since 
induced PfCyRPA-specific antibodies can be invasion inhibitory or non-inhibitory, an 
optimized PfCyRPA-based vaccine should be designed to maximize induction of inhibitory 
responses. This possibly implies the design of protein surface loops comprising epitopes 
associated with protection (116). 
We therefore investigated the crystal structure of PfCyRPA. Diffracting PfCyRPA crystals 
were obtained and the 3D structure has been solved, providing precious information that will 
facilitate the identification of the protective epitopes responsible for parasite-inhibitory 
immune responses (98). 
Prospects for a PfCyRPA-based malaria vaccine 
Recombinant protein-in-adjuvant formulations of PfCyRPA have been shown to elicit in mice 
high titers of antibodies that inhibit in a dose-dependent manner P. falciparum asexual blood 
stage parasite growth, both in vitro and in vivo.  
Although lower doses showed moderate growth inhibitory effects, only doses of 2.5 mg 
PfCyRPA-specific mAb considerably inhibited parasite growth in mice. The protective effect 
of a PfCyRPA-based vaccine may therefore depend on the ability to induce and maintain high 
titers of inhibitory antibodies. The concentration of PfCyRPA-specific mAb in the circulation 
of the passively immunized mice (receiving the 2.5 mg mAb/mouse dose) was estimated to be 
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300 µg/mL at the day of infection. For most human vaccines specific antibody concentrations 
from <1 µg/mL to ~200 µg/mL are sufficient to confer protection. However, it is feasible to 
induce much higher concentrations of specific antibodies, as shown by phase II studies of 
RTS,S adjuvanted with AS02 and AS01, where serum concentrations of CSP-specific 
antibody in the range mg/mL could be induced in malaria‐naïve adults (117, 118). 
Furthermore, polyclonal antibodies induced by active immunization may have higher 
affinities compared to monoclonal antibodies, and might also exert additive or synergistic 
activity. Hence, vaccine-induced antibody concentration required for protection of humans 
may be lower than the concentration of mAbs required for parasite growth inhibition in the 
SCID‐mouse model.  
However, full-length recombinant proteins may primarily elicit immune responses against 
hyper-variable and functionally not relevant antigenic determinants hampering the 
development of parasite-inhibitory immune responses. This obstacle can be overcome by the 
use of synthetic peptidomimetics with native-like folds, which mirror those antigen domains 
capable of inducing protective antibodies. Optimized peptidomimetics can be then delivered 
on the surface of immunostimulating reconstituted influenza virosomes (IRIVs), which 
function both as carrier and adjuvant system (119, 120). IRIVs are in vitro-assembled non-
replicating virus-like particles that mimic the structure and function of the parental influenza 
virus, but lack viral genetic material. Clinical studies (121) have demonstrated that IRIVs 
represent an optimal vaccine formulation for eliciting strong immune responses (either CD4 
T/B-cell and/or CD8 T-cell immune responses) against synthetic peptide loaded on their 
surface. Also, and most importantly, distinct peptidomimetics can be anchored on the surface 
of IRIVs and different populations of antigen-loaded virosomes can be combined to formulate 
multi-component subunit vaccines. Hence, IRIVs represent a modular and extremely versatile 
antigen delivery system. 
In this thesis, the 3D structure of PfCyRPA in complex with an inhibitory antibody has been 
elucidated (98). Diffracting PfCyRPA/Fab crystals were obtained producing a well-detailed 
definition of the epitope–paratope interactions. 
PfCyRPA adopts a six-bladed b-propeller fold and presumably acts as a binding platform to 
tether on the merozoite surface other proteins essential for the invasion process. b-propellers 
are quite successful structural modules (122): examples of six-bladed b-propellers include 
sialidases (123, 124) and protein ligand binding (125, 126), signaling (127), and structural 
(128) functions. The extension of b-sheets by attachment of b-strands from different proteins 
is a common protein-protein interaction motif. Outermost b-strands of several blades in 
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PfCyRPA are exposed to solvent and, although the interaction surfaces are not very large, 
may represent potential binding site for other proteins.  
PfCyRPA is a crucial component of a multiprotein complex that as a whole is essential for 
erythrocyte invasion (94, 129, 130). While it has been claimed that PfCyRPA anchors the 
ternary complex through a GPI anchor to the parasite membrane (94), recent results are not 
consistent with this suggestion (129, 130). These studies confirmed that CyRPA is a secreted 
protein, which directly interacts with PfRH5 and PfRipr, while the invasion complex is 
tethered to the merozoite surface by the GPI-linked protein P113 (130). In this light, secreted 
PfCyRPA would bind the P113-PfRH5-basigin complex and recruit PfRipr to the invasion 
complex, acting as a protein-protein binding platform essential for the assembly of the 
invasion complex. 
PfCyRPA, PfRH5 and PfRipr colocalize during parasite invasion at the junction between 
merozoites and erythrocytes. The complex seems to be required both for triggering Ca2+ 
release and establishment of tight junctions: while merozoites deficient in PfCyRPA or 
PfRH5 can still bind to erythrocytes, they do not attach irreversibly and cannot invade the 
host cells (129). However, further functional studies are required to elucidate the molecular 
mechanisms how the invasion complex is involved in erythrocytes invasion (129). In this 
context it may be relevant that the five sequential disulfide bonds of PfCyRPA are in blades 
1-5, leaving blade 6 of the b-propeller structure without such a local stabilization. Blade 6 is 
composed of b-strands from the N- and the C-terminus, and in principle could act as a gate to 
allow PfCyRPA to undergo substantial conformational changes.  
The crystal structure of PfCyRPA, together with the already elucidated structure of PfRH5 
(131), provides the structural insight into the multiprotein invasion complex. Also, the 
structure of PfCyRPA in complex with the inhibitory antibody c12 identified the protective 
protein surface epitopes to guide the rational design of next generation malaria vaccines 
against the blood-stage parasites.  
Synthetic peptide chemistry and sequential rounds of structural optimization of selected 
peptides, together with immunological profiling, will allow us to design optimal 
peptidomimetics, which stably mirror the native structure of the corresponding inhibitory 
epitopes, to be incorporated into IRIVs and elicit parasite blood-stage growth-inhibitory 
antibodies. 
The generation of optimized peptidomimetics is eagerly awaited for evaluating the potential 
of a virosomal, epitope-focused PfCyRPA-based candidate vaccine. 
  Discussion 
 
193 
Conclusion 
In this thesis, we exploited the great potential of genomics and other ‘omics’ sciences for the 
rational design of novel malaria subunit vaccine candidates. Our strategy was based on (I) the 
selection of hypothetical parasite proteins that are accessible to host immune surveillance by 
antibodies, (II) their functional characterization using antigen-specific monoclonal antibodies, 
and (III) their high-resolution structural analysis employing X-ray crystallography. 
Our findings lead to the following key conclusions:  
1. The cell-based immunization approach for the generation of antigen-specific and 
parasite cross-reactive mAbs represents a rapid and reliable tool for candidate antigen 
screening. The strategy can be applied to a wide range of cell‐surface proteins. 
2. Selected antigens can be easily expressed in a second step in HEK cells as soluble 
recombinant proteins and tested as adjuvanted vaccine formulations. 
3. The P. falciparum NOD/scid‐IL2Rγnull mouse model represents an unprecedented 
system to evaluate in vivo the functional potencies of raised malaria-specific Abs. 
4. Reverse vaccinology is an excellent strategy for the identification of novel malaria 
vaccine targets and structural vaccinology constitutes the most promising approach for 
the design of optimal vaccine formulations. 
5. Among the characterized candidate proteins, PfCyRPA has been identified as potential 
component for inclusion in a subunit malaria blood-stage vaccine: it (I) is target of 
potent parasite growth-inhibitory antibodies, (II) is highly conserved among P. 
falciparum isolates, and (III) has limited natural immunogenicity. 
6. PfCyRPA adopts a six-bladed b-propeller fold and acts as a crucial binding platform 
to bridge different merozoite surface proteins and assemble the invasion complex, 
essential for the invasion process into erythrocytes. The crystal structure identified the 
inhibitory epitopes and will guide the rational design of next generation epitope-
focused malaria blood-stage vaccine. 
The rational application of the described strategy could lead to the identification and 
characterization of additional potential P. falciparum and P. vivax vaccine targets. 
Results support the concept to apply reverse and structural vaccinology approaches for the 
selection of promising candidates and for the design of an effective multivalent malaria 
subunit vaccine.   
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